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ABSTRACT
Bartonella, a group of Gram negative facultative intracellular bacteria, are known
to cause diseases, such as Cat Scratch Disease, Trench Fever and Carrion’s Disease, that
involve angiogenesis during the infective cycle. B. bacilliformis, the etiological agent of
Carrion’s Disease, causes a bi-phasic infection resulting in the formation of blood-filled
angiogenic proliferative cutaneous nodules called verruga peruana. The work presented
here was undertaken to characterize the mechanism by which these nodules are produced.
Previous work in our laboratory suggested that the Bartonella henselae genome
contains a homologue to the virB operon, a set of genes coding for a Type IV Secretion
System (TFSS) that has been implicated in the pathogenesis of other !-2-proteobacteria.
We identified virB operons in two additional Bartonella pathogens, B. quintana and B.
clarridgeiae. No corresponding operon sequences were detected in B. bacilliformis
DNA, however. This finding suggests that virB gene products are not required for
verruga peruana formation. To continue our search for factors involved in B.
bacilliformis-induced angiogenesis, we conducted a microarray analysis of differential

gene expression in infected and uninfected endothelial cells. The results suggest
similarities between later stage (36 hours) B. bacilliformis infection and that of HHV-8,
the causative agent of Kaposi’s Sarcoma, particularly in relation to the host immune
response. Finally, our research focused on the secreted factors that B. bacilliformis
produces during its host infective cycle. Our data suggest that the B. bacilliformis
homologue to the molecular chaperone GroEL not only induces angiogenesis in
endothelial cells, but also protects endothelial cell tubule from the degradation seen when
these cells are in the presence of live B. bacilliformis. In summary, the induction of
verruga peruana nodules via B. bacilliformis may be the result of multiple factors over
the course of persistent infection. Early infection may cause vascular damage, which
induces VEGF and hypoxia factors. As infection persists, bacterial secretion of a unique
GroEL may result in continued angiogenesis and the ensuing activation of immune cells,
producing a localized environment of continual incomplete angiogenesis in areas of
cutaneous infection.
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General Introduction
Bartonella Species – Microbiological Aspects, Identification & Epidemiology
As emerging pathogens, Bartonella species show a wide variety of infective abilities
and potential hosts. Bartonella are Gram-negative bacilli, many of which possess polar
flagella and are highly motile. Clinical growth of Bartonella species requires incubation
between 25 and 37°C in 5% CO2 on a blood rich media, such as BHI (Brain Heart Infusion)
containing 5-10% sheep’s blood. Bartonella are extremely slow growing in vitro, typically
requiring 14 days for primary isolate culture growth. Although growth in liquid media is
possible, Bartonella species tend to be grown on solid media due to their fastidious nature
and lack of turbidity. Bartonella colonies tend to be sticky, irregular, raised, whitish, selfadherent and very small. Biochemically, Bartonella species tend to be carbohydratemetabolism inert, and catalase and oxidase reaction negative (Anderson, 1997; Maurin et al.,
1997). Bartonella species contain relatively small genomes, with sizes ranging from 1.5 –
2.0 Mbp, and a G+C content of approximately 40% (Schmidt, 1998). Diagnostic
identification of intraspecies differentiation has relied heavily on the use of 16S rRNA and
the gene for citrate synthesis (gltA) (Birtles et al., 1996; Ehrenborg et al., 2000).
Comparative sequence analysis places Bartonella in the !-2 subgroup of Proteobacteria, a
class that also contains Afipia, Agrobacterium and Brucella.
The first identified Bartonella species, Bartonella bacilliformis, was originally
described in 1909. This strain remained the only member of the Bartonella genus for more
than 80 years. In the early 1990s, however, detailed 16S rRNA analysis of several species
belonging to Rochalimaea, a genus previously classified as Rickettsiaceae, showed such a
close similarity to Bartonella bacilliformis that the decision was made to combine these two
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genera into a single genus (O'Connor et al., 1991). The taxonomic unification of
Rochalimaea and Bartonella added four more strains, B. quintana, B. henselae, B.
clarridgeiae and B. elizabethae, to the Bartonella genus (Brenner et al., 1993). Since that
time, numerous new Bartonella species have been identified, bringing the current total to
more than 20 (Birtles et al., 1995).
Of the many Bartonella species known, only a few have been identified as human
pathogens. The best characterized of these are B. henselae, and B. quintana. B. henselae, the
causative agent of Cat Scratch Disease (CSD), is the most widely-studied of all Bartonella
species. Initially identified as a member of the genus Rochalimaea, B. henselae causes the
highest number of infections of any of the human Bartonella pathogens. The bacterium is
transmitted to humans through the bite or scratch from a cat or other small mammal.
Symptoms begin with the formation of localized erythematous papules, followed by a mild
fever and lymphadenitis. Normally, the course of the infection is self-limiting in an
immunocompetent host (Brenner et al., 1993), with the localized swelling at the site of
infection being cleared quickly, and the fever and lymphadenitis disappearing over the course
of several weeks. (Dehio et al., 1997; Kordick et al., 1995; Maurin et al., 1997). In patients
with damaged or compromised immune function, however, infection by B. henselae can
result in bacillary angiomatosis (BA) and/or peliosis hepatitis (Koehler et al., 2003; Maurin
et al., 1997; Schmidt, 1998), two conditions characterized by the appearance of angiogenic
lesions on the skin and internal organs, respectively (Dehio, 2003). Several studies have
correlated the production of these lesions directly with B. henselae infection, and have
highlighted the role played by invading macrophages in the vascular proliferative process
(Kirby, 2004; McCord et al., 2005; McCord et al., 2006; Resto-Ruiz et al., 2002).
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B. quintana is transmitted via the body louse and is found predominantly among
homeless and immunocompromised individuals (Foucault et al., 2002; Jackson, 1996; Rolain
et al., 2003). Infection by B. quintana, which results in a condition known as Urban Trench
Fever, is often accompanied by recurring high fevers and severe pain in the back and shins
(Ohl et al., 2000). This repeating cycle of clinical symptoms is thought to be caused by the
process of B. quintana invasion and release from host cells, and can result in bacteremia and
BA. Studies have shown that both B. henselae and B. quintana are able to attach to and
invade multiple cell types, including erythrocytes, epithelial and endothelial cells (Batterman
et al., 1995). Once they have successfully invaded the cell, these bacteria are able to alter
normal cell cycle pathways. Apoptosis is turned off during the initial stages of infection and
vascular proliferation is induced, with both processes acting in concert to increase the
numbers of infected cells (Liberto et al., 2004; Liberto et al., 2003).
B. henselae and B. quintana are more closely related to each other than they are to
either of two other human pathogens, B. clarridgeiae and B. bacilliformis (Anderson, 1997).
Clinical manifestations of B. clarridgeiae infection are similar to those of CSD. Like B.
henselae and B. quintana, B. clarridgeiae can induce BA formation in an
immunocompromised host (Berger et al., 1993; Maurin et al., 1997). Little research has been
done regarding the molecular mechanisms underlying B. clarridgeiae infection or the role
host cells play during the process of infection.
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Bartonella bacilliformis – History & Epidemiology
In 1909, Dr. A.L. Barton described an erythrocyte-adherent bacillus-shaped
bacterium that he named Bartonella bacilliformis. This bacterium was later determined to be
the causative agent of Oroya fever, a disease characterized by severe hemolytic anemia and
an untreated mortality rate of 85% (Anderson, 1997; Chomel et al., 2003). The vector
responsible for host-to-host transmission of B. bacilliformis is Lutzomyia verriformis
(formerly known as Phlebotomus), a sandfly that inhabits the high-altitude valleys of the
Andes mountains (Anderson, 1997; Schultz, 1968b). Transmission of the bacterium takes
place when the female sandfly infects its human host during nocturnal blood-feeding; the
source of the bacterium in the sandfly is the previous human host on which it fed (Schmidt,
1998). Replication of B. bacilliformis is not known to occur in the sandfly nor does B.
bacilliformis infect the sandfly itself. Unlike other Bartonella species, B. bacilliformis has
not been conclusively shown to infect any host other than humans, although there have been
anecdotal reports of infection of farm animals as well (Anderson, 1997). The requirement for
the sandfly as a vector is very specific, and normally limits the infective range of B.
bacilliformis to the sandfly’s natural habitat in the inter-Andean mountains of Peru,
Columbia and Ecuador.
Bartonella bacilliformis is the causative agent of Carrion’s disease, a biphasic disease
consisting of the initial acute phase, Oroya fever, and a second, chronic phase, called verruga
peruana. During the Oroya fever phase (so named for a Peruvian valley where it has often
been reported), the bacteria invade nearly 100% of the host erythrocytes, causing a lifethreatening sepsis and hemolysis. Oroya fever epidemics have been recorded since pre-Incan
times. A particularly devastating outbreak occurred between 1869 and 1873, killing nearly
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10,000 railroad workers (Hertig, 1942; Schultz, 1968a). Survivors of Oroya fever may
subsequently develop verruga peruana, a condition characterized by the eruption of bloodfilled nodules on the skin of infected patients. The link between Oroya fever and nodule
formation was established by a Peruvian medical student, Daniel Carrion, who injected
himself with the bloody material from a patient suffering from verruga peruana, and carefully
documented the appearance of Oroya fever symptoms. Carrion died from the resulting
illness, and the disease that killed him was subsequently named Carrion’s disease in
acknowledgement of his sacrifice.
Bartonella bacilliformis – Known Virulence Factors
Invasion-related Factors
Bartonella bacilliformis is known to code for several virulence factors that help the
bacterium survive in both its arthropod and human host. Studies have shown that the
bacterium is able to invade a wide variety of cells, including red blood cells (RBCs),
endothelial and epithelial cells. The majority of research has focused on the invasion of B.
bacilliformis into host RBCs during the Oroya fever stage of the infection (Benson et al.,
1986). Red blood cells, which are nonendocytocic and unnucleated, are the first host cells to
be invaded (Dehio, 2001). During RBC infection, B. bacilliformis is known to use at least
three bacterial-encoded virulence factors: flagella, deformin and the invasion-associated
locus gene products IalA and IalB (Buckles et al., 2000; Cartwright et al., 1999; Coleman et
al., 2001; Mernaugh et al., 1992; Mitchell et al., 1995). The first, and most intensely studied,
virulence factor is the flagellum. B. bacilliformis contains several polar flagella and is highly
motile. The flagella are composed of multiple 42-kDa flagellin subunits and are highly
resistant to both protease K and trypsin treatment (Anderson, 1997; Scherer et al., 1993).
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Pre-incubation of B. bacilliformis with anti-flagella antibodies significantly reduces the
efficiency of invasion (Scherer et al., 1993). Moreover, a mutant lacking flagella exhibits a
75% reduction in its ability to bind to erythrocytes (Battisti et al., 1999). At the present
time, it is not known whether flagella play a direct role in binding to erythrocytes, or whether
the motility they provide simply increases the likelihood that the bacterium will collide with
a host cell, although studies with inhibitors of respiration and motive force support the latter
interpretation (Benson et al., 1986; Scherer et al., 1993). B. henselae and B. quintana do not
show the presence of flagella, thus leading some investigators to suggest that the motiveforce provided by the B. bacilliformis flagella is not necessary for invasion (Anderson, 1997).
Deformin, a second well-studied B. bacilliformis virulence factor, produces deep
invaginations within the RBC cell membrane. The secretion of deformin and the resulting
formation of membrane invaginations are believed to enhance the ability of the flagellated B.
bacilliformis to “push” itself into host RBCs (Mernaugh et al., 1992; Xu et al., 1995).
Studies of purified deformin show that it is able to achieve these invaginations even in the
absence of bacteria (Iwaki-Egawa et al., 1997). Deformin activity has been reported to
reside in a complex of several 36-kDa proteins with a small (1.4 kDa) hydrophobic molecule
(Hendrix and Kiss, 2003). The exact composition of the hydrophobic molecule has not yet
been determined. The role(s) of IalA and IalB in invasion by B. bacilliformis show genetic
similarities to invasion-associated genes products found in Yersinia species (Anderson, 1997;
Mecsas et al., 1995; Wachtel et al., 1995). The ialA gene is 510 bp and codes for a putative
NTPase core protein, while ialB is 558 bp and codes for a homologue of the Yersinia ail
(adhesion and invasion locus) protein (Cartwright et al., 1999; Coleman et al., 2001). B.
bacilliformis IalA acts as a (di)nucleoside polyphosphate hydrolase, and has distinct

7
homology to the nudix class of nucleotide pyrophosphatases produced by A. tumefaciens (Xu
et al., 2003). The function of IalB has not been determined, but it is known to be an inner
membrane protein that is also required for B. bacilliformis RBC invasion (Coleman et al.,
2003; Mitchell et al., 1995). Studies with E. coli harboring recombinant plasmids carrying
the ialAB locus have shown that both ialA and ialB are required for invasiveness in vitro, as
indicated by a 6- to 39-fold increase in invasion in the presence of both genes. Moreover,
expression of ialAB enhances the efficiency of invasion even in the absence of flagella
(Coleman et al., 2003).
B. bacilliformis is known to continue replication inside both the endosomal vacuole
and the cytoplasm of RBCs without lysing either cell type. While the purpose of RBC
colonization is still unknown, it is generally considered to increase the potential for
successful invasion, since it provides B. bacilliformis with direct access to host iron and any
other blood-supplied host growth factor(s) the bacterium might require. Colonization of
RBCs would also give B. bacilliformis a safe haven in which to replicate where it could
effectively evade the host immune response.
Investigations are ongoing to determine the mechanism(s) by which B. bacilliformis
invades host endothelial and epithelial cells (Dehio, 2001; Garcia et al., 1992), a process that
results in the verruga stage of the infection. Cellular invasion is known to require the activity
of B. bacilliformis flagella, as shown by a 50-90% decrease in invasion when cells are
incubated with anti-B. bacilliformis flagella antibodies (Scherer et al., 1993). The process is
also reported to be Rho-GTPase dependent, as indicated by a decrease in B. bacilliformis
invasion when endothelial cells are pre-incubated with C3 exoenzyme, a protein known to
inactivate Rho-GTPase (Verma et al., 2000; Verma et al., 2002). These data suggest that B.
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bacilliformis invasion is dependent upon actin rearrangement in host cells. This hypothesis is
supported further by the observation that uptake of the bacteria is significantly reduced in the
presence of cytochalasin D, which inhibits host actin rearrangement (Hoang et al., 2004).
Additional studies indicate that B. bacilliformis outer membrane proteins play a direct role in
invasion, as the presence of anti-Bartonella anti-sera causes a marked decrease in bacteria
uptake (Minnick, 1994). Within one hour of invasion, B. bacilliformis-induced actin
rearrangement leads to the formation of filamentous actin extensions called filopodia.
Filopodia formation is accompanied by host cell membrane ruffling, a phenomenon that may
implicate the activation of Rac and Cdc42 and other host signaling pathways (Verma et al.,
2002). Invasion is most often seen in the endothelial cells which line the capillary beds of
the host skin and related subcutaneous tissues. Host endothelial and epithelial cells contain
the invaded B. bacilliformis within a vacuole called the invasome, a term coined specifically
for B. bacilliformis (Dehio et al., 1997). The invasome has been shown to migrate from the
cell membrane to a position near the host nucleus, although the mechanism and effect of this
translocation are unknown. Bacterial invasion into these cells is characterized by two distinct
histological manifestations of verruga peruana. The first consists of spindle-form lesions that
contain fusiform cells with T cell and monocyte/macrophage infiltration. The second is
described as a pyogenic granulomatous hemangioma characterized by a hyperplastic
endothelium and extensive vascularization (Anderson, 1997; Maurin et al., 1997). When
examined histologically, the spindle-form lesions are strikingly similar to Kaposi’s sarcoma,
while the granulomatous forms tend to resemble the bacillary angiomatosis seen during
infection by B. henselae (Berger et al., 1993; Caceres-Rios et al., 1995; Cockerell, 1992).
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The invasion of epithelial cells has been shown to cause the up-regulation of
numerous growth factors, cytokines and interleukins, some of which are known to be
involved in angiogenesis (Claesson-Welsh, 1999; Fox, 2001). Previous work has indicated
that the invasion of B. bacilliformis into epithelial cells produces a transient up-regulation of
TNF-!, which is in turn known to up-regulate the production of various angiogenic factors.
Studies exposing cultured endothelial cells to B. bacilliformis extracts have led to the
suggestion that the bacterium itself produces a possible mitotic and/or angiogenic factor
(Garcia et al., 1990; Garcia et al., 1992). A B. bacilliformis heat shock protein, Bb65,
strongly activates T cells which in turn produce Eta-1/osteopotin, an inducer of vascular cell
proliferation (Knobloch et al., 1990).
Adherence-Related Factors
Several laboratories are involved in the characterization of factors responsible for
promoting adherence of B. bacilliformis to the host cell. Initially, work by Walker and
Winkler (1981) suggested that “fiber-like projections” on the polar surface of the bacterium
were responsible for contact with the RBC surface (Anderson, 1997; Walker et al., 1981).
These “projections” have been studied further and show a resemblance to the Bundleforming pili (BFP) found in E. coli and S. enteritidis. The bundles range in size from 50 to
600 nm and have been shown to be resistant to solubilization by SDS and formic acid.
The aforementioned flagella may also play a role in the adhesion of B. bacilliformis
to host cells (Krueger et al., 1995). Studies have shown that cultures of B. bacilliformis that
have been highly-passaged or have had their flagella removed bind poorly to host RBCs,
although this may be due less to a direct role of flagella in adhesion than to a requirement for
flagellar-motive force in promoting collisions between the bacterium and the host cell.
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Infection with B. bacilliformis begins a rapid and energy-dependent adhesion to and
invasion of RBCs. In vitro studies show a 15-30 minute lag time between introduction and
adhesion, with maximal adhesion at six hours post infection (Verma et al., 2001; Verma et
al., 2000; Verma et al., 2002). The treatment of B. bacilliformis with agents that inactivate
bacterial proton-motive force (N-ethylmaleimide) or respiration (KCN) results in a
significant decrease in their binding to RBCs. However, exposure of the RBCs to glycolysis
(NaF) or proton-motive force (N-ethylmaleimide) inhibitors has no affect on bacterial
adherence, suggesting that the RBC itself is passive in the adhesion process and does not
contribute energy (Verma et al., 2002). The host receptor for B. bacilliformis has not been
identified but the bacterium shows a definite predilection for rabbit or sheep RBCs.
Research in the Baumstark lab has shown that B. bacilliformis is able to invade both
enucleated (sheep) and nucleated (goose) RBCs (McCormick, personal communication).
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The virB Operon
Previous studies on the infectious process of the plant pathogen A. tumefaciens
identified a set of genes, termed the virB operon, that are required for the infection of plant
cells (Chen et al., 2002; Krall et al., 2002). In A. tumefaciens, the virB operon was found to
contain 11 genes, designated virB1 through virB11 depending on their location downstream
of the vir Box, a regulatory element found directly upstream of virB1. It was subsequently
proposed that the virB operon acts to form a Type IV secretion system (TFSS) that provides a
conduit for A. tumefaciens to transfer a single stranded copy of T DNA, or T strand, into
plant host cells (Boschiroli et al., 2002; Escudero et al., 1995; Ohashi et al., 2002).
Originally, Type IV secretion systems were identified in mating-pair formation systems (Mpf
systems) required for the conjugal transfer of plasmid DNA. They are thought primarily to
form pilus structures for DNA transfer to recipient cells. A. tumefaciens and E. coli have
been the only bacteria positively identified as having these systems (Chen et al., 2002). The
functions of all the virB proteins composing the A. tumefaciens virB operon have not yet been
elucidated. However, several virB proteins have been characterized and a model outlining
the structure and assembly of the secretion machinery has been developed (Figure GI.1)
(Baron et al., 2001; Sagulenko et al., 2001),. The best characterized virB gene products in A.
tumefaciens are VirB2, forming the transfer pilus, VirB4, a putative ATPase, and VirB9, 10
and 11, which interact to form a protein complex that anchors the TFSS to the cell membrane
(Figure GI.1) (Boschiroli et al., 2002; Krall et al., 2002; Sagulenko et al., 2001; Stephens,
Kathryn et al., 1995).
Previous work in our laboratory revealed the presence of a homologue to the A.
tumefaciens virB operon in B. henselae (Anderson, 1997; Padmalayam et al., 2000b;
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Schmiederer et al., 2001). The B. henselae virB operon is composed of 10 genes that exhibit
homology to the A. tumefaciens virB genes, as shown in Table GI.1, and are positioned in a
similar order within the operon. While mutagenesis studies and deletions of the virB operon
have not been conducted in B. henselae, it has been noted that continued passage of the cells
leads to a decrease in virulence, which may be related to the loss of VirB2 pilus formation
(personal communication, Padmalayam). Interaction studies with virB-encoded proteins
suggest that TFSS formation of the B. henselae virB operon is similar to that of A.
tumefaciens (Shamaei-Tousi et al., 2004). These studies indicate that the VirB2 protein acts
as the primary subunit of the TFSS pilus, with VirB3, VirB9, the 17kDa antigen (encoded by
virB5) and the15kDa antigen (encoded by virB7) serving as pore-forming anchors in the
periplasm. The inner member anchor proteins VirB4, VirB8, VirB10 and VirB11 are
proposed to interact to form a pore into the cytoplasm. Recently, identification of virB
protein homologues in S. meliloti, Brucella suis, Brucella abortus, Bordatella pertussis and
additional Bartonella species has been reported, with functional studies suggesting that they
play a role as TFSS transport machinery (Boschiroli et al., 2002; Gorvel et al., 2002; Ohashi
et al., 2002; Weiss et al., 1993).
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Figure GI.1 – Assembly of the virB gene products in A. tumefaciens.
The proposed assembly of the virB operon proteins, functioning as a TFSS, is shown above.
According to this model, A. tumefaciens VirB2 (in yellow) forms the pilus for cell-to-cell
contact, with VirB9 (dark red) as an outer membrane-bound anchor. VirB4, in dark blue, is
predicted to act as an ATPase and provide energy into the process for Ti DNA translocation.
The associated VirB9/10/11 protein complex (light blue and purple) forms the inner
membrane-bound anchor (Christie, 1997).

Figure GI.2 – Proposed Assembly of virB gene products in B. henselae.
The proposed assembly of the virB operon proteins, functioning as a TFSS, is shown above.
B. henselae VirB2 (in yellow) forms the pilus, interacting with the 17kDa antigen (VirB5,
shown in dark purple). VirB3 (orange), VirB9 (red) and the 15kDa antigen (purple) form a
periplasmic pore. The VirB4 (green) and VirB11 (blue) are membrane-bound and predicted
to act as ATPases. The associated VirB8/10/11 protein complex (yellow and blue) form the
inner membrane-bound anchor (Shamaei-Tousi et al., 2004).
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Table GI.1 – Homology of selected Bartonella virB operon genes compared to the A.
tumefaciens virB Operon.
The following table indicates the DNA sequence identity within the open reading frames
coding for virB proteins of A. tumefaciens and the Bartonella species.
(% DNA Sequence Identity)
Brucella
Suis

Sinorhizobium Bartonella
meliloti
henselae

Bartonella
tribocorum

virB2-homologue

47

45

34

36

virB3-homologue

43

39

44

41

virB4-homologue

47

45

50

49

17kDa Antigen

N/A

N/A

N/A

N/A

virB6-homologue

46

46

40

38

15kDa Antigen

N/A

N/A

N/A

N/A

virB8-homologue

48

48

38

43

virB9-homologue

46

46

41

42

virB10-homologue

48

48

44

43

virB11-homologue

42

42

48

48
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Angiogenesis
The verruga peruana stage of Carrion’s disease is marked by blood-filled skin
nodules, resulting from the uncontrolled up-regulation of angiogenesis in localized
endothelial cells (Caceres-Rios et al., 1995; Garcia et al., 1992). Up-regulation of
angiogenesis is initiated by the invasion of B. bacilliformis into host cells. The activation
and suppression of angiogenesis is normally tightly controlled by the balanced production of
both angiogenic stimulators and angiogenic suppressors in multiple cell types. In general,
however, angiogenesis is regulated by Vascular Endothelial Growth Factor (VEGF) and "Fibroblast Growth Factor ("FGF), and the presence of their respective receptors on
endothelial cells. VEGF, and its alternative splicing protein VPF, activate angiogenesis by
specifically increasing the microvascular permeability of endothelial cells to other plasma
proteins and by phosphorylating VEGFR-1 and 2 (VEGF receptors 1 and 2). This
phosophorylation causes the activation of phosopholipase C# and an increase in cytoplasmic
Ca+2 levels, resulting in the generation of inositol 1,4,5-triphosphate (IP3) and diacylglycerol
(DAG). Production of these intracellular messengers along with the activation of VEGFR-1
and -2 results in a strong cell proliferation response and the generation of matrix-degrading
proteases (Claesson-Welsh, 1999; Dong et al., 2001).

"FGF also functions as a mitogenic

protein, specifically stimulating endothelial cells to migrate and form tubules while also
increasing the production of proteases (Folkman et al., 1992). However, VEGF and "FGF
are not the only angiogenesis effecting factors, as shown in Table GI.2 (Bamias et al., 2003;
Conway et al., 2001; Sottile, 2004). The factors listed are all able to upset the natural
balance of angiogenesis, driving it in a specific direction, and can be produced by a variety of
cell types, including epithelial cells. The process of angiogenesis begins with the
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vasodilation and increased permeability of existing blood vessels, along with increased
permeability and degradation of the surrounding extracellular matrix. This allows for the
activated endothelial cells to migrate and form new lumen walls; generating a “pathway” for
returning to a larger blood vessel (Carmeliet, 2000; Neufeld et al., 1999). These endothelial
cells mature by remodeling themselves to supply the surrounding area with their specific
requirements, and are functional once a stable matrix and musculature are established
(Neufeld et al., 1999). In the verruga peruana stage of B. bacilliformis infection, the blood
vessels produced are not seen in a mature form; instead, they are open-ended and allow blood
to leak into the cutaneous and interstitial spaces around them. The invasion of epithelial cells
is known to cause the up-regulation of numerous growth factors, cytokines and interleukins,
some of which (Table GI.2) are known to be involved in angiogenesis (Claesson-Welsh,
1999; Folkman et al., 1992). Previous work has indicated that the invasion of endothelial
cells by B. bacilliformis produces a transient up-regulation of TNF-!, which in turn is known
to up-regulate VEGF production. BB65, a heat shock and highly immunogenic B.
bacilliformis protein, strongly activates T cells which in turn produce host Eta-1/osteopotin, a
protein that is then transiently able to induce vascular cell proliferation. Interestingly, almost
all skin disorders, such as psoriasis, show an increase of VEGF and VEGF-related proteins in
epithelial cells as well as an increase in VEGF receptors in endothelial cells (Carmeliet,
2000; Hudlick et al., 1986; Knobloch et al., 1990; Takahashi et al., 2002).
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Table GI.2 – Factors produced by host cells involved with angiogenesis.
The table below shows the wide variety of host cell products which are involved in
angiogenesis.
Protein
Activators

Function

Protein
Inhibitors

Angiopoietin-1

Stabilization of vessels
via tightening
endothelial-smooth
muscle interactions

Angiopoietin-2

Angiotropin

Endothelial growth
factor

Angiostatin

avb3 Integrin
avb5 Integrin
COX2

Endoglin
Ephrins
FGF
Fibronectin
HIF1a
IL-6
IL-8
Laminin 1
Matrix
Metalloproteinase

Receptor of matrix
macromolecules
Receptor of matrix
macromolecules
Essential for tumor
angiogenesis
Stimulation of
extracellular matrix
production
Regulation of
artery/vein phenotype
Stimulates angiogenesis
& arteriogenesis
Promotion of endothelial
adhesion, growth and
survival
Hypoxia-induced
endothelial growth
factor
Endothelial growth
factor
Endothelial growth
factor
Promotion of
Endothelial tube
formation
Cellular migration and
matrix remodeling

Endostatin
IP-10
Thrombospondin1
Vasostatin

Function
Induction of vessel
regression without
further
angiogenesis
signals
Inhibition of
growth and
migration
Inhibition of
growth and survival
Inhibition of
endothelial growth
Inhibition of
endothelial
migration, growth
and differentiation
Endothelial cell
growth inhibitor

18
Protein (con’t)
Activators

Function

Stimulation of
arterogenesis
Stimulation of
NO Synthase
angiogenesis and
vasodilation
Recruitment of smooth
PDGF and receptors
muscle cells
Endothelial junction
PECAM
molecule, essential for
cell survival
Enhancement of FGF
Perlecan
Signaling
Pro-angiogenic
Ras
oncogene
Stimulation of
TGF-B & B1
extracellular matrix
production
Angiogenic signaling
VEGF Receptors
receptor
VEGF, VEGF-C,
Stimulation of
PIGF and various
angiogenesis
homologues
Promotion of endothelial
Vitronectin
survival and migration
MCP-1
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The goal of this study is to gain insights into the molecular mechanism by which B.
bacilliformis induces the formation of verruga peruana during Carrion’s disease. Our
research has revealed that B. bacilliformis does not contain any homologues to the virB
operon found in several other Bartonella species and has led us to conclude that this operon
does not play a role in verruga peruana formation. Interestingly, using microarray-based
analysis of infected HMEC-1 cells, we have determined that several hypoxia and angiogenic
factors are up-regulated or significantly altered, which may aid in the induction of
angiogenesis. We also show that infected HMEC-1 cells produce high levels of immune
response genes, corresponding to an interferon-based immune response; this would likely
result in the recruitment of immune effector cells which could in turn produce more
angiogenic up-regulatory factors. Finally, we have found the secretion, by B. bacilliformis,
of a unique GroEL protein. Motif analysis indicates that this GroEL contains a
staphylocoagulase binding site, which may interact with host integrins up-regulate multiple
pathways, including angiogenesis. While this GroEL may be angiogenic, it may also
function to protect HMEC-1 cells from the tubule degradation effects seen in the presence of
live B. bacilliformis. Taken together, these results suggest to us that the infection of host
endothelial cells by B. bacilliformis induces a strong interferon-based immune response that
is coupled with host cell hypoxia in a microenvironment containing high concentrations of an
angiogenic GroEL protein, and that this series of events results in the localized formation of
verruga peruana.
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GroEL
The cellular environment is often inhospitable to the folding and unfolding of proteins
in their biologically active confirmation. Therefore, both prokaryotes and eukaryotes contain
proteins, called molecular chaperones, that allow this confirmation to occur on a
physiological timescale (Fenton et al., 2003). Chaperones are classified into two groups
according to their sequence homologies: Type I, represented by GroEL; and Type II,
represented by eukaryotic CCT (cytosolic chaperonin containing TCP-1) and archaebacterial
chaperones (Carrascosa et al., 2001). GroEL and the CCT chaperones differ in several ways.
Firstly, GroEL is considered nonspecific with respect to its substrate binding while CCT is
more specialized. Secondly, GroEL is a homeric-protein whereas CCT is a heteromeric
complex built of eight different polypeptides (Carrascosa et al., 2001). Finally, GroEL
requires a cofactor while CCT does not (Carrascosa et al., 2001). The main Type I
cytoplasmic chaperones identified to date include HtpG, the Clp system, trigger factor, the
DnaK system, and the GroE system. Little is known about the role of the HtpG system in
promoting proper folding, although the chaperone is highly expressed during heat shock.
Bacterial strains that do not contain the HtpG system behave like wild-type strains and show
no distinctive phenotype associated with the loss of the chaperone (Wong et al., 2004). The
Clp family of chaperones consists of a group of ATP-binding proteins that were originally
isolated based on their association with the serine protease ClpP. ClpA, ClpX and HslU all
exhibit ATP hydrolytic activity, which provides the energy required for ClpP-mediated
proteolysis. ClpB also binds to the serine protease, but does not hydrolyze ATP. Clp
proteins can be further divided into two classes according to the number of nucleotide
binding domains in each protein. ClpA and ClpB contain two nucleotide binding domains
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while ClpX and HslU contain only one nucleotide binding domain (Wong et al., 2004).
These ATP binding proteins not only target misfolded or foreign proteins for degradation, but
can also act as chaperones to promote refolding of improperly folded proteins.
Trigger factor is a chaperone that is common to all eubacteria. In E. coli, it has been
shown to interact with nascent chains and to bind closely to the nascent chain exit site of the
ribosomal complex (Wong et al., 2004). Trigger factor is involved in the prevention of
misfolding and the aggregation of nascent chains as they are translated by the ribosome.
DnaK is an ATP-dependent chaperone that functions in concert with the co-chaperone DnaJ.
DnaK recognizes hydrophobic sequences in extended polypeptide chains. Like trigger
factor, it binds to nascent chains (Wong et al., 2004). In eukaryotes, DnaK is present in the
cytosol, endoplasmic reticulum, mitochondria and chloroplasts, and acts in concert with
DnaJ and GrpE (Ranson et al., 1998). GroEL often acts in concert with a second protein,
GroES. The GroESL system promotes protein refolding in two stages. First, it prevents the
aggregation of non-native nascent peptides by forming complexes with them and thus
lowering the concentration of aggregation-prone peptides in solution. Second, it releases the
bound substrates into the central cavity of the GroEL complex, allowing folding in a
protected environment without intramolecular interactions. It has been suggested that
GroESL has the ability to unfold kinetically-trapped folding intermediates, thereby giving
them a new chance to fold correctly (Wong et al., 2004).
GroEL is an oligomeric complex of 14 identical 57-kilodalton subunits arranged in 7member rings sticking back to back. The crystal structure of GroEL shows a hollow
cylindrical complex 135Å in diameter with a height of 145 Å (Grallert et al., 2001). The
openings at each end of the cylinder form the entrance to a cavity with a diameter of 45 Å
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(Grallert et al., 2001). The GroEL monomer consists of 547 amino acids arranged in three
distinct domains: equatorial, intermediate and apical. The equatorial domain, which contains
a nucleotide binding site, is also used for the inter-and intra-ring interactions of a protein
complex. This domain also contains the ATP binding site, which is located on the inner sides
of the GroEL cylinder (Gomez-Puertas et al., 2004; Grallert et al., 2001; Wong et al., 2004).
The apical domain binds to both the substrate and GroES (Gomez-Puertas et al., 2004;
Grallert et al., 2001). The intermediate domain of each subunit transfers the ATP-induced
conformational changes from the equatorial domain to the apical domain (Grallert et al.,
2001; Wong et al., 2004). GroES, a seven-member ring structure composed of 10- kilodalton
subunits, binds ATP on one or both ends of the GroEL cylinder. GroES exhibits a domeshaped structure with outside dimensions of 80 Å in diameter and 30 Å in height, and inside
dimensions of 30 Å in diameter and 20 Å in height (Grallert et al., 2001). Transcription of
the E. coli GroESL system is positively controlled by the product of rpoH, the heat shock
promoter-specific $32 subunit of RNA polymerase (Arsene et al., 2000). The heat shock
response is induced as a consequence of a rapid increase in $32 levels and the stimulation of
$32 activity. Down-regulation of the GroESL response occurs as a consequence of declining
$32 levels as heat stress signaling decreases (Arsene et al., 2000).
GroEL activity requires communication between the three ring domains, which is
accomplished by the interaction of GroES and ATP at specific times during the nascent
protein binding cycle (Amir et al., 2004). In the ATP-free conformation, the GroEL
chaperone has an open structure and a high affinity for unfolded substrates. In contrast, in
the ATP-bound conformation the cavity structure is closed and has a low affinity for
substrates (Gomez-Puertas et al., 2004; Ranson et al., 1998). Substrate recognition is
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achieved by the presence of hydrophobic residues on the unfolded polypeptide, which are
exposed to the surface and are recognized by interaction with hydrophobic residues of the
chaperone-binding site (Gomez-Puertas et al., 2004). Functional protein folding in the
presence of the whole GroESL chaperone system proceeds by a reaction cycle that begins
with the binding of protein substrate to the intermediate domain. This then allows for the
binding of GroES. Binding of ATP subsequently produces a conformational change that
leads to the closure of the inner GroEL cavity (Amir et al., 2004; Poso et al., 2004; Wong et
al., 2004). In the folding cavity, the substrate binds to the apical domain in the top cylinder
of GroEL (Gomez-Puertas et al., 2004; Poso et al., 2004; Wong et al., 2004). The folding of
the nascent protein is thought to be accomplished, in part, by the binding of both GroES and
ATP, which provides a physical stress on the GroEL ring subunits, thereby constraining the
hydrophobic interactions and allowing for different conformational structures to be achieved
(Keskin et al., 2002; Poso et al., 2004; Sot et al., 2003; van der Vaart et al., 2004; Walter,
2002). Following the conformational changes in the nascent protein, the hydrophobic
binding site is altered and the now-folded protein is ejected into the bulk solution (Sot et al.,
2003; Walter, 2002). Since each GroEL subunit acts as a protein-binding unit, a full cycle
involves binding of both substrate and GroES to one ring of the complex followed by the
same steps on the opposite ring (Poso et al., 2004). Inner ring communication is of pivotal
importance as it mediates a structural symmetry that imposes alternating functions (Poso et
al., 2004). It is been shown that while positive cooperativity governs the binding of ATP, it
is negative cooperativity that regulates the communication between rings (Poso et al., 2004).
GroEL homologues are found in nearly all prokaryotic and eukaryotic organisms. In many
organisms, they were originally isolated as heat shock proteins. This observation, coupled
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with their monomeric migration pattern on denaturing gels, led to their early general
designation as “hsp60 proteins.” More recently, they have also been called “cpn60”
(chaperonin60) proteins.
Recent research has given scientists insight into possible immunological aspects of
the presence of GroEL in bacterial-host disease interactions. Chaperones are known to be
potent immunogens in both humans and rodents. Given the high degree of sequence
similarity between bacterial and the mammalian molecular chaperones, it is surprising that
bacterial chaperones elicit such a strong immune response (Ranford et al., 2000). It can often
be difficult to extract purified GroEL, as many other bacterial contaminants are often found
in GroEL preparations, including LPS (lipopolysaccharide), LAM (lipoarabinomannan),
peptidoglycan, or other bacterial exotoxins (Ranford et al., 2000). However, studies that have
been done using GroEL homologues from other bacteria have shown that even with the
complete removal of these contaminants GroEL is able to induce cytokine activity and is
therefore able to elicit an immune response (Ranford et al., 2000). In mice infected with M.
tuberculosis, up to 20% of the reactive T cells are responsive toward the chaperonin 60.2 (the
GroEL homologue in this organism); moreover, leukocytes, fibroblasts and epithelial cells
are also induced to produce pro-inflammatory cytokines in the presence of chaperone 60.2
proteins (Ranford et al., 2000). GroEL homologues from several different Mycobacteria
species and from E. coli have been shown to stimulate cytokine-dependent up-regulation of
vascular endothelial cell adhesion molecules and are potent inducers of human monocyte IL1b and IL-6 production (Retzlaff et al., 1994). GroEL from E. coli has also been tested for its
ability to induce the expression of various cytokines in HUVEC cells cultures. Incubation of
purified GroEL with these endothelial cells resulted in increased GM-CSF, IL-6, E-Selectin,
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ICAM-1 and VCAM-1 release in a dose-dependent fashion (Galdiero et al., 1997; Ranford et
al., 2000; Retzlaff et al., 1994). The induction of the latter three proteins is controlled by the
production of cytokines IL-1 and TNF-alpha (Ranford et al., 2000). Not surprisingly,
Mycobacterium and E. coli are not the only bacteria that produce GroEL proteins with
immunological activity. Cpn60 proteins from several bacteria have been reported to localize
to the bacterial cell surface, where they can serve as potential antigens. These include
proteins from Helicobacter, which play a role in preventing bacterial aggregation, from
Legionella, which increase host intracellular uptake, and Actinobacillus, which act as
adhesion molecules (Garduno et al., 1998; Ranford et al., 2000). Studies have shown a wide
variety of extra-chaperone functions for GroEL as well, including roles in cellular adherence
of Clostridium difficle, endocarditis in S. aureus, and the infection cycle in Chlamydia
trachomatis and Rhizobium leguminosarum (George et al., 2004; Hennequin et al., 2001;
Karunakaran et al., 2003; Qoronfleh et al., 1998). Interestingly, a study using Actinobacillus
actinomycetemcomitans Cpn60 with epithelial cells shows strongly induced
phosophorylation and activation of ERK1/2 which inhibits caspase 3 activity in UV-radiation
exposed cells, thereby avoiding apoptosis-induced cell death (Zhang et al., 2004).
Several studies have reported the use of GroEL comparisons to establish phylogenetic
relationships among the !-2 proteobacteria, and for bacterial identification during infection
(Haake et al., 1997; Lee et al., 2003; Paddock et al., 1997). Work with Rickettsial GroEL
has shown it to be up-regulated early during the infection cycle, where it may act to enhance
intracellular survival (Gaywee et al., 2002). Based on their investigation of factors in B.
bacilliformis lysates that induce proliferation in HUVEC cells cultures, Minnick et al. (2003)
proposed that GroEL is a mitogen, and as such may play a direct role in the production of the
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vasculoproliferative nodules seen during the verruga peruana stage of B. bacilliformis
infection (Minnick et al., 2003). Their conclusion was based on: 1) the identification of a
mitogen that is heat and trypsin sensitive; 2) a correlation between mitogenicity and the
levels of GroEL in B. bacilliformis lysates; and 3) the inhibition of mitogen activity in the
presence of anti-GroEL antibodies. Subsequent experiments by these authors involving
infection of HUVEC cells with GroEL-overproducing strains of B. bacilliformis showed a
correlation between high levels of GroEL and the acceleration of apoptosis, however. These
observations led to the proposal that intracellular B. bacilliformis GroEL functions as an
ortholog to eukaryotic hsp60 proteins, which are known to accelerate pro-caspase3 activation
by enhancing its vulnerability to upstream activator caspase. Since both cell proliferation
and the inhibition of apoptosis are believed to be involved in the induction of verruga
peruana, the finding that GroEL increases the rate of apoptosis would appear to compromise
its role in the angiogenic process. This issue remains unresolved.
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Chapter I – Search for virB operon homologues in selected Bartonella species
Introduction
Bartonella species have been assigned to the alpha-2 proteobacterium subgroup, a
category that also includes Brucella abortus, Sinorhizobium meliloti and Agrobacterium
tumefaciens. Although they are diverse in terms of their host range and growth conditions,
alpha-2 proteobacteria all interact directly with the cells of the organisms they infect. The
mechanism of interaction has been particularly well-characterized in the plant pathogen A.
tumefaciens (Chen et al., 2002; Christie, 1997; de Paz et al., 2005; Krall et al., 2002).
Direction interaction by A. tumefaciens with host cells results in the production of tumors
called Gall Tumors. The cellular proliferation leading to the formation of Gall Tumors is
induced by the expression of genes located on a segment of bacterial DNA, called the Ti
DNA, that is transferred to the host cells during the process of infection. Transfer is
mediated by the products of the virB operon, a set of 11 genes encoded on the A. tumefaciens
chromosome (Christie, 1997; Escudero et al., 1995; Loubens et al., 1997). The virB operon
of A. tumefaciens has been shown to code for a Type 4 Secretion System (TFSS), a complex
of proteins that uses ATP hydrolysis to promote the movement of the Ti DNA through the
VirB pilus and into the host cell (Baron et al., 2001; Baron et al., 1997; Berger et al., 1994;
Dang et al., 1997; Das et al., 1997; Finberg et al., 1995; Rashkova et al., 1997; Stephens,
Kathryn et al., 1995; Thorstenson et al., 1993).
In 2000, a set of genes was reported in Bartonella henselae that exhibits a high degree
of sequence similarity to those encoded by the A. tumefaciens virB operon (Padmalayam et
al., 2000a; Schmiederer et al., 2000). The B. henselae operon consists of 10 genes, eight of
which have homologues in the A. tumefaciens virB operon. Expression of B. henselae virB
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genes is induced following uptake of the bacterium by the host cell (Schmiederer et al.,
2001). The virB gene products play essential roles in the processes used by B. henselae to
colonize the host cell, including the rearrangement of the host cytoskeleton and the inhibition
of apoptosis (Batterman et al., 1995; Dehio et al., 1997; Kordick et al., 1995; Schmid et al.,
2004). To date, the virB operon has been identified in three Bartonella species (de Paz et al.,
2005; Padmalayam et al., 2000a; Seubert et al., 2003b; Woestyn et al., 2004).
The biphasic infection caused by B. bacilliformis, like the infections produced by
other members of the alpha-2 proteobacteria subgroup, involves direct interaction with the
cells of the host. During the initial phase, B. bacilliformis invades red blood cells,
successfully infecting up to 100% of erythrocytes (Benson et al., 1986; Dehio, 2001;
Schulein et al., 2002). The second phase, or verruga phase, is marked by the colonization of
epithelial and endothelial cells, which induces the vascular proliferation that is responsible
for the cutaneous and subcutaneous vascular lesions that are a hallmark of this phase (Dehio,
2001; Dehio, 1999; Dehio et al., 1997; Kirby, 2004; Verma et al., 2000). While genetically
similar to other Bartonella species, B. bacilliformis is unique among Bartonella species for
its relatively small genome (1.5 Mbp) and more severe clinical presentation. Its interactions
with host cells are also distinct: unlike that of B. henselae and B. quintana, induction of
vascular proliferation in B. bacilliformis can occur in an immunocompetent host (Battisti et
al., 1999; Krueger et al., 1995).
Given the role the virB operon plays in both A. tumefaciens and B. henselae
pathogenesis, we sought to determine whether a homologous operon is present in the genome
of B. bacilliformis and other Bartonella species. This study reports the identification of a
virB operon in B. quintana, the causative agent of trench fever, and in B. clarridgeiae, a
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species that, like B. henselae, has been associated with Cat Scratch Disease (CSD). In
contrast to the results obtained with these Bartonella species, our work with B. bacilliformis
produced no evidence of virB homologues. Based on our results, we propose that B.
bacilliformis, unlike other clinically significant Bartonella, does not make use of a virBencoded Type 4 Secretion System to invade cells and induce cellular proliferation.
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Materials and Methods
Bacterial Growth and Culture. The following Bartonella species were obtained from the
American Type Culture Collection (ATCC): B. henselae Houston-1, B. quintana subspecies
Fuller, B. clarridgeiae, and B. bacilliformis KC584. All Bartonella species were grown on
Brain Heart Infusion (BHI) agar supplemented with 10% sheep’s blood. Bartonella
henselae, B. quintana and B. clarridgeiae were incubated at 37°C, while B. bacilliformis was
incubated at 25°C for 5-7 days. Growth was monitored by visual inspection. Once confluent
colonies were visible, the Bartonella was harvested by the addition of 15 ml of sterile
Phosphate Buffered Saline (PBS), pH 7.4, and the plate was gently scraped using a cell
scraper (Fisher). The PBS-Bartonella mixture was removed by aspiration and placed in a
sterile 15 ml tube (Falcon). Bartonella to be used for genomic DNA extraction was then
centrifuged at 2000xg for 10 minutes at 4°C, and then the PBS was decanted. Unused
Bartonella was stored at -80°C in 50% PBS/50% glycerol until needed.
Genomic Isolation of Bartonella DNA. Harvested Bartonella were resuspended in 300 µL
of sterile PBS, pH 7.4. To this mixture, 30 µL of 10% Sodium dodecyl sulfate (SDS) and 3
µL of Proteinase K (10mg/ml) was added. The mixture was then incubated at 55°C for 2
hours while shaking at 600 rpm. The Bartonella DNA was subsequently extracted three
times with a 25:24:1 mixture of phenol:chloroform:isoamyl alcohol (Boehringer Mannheim).
After each extraction the phases were separated by centrifugation at 14,000xg at 4°C. The
DNA in the aqueous phase was precipitated with 1/10 volume of 3M sodium acetate (pH 4.8)
and 3 volumes of ice-cold 100% ethanol. This mixture was then incubated overnight at 80°C. The mixture was centrifuged at 14,000xg for 15 minutes at 4°C then decanted and
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allowed to air dry. The precipitated DNA was dissolved in the appropriate volume of TrisEDTA pH 8.0 (TE) buffer, containing RNase A (10mg/ml) and stored at 4°C until needed.
Design of Consensus Primers and virB Gene Sequencing via PCR. Sequences of A.
tumefaciens, B. henselae, and other members of the alpha-2 proteobacterium family were
compiled and placed into a Clustal alignment for each respective virB gene. From these
analyses, regions of similar sequence were identified and used to make PCR primers (Table
1.1). PCR products were purified on Qiagen columns according to the manufacturer’s
instructions and sequenced using capillary sequencing techniques (ABI). These products
were then analyzed using Vector NTI Sequence Analysis software (Invitrogen) for restriction
sites; open reading frames and the formation of any contiguous regions of DNA. The Vector
NTI software was then used to prepare new Bartonella-specific PCR primers which were
used in a low-stringency cycle of PCR. This process continued until entire open reading
frames were identified. All completed sequences were submitted to GenBank.
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Table 1.1 – Consensus and Bartonella-specific virB Operon Primers.
A. Consensus PCR primers were prepared by Clustal alignment of DNA sequences from
alpha-2-proteobacteria bacteria known to contain homologue virB operon genes. B.
Bartonella-specific primers were generated using Vector NTI (Invitrogen) software from
DNA sequence data garnered from the use of consensus primers on B. quintana and B.
clarridgeiae.
A. Consensus Primers
Locus
Primer Name
virB2-homologue
CVirB2Fwd
CVirB2Rvc
virB3-homologue
CVirB3Fwd
CVirB3Rvc
virB4-homologue
CVirB4Fwd
CVirB4Rvc
virB6-homologue
CVirB6Fwd
CVirB6Rvc
virB8-homologue
CVirB8Fwd
CVirB8Rvc
virB9-homologue
CVirB9Fwd
CVirB9Rvc
virB10-homologue
CVirB10Fwd
CVirB10Rvc
virB11-homologue
CVirB11Fwd
CVirB11Rvc

Primer Sequence (5’ – 3’)
GCTGTTGCGCGTGATATCGG
CGCCAAATACGATGGCAACG
AGCTTATGGACGACGATCCC
GTGCAGCCAAGGGGGATATG
GCACATCAGCCAGCATGTCG
AAAACGGCGCCCATCGATAA
TTAGTTTTCTGTTGCGTTTAACGGC
ATTGCCACCAATCGGACGAT
CCTTGGCTGTTGCGGTGGTT
CGTGACATCAAAACCAAGCG
GCACTCTTCATTGCTTGCAT
ATACAAAGCACGTCGTTGCC
TCAACGGGATGAAAACCGGA
AAGCGGGTGATGAGCGTCCT
GTGAACTTCCATCTGGAACC
ATCGATCACCAGATACAGCA

B. Bartonella-specific virB Primers
Locus
Primer Name
virB2-homologue
VirB2Fwd
VirB2Rvc
virB3-homologue
VirB3Fwd
VirB3Rvc
virB4-homologue
VirB4Fwd
VirB4Rvc
17kDa Antigen
17kdaFwd
17kdaRvc
virB6-homologue
VirB6Fwd
VirB6Rvc
15kDa Antigen
15kdaFwd
15kdaRvc
virB8-homologue
VirB8Fwd
VirB8Rvc
virB9-homologue
VirB9Fwd
VirB9Rvc

Primer Sequence (5’ – 3’)
ATGACAGAGACTATATCCAGAAATATT
TGATGAGCCCATTAATGTACTAACA
ATGAATGAAGATACTCTTTTTCTTG
TAATTGACATCTGTTCAGTTCCTTA
ATGTCAATTATGAAACGGGAGTCTT
TTGATTTTCTCTCCTTTGGTGAAAT
ATGGCTGCCTATATTTCACCAAAGG
AAGTCGGACATCAGAATTCCCAAGT
ATGAATACGACAGTGAGTGGGTTGTCT
AAATCGACCACGGCCTCTATCTCCA
ATGAAACGAAAAATAACTTTTTTTA
CTTTTCACGAGCGATTTCCGTATTT
ATGAAAAATTCTCTGATCAAAATACGG
TTTTATCACCTCTGGATCAGATCGAT
ATGATGAGATTTTCAAAAATAATCTTT
TCCTTCATGACCATTTCCTATGTTC
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Locus (con’t)
virB10-homologue
virB11-homologue

Primer Name
VirB10Fwd
VirB10Rvc
VirB11Fwd
VirB11Rvc

Primer Sequence (5’ – 3’)
ATGGTCATGAAGGATGAAATGGATGAA
TTTCAAAATCACCGCAGAATTTTTA
ATGAACAAAACCTGCATAAAT
TAAGCTCCCGACAACTAAATC

Design and Synthesis of virB probes for Phage Library Construction and Southern Blot
Analysis. Using Bartonella-specific sequence data, probes were prepared as follows for %
phage library construction and Southern blot analysis. A PCR amplification was carried out
using the PCR DIG Probe Synthesis kit (Roche) to produce digoxigenin (DIG)-labeled PCR
products. These products were analyzed on a 1% agarose gel to verify that they were of the
predicted size. Following verification, probes were denatured by heating at 95°C for 10
minutes and were then added to 45 ml of hybridization solution (Roche). The probes were
stored at -20°C until needed.
Southern Blot Analysis of the B. bacilliformis Genome.
Digestion of Bartonella Genomic DNA. Genomic DNA samples from B. quintana, B.
clarridgeiae and B. bacilliformis were probed using previously prepared virB gene-specific
DIG-labeled probes as follows (Southern, 1975). Briefly, previously purified genomic DNA
was incubated with EcoRI at 37°C for approximately 16 hours in an Eppendorf variable
shaker. To the digested genomic DNA, 10µL of 3M sodium acetate and 1ml of ice-cold
100% ethanol were added, and the samples were incubated for one hour at -80°C. The
precipitated DNA was then collected by centrifugation at 14,000xg for 20 minutes at room
temperature. The supernatant was decanted and the digested genomic DNA was dried at
room temperature. The digestion products were separated by 0.8% agarose gel
electrophoresis. The agarose gel was then soaked in 0.25N HCl for 10 minutes and
subsequently transferred to 0.5M NaOH and 1.5M NaCl for soaking twice (15 minutes per
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soak). An apparatus was then set up to allow the transfer of DNA from the agarose gel to a
nitrocellulose membrane that had been rinsed with deionized water. This transfer was
completed by placement in a reservoir containing of 20x Standard Saline Citrate (SSC)
overnight. The nitrocellulose membrane containing the DNA was rinsed in 5X SSC for five
minutes, then UV cross-linked (FisherBiotech) using “Optimal cross-link” settings with the
cross-linking step being repeated three times. Cross-linked membranes were stored in
airtight bags at -80°C until needed.
Hybridization and Development of Southern Blot Membranes. Prepared nitrocellulose
membranes were thawed at room temperature as needed, and pre-hybridized with DIG Easy
Hyb solution (Roche) at 42°C for two hours with rotation. The appropriate probe (Table 1.2)
was removed from storage at -20°C, thawed in a hybridization oven at 80°C for one hour and
then denatured at 99°C for 20 minutes before use. After decanting the DIG Easy Hyb
solution, the probe was added to the nitrocellulose membrane and the membrane was
hybridized at 42°C overnight with rotation. After incubation overnight, the probe solution
was removed and stored at -20°C while the membrane was washed twice with 2X SSC
containing 0.1% SDS for five minutes per wash at room temperature. The wash solution was
decanted and the membrane was washed twice with 2X SSC containing 0.1% SDS at 60°C.
This solution was decanted and the membrane was washed by incubating for two minutes
with constant shaking at room temperature in the Washing Buffer (Roche) supplemented
with 1X malic acid solution (Roche) containing 0.3% Tween-20 (Sigma). The Wash Buffer
was decanted and replaced with Blocking Buffer (Roche), consisting of Wash Buffer
supplemented with 1:10 Blocking Buffer concentrate for 30 minutes with constant shaking,
at room temperature. The Blocking Buffer was decanted, and 100 ml of anti-DIG antibodies
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(Roche) diluted 1:5000 in Blocking Buffer was added to membrane. The membrane was
incubated with the antibody mixture for one (1) hour, with shaking at room temperature. The
Anti-DIG antibody mixture was decanted and saved at -20°C for further use, and the
membrane was again washed twice in Washing Buffer for 15 minutes at room temperature.
Finally, the membrane was equilibrated in Detection Buffer (Roche), containing 0.1M TrisHCl, 0.1M NaCl, pH 9.5, for three minutes at room temperature. The Detection Buffer was
decanted and the membrane was developed using Nitro-blue tetrazolium chloride/5-bromo-4chloro-3’-indolyphosphate (NBT/BCIP; Roche) to visualize the banding pattern. After the
bands were clear, the membranes were washed with deionized H2O followed by TE buffer,
and allowed to air dry.
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Table 1.2 – DIG-Labeled Probes for Southern Blot Analysis.
The following table shows the DNA primer sequences for Southern Blot probes, designed
from B. bacilliformis, B. quintana and B. clarridgeiae DNA sequences as noted below.
Bartonella
Probe Target
Species
B.
18.5kDa
bacilliformis Antigen
B.
bacilliformisspecific
Control
B.
Internal
clarridgeiae Fragment of
virB4
B. quintana virA
Fragment
B. quintana virB3homologue
Fragment
B. quintana virB6homologue
Fragment
B. quintana virB8homologue
Fragment
B. quintana virB11homologue
Fragment

Primer
Name
SB18.5 Fwd
SB18.5 Rvc

Primer Sequence (5’ – 3’)

SBV4IntFwd
SBV4IntRvc

CTCTTCGTTTCACTGCTGTGGAATC
CCAGCTTGTGTTTTCAGGAATGCCAC

SBVirAFwd
SBVirARvc
SBVir3Fwd
SBVir3Rvc

CTTGCAGGGTGAATGTCTTGAG
CGTAAATCAATAAAGCCGGACA
AATGAAGATACTCTTTTTCTTGCC
TGACATCTGTTCAGTTCCTTATAA

SBVir6Fwd
SBVir6Rvc

TGCAAAATCAGAAACAGCGGAATCTA
TATAATCAAAAACATTTGCGCTAGCG

SBVir8Fwd
SBVir8Rvc

ATGAAAAATTCTCTGATCAAAA
TTTTATCACCTCTGGATCAGAT

SBVir11Fwd
SBVir11Rvc

TGTTTTAACAAAACTTGAACCCATC
TTCAATGGTGATAATACGCTCATTA

CTATGCCCTTAAGCAGTTAACAC
AATGCAGAGTATAGTTATGGG

Plaque hybridization of a B. bacilliformis Genomic DNA Library
Construction of a B. bacilliformis % Phage Library. A genomic DNA % phage library was
created by digesting B. bacilliformis DNA with TSP5091 (New England Biolab). Briefly,
purified B. bacilliformis genomic DNA was digested for 22 minutes with TSP5091 (1:1
diluted with Reaction buffer (10mM Bis-Tris-Propane HCl, 10mM MgCl2, 1mM
Dithiothreitol, pH 7.0)) at 65°C until the reaction was stopped by the addition of 25:24:1
mixture of phenol:chloroform:isoamyl alcohol (Boehringer Mannheim). The digested
genomic DNA was then extracted three times with phenol:chloroform:isoamyl alcohol
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(Boehringer Mannheim); after each extraction the phases were separated by centrifugation of
14,000xg at 4°C. The DNA in the aqueous phase was precipitated by the addition of 1/10
volume of 3M sodium acetate (pH 4.8) and three volumes of ice-cold 100% ethanol. This
mixture was then incubated overnight at -80°C. The mixture was centrifuged at 14,000xg for
15 minutes at 4°C, then decanted and allowed to air dry. The precipitated DNA was
dissolved in the appropriate volume of TE buffer containing RNase A (10mg/ml), and stored
at 4°C until needed. Digested genomic DNA was ligated into EcoRI-digested Lambda ZapII
arms (Stratagene) according to the manufacturer’s instructions and the reaction mixture was
incubated overnight at 4°C. The ligated genomic DNA library was then packaged into the %
phage using the Stratagene Gigapack II gold packaging kit per the manufacturer’s
instructions. Briefly, the ligated genomic DNA library was incubated with XL-1 Blue MRF’
cells at an MOI of 10:1 in the presence of the ExAssist phage at 37°C for 15 minutes. LuriaBertani (LB) Broth was added to the reaction mixture and allowed to incubate three hours at
37°C. The cells were then allowed to lyse by heating at 65°C. SOLR cells were added to
titer the excised plasmids and were subsequently grown on LB-ampicillin overnight at 37°C.
The packaged library products were incubated with XL-1 Blue MRF’ cells infected for 15
minutes and plated onto NZY agar plates, then incubated overnight at 37°C. SM buffer
(0.1M NaCl, 0.05M MgSO4, 0.001% (w/v) gelatin) was used to cover each plate. Following
overnight incubation at 4°C, the contents were pooled, chloroform was added to give a 5%
solution, and the sample was centrifuged at 5000xg for 10 minutes. After centrifugation, the
% phage library was divided into 1.5 ml aliquots. Samples were stored at -70°C for future
use.
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B. bacilliformis-Phage Library Analysis using Bartonella-specific virB probes. The %
phage library was screened for B. bacilliformis genomic DNA and specifically for the
presence of various genes of the virB operon. DIG- labeled probes were reacted against the
library contents as follows. Briefly, XL-1 MRF’ cells were incubated with 5-10µL of %
phage library for 15 minutes. This cell/phage mix was plated onto NZY plates and incubated
at 37°C overnight. The plates were transferred to plaque hybridization membranes (Perkin
Elmer) and washed with denaturation, neutralization and SSC solutions (Roche). The
membranes were UV cross-linked and pre-hybridized in EZ Hyb (Roche) solution at 42°C
for two hours. The membranes were probed overnight with previously prepared virB genespecific DIG-labeled probes. The membranes were washed and blocked in a 5% skim milk
solution overnight at 4°C. Goat anti-DIG alkaline phosphatase- (AP) labeled antibodies were
added and the membranes were incubated at room temperature. Then the membranes were
washed again, BCIP-NBT substrate was added, and the membranes were placed in the dark
for color development. Plaques that were positive were cored and placed into 1 ml of SM
buffer containing chloroform and stored at 4°C, until needed. SOLR cells were used to
excise the phagemids, which were then allowed to circularize. Plasmids were subsequently
isolated from the SOLR cells according to the manufacture’s instructions for plasmid
purification (Omega Bio-Tek). These plasmids were sequenced using T3/T7 primers for the
initial screening. The DNA sequences were entered into Vector NTI (Invitrogen) and
analyzed for open reading frames and the formation of contigs. BLAST searches were also
done to find homologous regions/genes.
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GenomeWalking Sequence Analysis. GenomeWalking was used with both B. quintana and
B. bacilliformis genomic DNA in order to fill in any sequence gaps. After preparation of
Bartonella genomic DNA, a GenomeWalking DNA library was prepared per the
manufacturers instructions (CloneTech) using the supplied EcoRV, DraI, PvuII and SspI
restriction enzymes. Briefly, Bartonella genomic DNA was digested at 37°C for two hours
in separate reaction mixtures for each restriction enzyme, then vortexed briefly and incubated
at 37°C overnight. The mixture was purified using phenol (Sigma) followed by
centrifugation at 14,000xg at room temperature to separate the aqueous layer. The top,
aqueous, layer was removed and chloroform (Sigma) was added followed by another
14,000xg centrifugation at room temperature. This aqueous layer was then removed and
incubated with 95% ethanol and 3M sodium acetate (pH4.5), followed by centrifugation at
14,000xg for 15 minutes at 4°C. The supernatant was decanted and 80% ethanol was added
followed by 14,000xg centrifugation for 10 minutes at room temperature. The supernatant
was again decanted and the digested DNA was dried, then dissolved in 20 µl of TE buffer, all
per manufacturer’s instructions (CloneTech). The GenomeWalk libraries were kept at 4°C
until needed. In order to screen the libraries for specific regions of unknown sequence,
previously sequenced virB regions were used to design GenomeWalk-specific virB primers
according to the manufacturer’s instructions. After the completion of the primary PCR
GenomeWalk cycle using Gene Specific Primer 1 was complete (Table 1.3), the products
were analyzed for expected base pair size using 1% agarose gel electrophoresis, and samples
corresponding to the predicted size were subjected to secondary PCR GenomeWalk PCR
cycles with the previously designed Gene Specific Primer 2. The secondary
GenomeWalking products were again analyzed using a 1% agarose gel and those of the
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predicted size were sequenced. The DNA sequences were entered into Vector NTI
(Invitrogen) and analyzed for open reading frames and the formation of contigs. BLAST
searches were also done to find homologous regions/genes.
Table 1.3 – Gene Specific Primers for GenomeWalk Analysis of B. bacilliformis.
GenomeWalker (Clonetech) primers which were used to scan the B. bacilliformis genome for
specific virB operon homologues.
Locus
virB4homologue
virB6homologue
virB8homologue
virB10homologue
virB11homologue

Primer Name
GWVirB4Fwd
GWVirB4Rvc
GWVirB6Fwd
GWVirB6Rvc
GWVirB8Fwd
GWVirB8Rvc
GWVirB10Fwd
GWVirB10Rvc
GWVirB11Fwd
GWVirB11Rvc

Primer Sequence 5’ – 3’
TGTCAATTATGAAACGGGAGTCTTTACCTG
GGTCATGTCATAACCAATGAATTGTGAGTC
ATGAATACGACAGTGAGTGGGTTGTC
CCACTATCGAGATAACGACAACAGGT
ATTCTCTGATCAAAATACGGAAATCGCTCG
GGATCGAGACCCAATGGGAAATATTTTCTT
ATGATCGCAGTACAATAAAAGACGGTC
GATACAAGAAGCGCAGATCCAATCCG
ACCTGCATAAATTGAGCAATGAAACTGTCG
TTGGACCAACAGAGGCTAAGCCTTGA
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Results
Isolation of the B. quintana virB Operon.
Since the original demonstration of a virB operon in B. henselae, there have been
reports of virB homologues in at least three other Bartonella species (Padmalayam et al.,
2000a). This raises the possibility that virB-encoded secretion systems are an integral part of
the Bartonella molecular repertoire.
In order to search for the virB operon in other Bartonella species, we designed
consensus primers for gene amplification using sequences from other !-2-proteobacteria,
such as A. tumefaciens, as a template. Initially, the virB4 gene was selected for
amplification, as it is the most conserved of the virB genes. Plaque hybridizations on a newly
created DraI-generated B. quintana phage library, prepared in our laboratory, were conducted
using a virB4 probe created from the B. henselae virB4 gene. This approach proved
unsuccessful, however, and the GenomeWalking protocol was subsequently employed using
newly prepared GenomeWalk-specific primers for the virB4 gene. This protocol gave a
single 1550 bp product from the B. quintana library. Another primer for the B. quintana
virB4 sequence (GSP2) was prepared using the B. quintana sequence obtained from the first
GenomeWalk and yielded a 2000 bp product from a second GenomeWalk. BLAST results
indicated that the gene product from this round of GenomeWalking corresponded to the
middle region of the B. henselae virB4 gene, as expected. Unfortunately, due to the A-T rich
nature of the B. quintana genome no further GenomeWalk primers could be designed which
gave definitive products.
Plaque hybridizations were also used to search for homologues to the virB9, virB10
and virB11 genes. Initially, a screening for virB11 using a B. henselae-derived probe gave
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rise to a plasmid, designated 2A2, that contained B. quintana sequences with partial
homology to B. henselae virB11. Further GenomeWalking using a combination of B.
henselae-based virB and T3/T7 primers to amplify 2A2 plasmid sequences revealed the
presence of virB9, virB10 and the remainder of the virB11. The remaining virB operon
genes from B. quintana were determined using overlapping PCR reactions based on the
sequences obtained from the above plaque hybridizations. The known sequence for the
17kDa antigen gene was used to design Bartonella-specific primers for both upstream and
downstream PCR products, which allowed for the sequencing of the virB2, virB3, virB4,
virB6, 15kDa antigen gene, virB8 and virB9 homologues to be completed. After each
sequencing round, the gene products were assembled into contigs and compared with known
virB operon sequences from other species to ensure no sequence gaps were remaining. The
sequence was verified with the preparation of B. quintana-specific virB primers and the
sequences were placed in GenBank (Accession Number: AY216720).
Sequencing of the virB operon gene homologues from B. clarridgeiae was
accomplished in much the same manner, with a higher level of success using Bartonellaspecific virB operon primers generated from previously sequenced virB genes from B.
henselae and B. quintana. Initially, the virB4 gene was sequenced using Bartonella-specific
consensus primers. This approach yielded a 1250-bp product, with BLAST analysis
suggesting that the gene product corresponded to the distal portion of the B. clarridgeiae
virB4 gene. Bartonella-specific primers based on BLAST homologies for sequencing the
virB2, virB3 and missing portions of the virB4 homologies were then used for PCR
amplification in order to give rise to the corresponding B. clarridgeiae virB genes.
Amplification of the virB11 and virB10 genes was accomplished using Bartonella-specific

43
consensus primers designed from information obtained after another round of PCR
amplifications. Finally, the remaining virB gene homologues, the 15kDa Antigen, VirB6,
VirB8 and VirB9, were sequenced using a series of Bartonella-specific consensus primers
initially designed from the published B. clarridgeiae 17kDa antigen sequence (Accession
number: AF195506). These primers were designed to target 1000-bp PCR products
extending from the 17kDa antigen homologue upstream to the middle of the virB10 gene.
These sequences were then verified by the preparation of B. clarridgeiae-specific primers to
produce PCR primers of 1000-1250 bp which were then subjected to BLAST and AlignX
(Invitrogen) analysis for accuracy.
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Physical Arrangement of the virB Operon in B. quintana and B. clarridgeiae.
Sequence analysis using Vector NTI (Invitrogen) was conducted in order to identify
the open reading frames of the newly determined virB homologues from B. quintana and B.
clarridgeiae, and to compare these open reading frames to those of B. henselae and B.
tribocorum (Figure 1.1; a-d). In all cases analyzed the gene organization within the virB
operon was identical. The physical arrangement indicates the first gene to be virB2, the
smallest gene at 312-366 bp, followed by virB3 and largest gene of the operon virB4, at
2361-3807 bp. The location of the 17kDa antigen and 15kDa antigens remains constant in all
Bartonella species examined, in every case flanking the ORF of the virB6 homologue.
Similarly, each Bartonella contains a virB9, virB10 and virB11 homologues downstream of
the virB8 homologue. One feature that is unique to the B. quintana virB operon is the
existence of two potential start codons for the virB8 gene, which would potentially generate
both a long-form and a short-form version of the gene product. The extra start codon is not
present in any of the other Bartonella species that have been characterized.
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a.

b.
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d.

Figure 1.1 – Physical Arrangement of the virB Operon in Bartonella Species.
Vector NTI (Invitrogen) was used to analyze the open reading frames of the sequenced virB
operon homologues in B. henselae (a), B. tribocorum (b), B. quintana (c) and B. clarridgeiae.
Arrows indicate the direction of the designated open reading frames.
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Homology analysis of the Bartonella species virB operons to the A. tumefaciens operon.
DNA-based alignments were created using AlignX (Invitrogen) to determine the
degree of sequence identity between various Bartonella and A. tumefaciens virB-homologues
(Table 1.4). Identity levels between the Bartonella species virB genes and those of A.
tumefaciens range from 34 to 50%. The highest identify values are seen in the Bartonella
virB4 genes, with an average of 49.5% identity to the A. tumefaciens homologue, while the
lowest identity, averaging 35%, is observed with the virB2 gene.
Table 1.4 – Comparison of virB Operon Sequences between A. tumefaciens and various
Bartonella-species.
Using the AlignX program (Invitrogen), DNA-based alignments were created to determine
the degree of sequence identity between various Bartonella and A. tumefaciens virBhomologues (Seubert et al., 2003a). Alignment was conducted on virB gene open reading
frames corresponding to each virB gene homologue (Padmalayam et al., 2000a; Schulein et
al., 2002).

virB2
virB3
virB4
17kDa
virB6
15kDa
virB8
virB9
virB10
virB11

B. henselae
34
44
50
N/A
40
N/A
38
41
44
48

% Identity to A. tumefaciens virB genes
B. quintana
B. clarridgeiae
B. tribocorum
34
35
36
44
43
41
49
49
49
N/A
N/A
N/A
41
40
38
N/A
N/A
N/A
42
42
43
41
40
41
43
42
42
43
44
47
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VirB operon gene homology among Bartonella species.
DNA-based alignments were created using the AlignX program (Invitrogen) to
determine the degree of sequence identity between virB operons of each of the Bartonella
species analyzed (Table 1.5). A comparison of virB genes from B. quintana and B.
tribocorum with the counterparts in B. henselae suggests a high level of homology.
Interestingly, B. clarridgeiae shows a lower overall level sequence identity for most of the
virB genes, with the exception of virB3, the 17kDa antigen and virB8.
Table 1.5 – Comparison of VirB Operon Sequences between Bartonella species.
Using the AlignX program (Invitrogen), DNA-based alignments were created to determine
the degree of sequence identity between B. henselae virB operon open reading frames and
those of other Bartonella species.
% Homology to B. henselae
B. quintana
B. clarridgeiae
B. tribocorum
virB2
84
42
79
virB3
87
82
84
virB4
91
54
86
17kDa
87
75
65*
virB6
90
63
79
15kDa
52
49
48
virB8
78
75
78
virB9
86
37
85
virB10
72
52
81
virB11
80
72
83
* the 17kDa antigen was renamed VirB5 (CA51480.1) in B. tribocorum
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Comparison of VirB protein sequences of B. quintana and B. clarridgeiae with those of
other alpha-2 proteobacteria.
An AlignX-based (Invitrogen) virB protein analysis was completed on B. quintana
(Table 1.6) and B. clarridgeiae (Table 1.7) VirB-homologue proteins in order to determine
their relative identity and similarity. As Table 1.6 shows, there is a wide variation in the
levels of amino acid sequence identity between the B. quintana VirB proteins and those of B.
henselae, ranging from the low of 13.5% for VirB9 to a high of 88.7% for VirB3. Overall,
the level of identity between B. quintana and B. henselae VirB sequences averages 70%.
When B. quintana virB protein sequences were compared to those of A. tumefaciens, the
level of identity was significantly less, ranging from 6.7% for the 15kDa antigen to 35% for
VirB4 and averaging approximately 21%. Analysis between B. quintana and B. clarridgeiae
indicates an average identity of 57%, with the lowest identity between the VirB11 protein at
10.5% and the highest identity with VirB8 at 92%. A similar degree of identity was observed
when VirB comparisons were made between B. quintana and S. meliloti, where the average
identity was 43%. In this case, the highest level of amino acid identity between the two
species was observed with VirB4 (60%) and the lowest was with VirB10 (33%). Table 1.7
shows a comparison of B. clarridgeiae VirB-homologue proteins with those of other alpha-2
proteobacteria. The overall variation between the VirB homologues of B. clarridgeiae to B.
henselae ranges from 11.7% (for VirB11) to 97% (for VirB6), while the overall average of
identity between the B. clarridgeiae and B. henselae virB operons is approximately 59%.
When the sequences of B. clarridgeiae and A. tumefaciens VirB proteins are compared, there
is an overall identity average of 16.6%, with the VirB10 homologues exhibiting the lowest
identity level (9.5%), and the VirB2 homologue exhibiting the highest identity level (27%).
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Interestingly, B. clarridgeiae and S. meliloti VirB operons show a lowest identity with
virB11 (11%), and the highest identity with the VirB8 (46%). Overall, the average identity
of these VirB operons averages approximately 57%. Finally, Table 1.8 shows the similarity
between the amino acid sequences of B. henselae, B. clarridgeiae, B. quintana and S. meliloti
with A. tumefaciens VirB operon proteins. Our results indicate that while overall S. meliloti
is most similar to A. tumefaciens, with 41% average similarity in analysis of VirB proteins;
the Bartonella VirB proteins have a 33.9% similarity with A. tumefaciens across the proteins
examined. Our data shows that B. henselae is, of the Bartonella species, most similar to A.
tumefaciens with 37%, B. quintana 36.1% and B. clarridgeiae the least similar at 28.8%
average similarity of VirB proteins. Given the protein identity and DNA sequence homology
above it is not surprising that these Bartonella species overall very similar to A. tumefaciens
(34%), while S. meliloti is 41.3% similar to A. tumefaciens. Among the Bartonella VirB
proteins examined, VirB4 shows the highest level of similarity between all species at 49%,
while the 15kDa antigen homologue shows the lowest similarity, without the inclusion of S.
meliloti, at 16%.
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Table 1.6 - Comparison of VirB Protein Sequences of B. quintana and B. henselae, B.
clarridgeiae, A. tumefaciens and Sinorhizobium meliloti.
Amino acid sequences of each of the above VirB homologues were compared to those of B.
quintana using the AlignX program (Invitrogen). Open Reading Frame (ORF) analysis
utilized Vector NTI (Invitrogen) and was verified by BLAST analysis.
B.
quintana
virB2
virB3
virB4
17kDa
virB6
15kDa
virB8
virB9
virB10
virB11

B.
henselae
80.4
88.7
88.7
68.3
87.9
56.8
78.6
13.5
54.8
81.5

% Identity to B. quintana
B.
A. tumefaciens
clarridgeiae
90.7
27.3
90.5
26.4
34.6
35.5
66.5
N/A
89.4
16.0
14.0
6.7
92.1
21.5
49.4
9.7
33.6
18.9
10.5
32.9

S. meliloti
38.5
36.8
59.6
N/A
28.3
N/A
49.8
50.5
33.2
50.0

Table 1.7 - Comparison of VirB Proteins of B. clarridgeiae and B. henselae, B. quintana, A.
tumefaciens and Sinorhizobium meliloti.
Amino acid sequences of each of the above VirB operon homologues were compared to
those of B. clarridgeiae using the AlignX program (Invitrogen). Open Reading Frame
(ORF) analysis utilized Vector NTI (Invitrogen) and was verified by BLAST analysis.
% Identity to B. clarridgeiae
B.
clarridgeiae
virB2
virB3
virB4
17kDa
virB6
15kDa
virB8
virB9
virB10
virB11

B.
henselae
89.7
85.4
35.6
87.2
96.9
8.7
72.4
61.3
39.9
11.7

B. quintana

A. tumefaciens

S. meliloti

90.7
90.5
34.6
66.5
89.4
14.0
92.1
49.4
33.6
10.5

27.3
26.9
16.5
N/A
17.3
9.6
19.8
12.5
9.5
10.1

38.9
34.9
22.8
N/A
29.9
N/A
45.9
33.0
18.8
11.3
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Table 1.8 - Comparison of VirB Protein Similarities of A. tumefaciens and B. henselae, B.
clarridgeiae, B. quintana and Sinorhizobium meliloti.
Amino acid sequences of each of the above VirB operon homologues were compared for
similarity to those of A. tumefaciens using the AlignX program (Invitrogen). Open Reading
Frame (ORF) analysis utilized Vector NTI (Invitrogen) and was verified by BLAST analysis.

A. tumefaciens
virB2
virB3
virB4
17kDa
virB6
15kDa
virB8
virB9
virB10
virB11

B. henselae
40.5
41.7
56.2
N/A
34.3
13.1
36.6
22.2
37.7
50.4

% Similarity to A. tumefaciens
B. clarridgeiae
B. quintana
38.8
40.5
43.5
43.6
29.3
52.8
N/A
N/A
34.3
32.4
17.3
18.1
37.0
40.1
21.0
20.3
16.6
30.0
21.3
47.8

S. meliloti
43.0
39.1
57.3
N/A
37.7
N/A
40.5
20.5
41.3
50.7
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Search for a virB Operon in the B. bacilliformis genome.
Both a GenomeWalk and a % Phage Library were prepared from isolated B.
bacilliformis genomic DNA using the procedures that had successfully identified the virB
genes in B. quintana and B. clarridgeiae. Initially, the GenomeWalk library was screened
using PCR primers prepared from consensus sequences derived from B. henselae, B.
quintana and B. clarridgeiae genes in order to ensure the most Bartonella-specific
GenomeWalking primers possible. These GenomeWalk reactions did not yield any virBspecific amplified products. In those cases where PCR products were observed, subsequent
sequence analysis revealed partial homology to genes that are unrelated to the virB operon
(Table 1.9). Further screening to verify the presence or absence of the virB operon in B.
bacilliformis was conducted by carrying out a series of plaque hybridizations with the B.
bacilliformis % Phage Library. While the probes used were successful in screening both the
B. quintana and B. clarridgeiae % phage libraries, once again no virB-specific cloned product
was identified.
Table 1.9 – Putative products identified from probes of the B. bacilliformis genome by virB
gene-specific probes.
The B. bacilliformis genome was probed using Bartonella-based virB-specific PCR primers.
The sequence data obtained were then added to a Vector NTI (Invitrogen) database and
BLAST analysis was used to identify homologues for each gene sequence. The product of
the gene exhibiting the highest homology is given.
Probe
virA
virB2
virB3
virB4
17kDa
virB6
15kDa
virB8

Putative Product
Methyltransferase, SocE
Cytosolic Protein
Lysostaphin
alanyl TRNA synthetase
Possible Flagellar
Structural Genes
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Southern hybridization of virB-specific probes to B. bacilliformis DNA.
The inability to recover a virB operon homologue from B. bacilliformis DNA could
be due to the lack of this operon in this species. Alternatively, all or part of the virB operon
sequences could be present, but these sequences might be organized in a way that precludes
their identification. To address this possibility, primers used in the PCR reaction were
labeled with DIG and used as probes for Southern hybridization against enzymatically
digested DNA from B. quintana, B. clarridgeiae, and B. bacilliformis. Probing with the
sequences from the 18.5 kDa antigen and virA, two genes known to be in B. bacilliformis, B.
quintana, and B. clarridgeiae, clearly shows the presence of a single strong banding pattern,
indicating the presence of those genes in the genomic DNA of each selected Bartonella
species (Figure 1.2). Screening of B. quintana and B. clarridgeiae DNA with probes derived
from virB homologues also reveals hybridizing fragments, including characteristic banding
patterns for homologues of virB4 and virB6, based on expected gene product sizes, and
multiple banding patterns with the screening of virB3, virB9 and virB11 derived probes. In
no case, however, was positive hybridization observed with B. bacilliformis DNA (Table
1.9). From these data we conclude either that the genome of B. bacilliformis lacks an intact
virB operon, or that any B. bacilliformis virB homologues present in the genome are so
distinct from those of other Bartonella species that they do not cross-hybridize under any of
the conditions tested.
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Southern Blot Analysis in Search of a virB Operon in B. bacilliformis.
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Figure 1.2 – Hybridization of virB DNA probes to Bartonella Genomic DNA.
Southern blot analysis was carried out on EcoRI-digested Bartonella genomic DNA probed
with DIG-labeled DNA probes from various virB genes. Each membrane lane is as follows:
1) DNA Marker, 2) B. bacilliformis, 3) B. quintana and 4) B. clarridgeiae digested DNA.
Panel A, the derivation of the DNA probes is indicated at the bottom of each gel.
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Table 1.9 – Hybridization of virB Operon Fragments to Bartonella Genomic DNA
Southern blot analysis was conducted using probes from the designated Bartonella species
after digestion of genomic DNA digestion by EcoRI, as indicated in Figure 1.2.
Probe

Specificity

B. quintana

B. clarridgeiae

B. bacilliformis

18.5kDa
B.
Negative
Antigen (B. bacilliformis
bacilliformis
Ctrl)

Negative

Present

virA

B. quintana Positive

Positive

Negative

virB3

B. quintana Multiple
Fragments

Positive

Negative

virB4
Internal
Fragment

B.
Positive
clarridgeiae

Positive

Negative

virB6

B. quintana Positive

Positive

Negative

virB9

B. quintana Multiple
Fragments

Positive

Negative

virB11

B. quintana Multiple
Fragments

Multiple Fragments Multiple Fragments
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Discussion
In this study, we attempted to isolate the virB operon from three different Bartonella
species using a variety of methods. We report here the successful isolation and
characterization of the operon from B. quintana and B. clarridgeiae, two of the three species
we analyzed.
The virB operon was initially identified in A. tumefaciens, where it codes for a TFSS
that allows the transfer of the Ti DNA from the bacterium into the host cells, where it causes
the formation of gall tumors in infected plants (Chen et al., 2002; Escudero et al., 1995;
Loubens et al., 1997). The A. tumefaciens virB operon is composed of 11 genes that are
under the control of a virBox regulatory element located upstream of the operon (Berger et
al., 1994; Christie, 1997). VirB operon homologues have been identified in two Bartonella
species, B. henselae and B. tribocorum (Maurin et al., 1997; Padmalayam et al., 2000a;
Schulein et al., 2002). Functions ascribed to the virB operon of B. henselae and B.
tribocorum include bacterial uptake, host cytoskeletal rearrangement and inhibition of
apoptosis (de Paz et al., 2005; Dehio, 1999; Schmid et al., 2004; Schulein et al., 2005;
Seubert et al., 2003a). In addition, the 17kDa antigen, the fourth gene in the Bartonella virB
operons, produces a protein that shows high antigenicity and is reactive with CSD-positive
host sera (Padmalayam et al., 2000a; Sweger et al., 2000). Despite the information that has
been obtained about this operon, there has not yet been convincing evidence presented for a
direct role for virB gene products in virulence.
Motif analysis was conducted on each B. quintana and B. clarridgeiae VirB
homologue in order to determine the similarity of these genes to those of other bacteria, and
to correlate predicted protein structure with possible functions (Soni, personal
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communication). Due to their high homology analysis for both of these Bartonella species is
given below.
VirB2: The virB2 gene was originally identified in A. tumefaciens, and has now been found
in several Bartonella species, including B. henselae and B. tribocorum. The virB2 genes
from all three of these bacteria show high homology to the E. coli traA gene, a 12.3-kDa
protein. TraA contains an N-terminal cleaved signal sequence that is responsible for the
export of the gene product to the inner membrane where it aggregates as part of the F-pilin
subunit. F-pilin is using by E. coli during conjugation and is polymerized at the cell surface
to form the F-pilus (Harris et al., 1999; Paiva et al., 1992). Though it also contains a signal
sequence, the VirB2 homologue from B. quintana exhibits less homology than the other
Bartonella species to the E. coli traA gene product, and instead shows 36.8% amino acid
identity to the type IV secretion protein of S. meliloti. The B. clarridgeiae VirB homologue
shows a 38.9% degree of identity to the S. meliloti secretion protein.
VirB3: The role of the VirB3 in bacteria has not yet been fully determined. It is known that
the A. tumefaciens VirB3 shows homology to the E. coli traL protein, which is required for
assembly of the F-pilus (Hapfelmeier et al., 2000; Paiva et al., 1992). Studies with B.
henselae suggest that VirB3 interacts with the 15kDa antigen and VirB9 homologues to
stabilize the periplasmic proteins which support the TFSS (Shamaei-Tousi et al., 2004). It is
likely that the virB3 of gene products of both Bartonella species examined here function
similarly due to their high level of sequence identity (85.4% and 90.5% for B. quintana and
B. clarridgeaie, respectively) to the corresponding B. henselae protein.
VirB4: The largest open reading frame encoded by the virB operon, the virB4 gene codes for
a protein of undetermined function. Although the VirB4 protein produced by B. quintana, B.
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clarridgeiae and other Bartonella species is predicted to the highly hydrophilic in our
laboratory suggests the B. henselae VirB4 protein is not immunoreactive with human sera
from Bartonella-infected patients (Soni, personal communication). All of the Bartonella
VirB4 proteins contain a NTP binding domain, but binding to NTPs has not yet been
demonstrated.
17kDa Antigen: The 17kDa Antigen is a highly immunogenic protein originally identified
by its reactivity with human anti-sera from B. henselae-infected patients (Sweger et al.,
2000). In fact, it was the characterization of the 17kDa antigen gene and the surrounding
region that initially led to the discovery of the B. henselae virB operon (Padmalayam et al.,
2000a). To date, no A. tumefaciens protein homologous to the 17kDa Antigen has been
reported, although this protein is highly conserved among most of the Bartonella species.
Instead, A. tumefaciens contains a distinct gene upstream of virB4, termed virB5, that does
not have a counterpart in Bartonella species. While the function of this gene has not been
determined, the virB5 gene product is known to interact with VirB8 and VirB10 in A.
tumefaciens (Yuan et al., 2005). Studies with B. henselae show that the expression of the
17kDa Antigen is triggered by a yet to be determined host cell signal (Schmiederer et al.,
2001). Analysis of the open reading frame suggest that the 17kDa Antigen has an N-terminal
cleavage signal and a high antigenic index (Jameson et al., 1988), a finding that correlates
well with its immunoreactivity to human anti-sera from infected patients.
VirB6: The role of VirB6 in A. tumefaciens has yet to be determined, but it is predicted to
have six transmembrane domains and may form several complexes with other virB proteins.
The hydrophobicity plots of the B. quintana and B. clarridgeiae virB6 gene products show
them to be hydrophobic and to have a predicted inner membrane location.
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15kDa Antigen: As with the other Bartonella species that contain this gene, the B. quintana
and B. clarridgeiae 15 kDa antigen genes do not have a counterpart in A. tumefaciens.

In A.

tumefaciens, the product of virB7, the gene located at this position, functions as a
ribonucleotide reductase, converting ribonucleotides into their corresponding
deoxyribonucleotides. Instead the B. quintana and the B. clarridgeiae 15kDa antigens show
a low protein sequence identity to the 15kDa antigen of B. henselae of 8.7% and 14.0%,
respectively. The two proteins appear to be truncated versions of the B. henselae homologue,
however. When compared to the 489-bp B. henselae 15kDa antigen, the B. quintana open
reading frame for this protein contains only 312 bp while the B. clarridgeiae 15kDa antigen
is encoded by 315 bp. This truncation affects the N-terminal portion of both examined
Bartonella species, with the B. henselae 15kDa antigen open reading frame containing 177
bp, corresponding to approximately 59 amino acids, that neither the B. quintana nor the B.
clarridgeiae 15kDa antigens possess.
VirB8, VirB9 and VirB10: Previous work with A. tumefaciens suggests that the virB8, virB9
and virB10-encoded proteins are able to interact with one another to form a transport pore
complex (Das et al., 1997; Finberg et al., 1995; Krall et al., 2002). These studies also
suggest that this three-protein interaction is required for DNA transfer and is inner membrane
bound. Studies with B. henselae suggest that the interaction of these virB gene homologues
are similar to those in A. tumefaciens. Analysis of VirB9 interactions suggests that it binds to
the 15kDa antigen in the periplasm and may provide a periplasmic anchor of the virB2encoded pilus. Further analysis has shown that VirB8 and VirB10 interact in the inner
membrane, aided by the ATPase activity of VirB11, and that this complex acts in an
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anchoring capacity for the TFSS formed by the virB gene products (Shamaei-Tousi et al.,
2004).
VirB11: Studies with A. tumefaciens virB11 reveal that it functions as an ATPase
(Sagulenko et al., 2001; Stephens, KM et al., 1995; Stephens, Kathryn et al., 1995). This
ATPase activity is due to the presence of a NTP binding site and the localization of the
virB11 protein in the membrane is directly tied to its ATPase activity. Moreover, work has
suggested that the virB11 gene product is required for pilus formation and the export of Ti
DNA substrate in A. tumefaciens (Sagulenko et al., 2001). In Bartonella, the VirB11
homologue is known to interact with VirB8 and VirB10 in the inner membrane and may
form a pore for the movement of various factors through the inner membrane and out the
virB2-encoded pilus. This pore-forming potential is augmented by the ATPase activity of
VirB11 which may provide energy for factor movement through the putative virB-encoded
TFSS (Shamaei-Tousi et al., 2004).
The DNA sequence level-homology between A. tumefaciens and Bartonella suggests
that the role of the virB operon in Bartonella may be similar to that of A. tumefaciens, or at
least that the structures are similar. The individual virB genes also show an almost identical
pattern of physical arrangement among all of the Bartonella species studied. Only B.
quintana shows a slight differentiation with the inclusion of a long-form virB8 homologue
which shows multiple start sites, possibly indicating the production of slightly differing
proteins. The long-form virB8 contains 702 bp, coding for approximately 234 amino acids,
while the short-form virB8 contains only 610 bp, resulting in a 203 amino acid protein. DNA
sequence analysis of these different virB8 forms indicates the long-form contains 96 bp
upstream of the short-form start codon, encoding for 32 amino acids. Collectively, the first
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seven applicable virB operon genes of Bartonella show an average 41% DNA sequence
identity to those of A. tumefaciens. Examination of the extent of homology among all 10
virB homologue genes reveals that a close homology between the B. quintana and B.
henselae operons (80.7%) with a slightly lesser degree of homology between those of B.
quintana and B. tribocorum (76.7%). Studies were conducted to examine the extent of
amino acid identity between virB proteins from A. tumefaciens and their counterparts in B.
quintana and B. clarridgeiae. B. quintana had the highest identity (21%) while B.
clarridgeiae is slightly lower at 16.6%. Protein similarity between the Bartonella VirB
proteins and A. tumefaciens indicates a lower level of similarity between the two organisms.
Our data shows an average 34% similarity between A. tumefaciens VirB proteins and
Bartonella species examined with B. henselae having the highest similarity (37%) and B.
clarridgeiae the lowest (28.8%). While this similarity may be low as compared to S. meliloti
(41.3%), it is important to point out that the role of the VirB proteins in Bartonella has not
yet been fully elucidated and may be functionally different from A. tumefaciens.
Interestingly, motif and cellular localization analyses of the virB homologues found in B.
quintana and B. clarridgeiae reveal similarities to their A. tumefaciens counterparts,
providing further evidence for the structural similarities between the Agrobacterium and
Bartonella virB gene products while allowing them to provide differing functions.
Following the successful sequencing of the virB operon from both B. quintana and B.
clarridgeiae, we attempted to isolate the virB operon from B. bacilliformis. While little
research has been completed regarding the virulence factors produced and secreted by B.
bacilliformis, this bacterium has been shown to use a variety of gene products to afford itself
invasion into host cells. Although the mechanics of invasion by B. bacilliformis into RBCs is
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not yet elucidated, it is known that IalA and IalB are involved in the process, as is Deformin,
the bacterially encoded protein that is able to produce invaginations into RBC membranes
(Coleman et al., 2001; Hendrix et al., 2003; Mitchell et al., 1995; Xu et al., 1995). Even less
is known about the process by which B. bacilliformis invades host tissues, such as endothelial
and epithelial cells, or the gene products that are involved. Attempts to correlate virulence
with virB operon gene products have been singularly unsuccessful. In fact, B. bacilliformis,
arguably the most virulent of all known Bartonella species, is the only Bartonella species
tested to date that does not react with antisera directed against the highly immunogenic
17kDa Antigen of B. henselae that is encoded within the virB operon. DNA sequencing
studies completed during screening of various Bartonella species had previously suggested
that the 17kDa antigen was not found in the B. bacilliformis genome, even with the use of
multiple PCR primer probes (Sweger et al., 2000).
The attempted sequencing of a virB operon from B. bacilliformis was initiated using
Bartonella specific virB primers designed from the previously determined Bartonella virB
operon homologue gene sequences. Sequence analysis of the PCR products found using
these primers (Table 1.7) revealed similarities to several genes, including those coding for
SocE, Lysostaphin, and some putative flagellar proteins, but no VirB homologues were
identified. The virB-specific primers were subsequently labeled with DIG and used as
probes for screening several Southern Blots prepared using enzymatically digested DNA
from B. quintana, B. clarridgeiae, and B. bacilliformis. The results (summarized in Table
1.8) reveal a strong banding pattern with probes against two genes, the 18.5kDa antigen gene
and virA, that are known to be present in all three Bartonella species. The use of virBspecific probes reveals the presence of all other virB homologues in DNA from B. quintana
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and B. clarridgeiae, including the expected banding pattern, based on gene size, for
sequences corresponding to virB4 and virB6 and multiple banding patterns with screening
involving virB3, virB9 and virB11 sequences. The presence of multiple bands in the
Southern blot screenings could be due to incomplete hybridization of the probes to the
digested DNA targets or the presence of multiple copies of these genes in their respective
Bartonella genomes, and could be reflective of the overall genetic similarity among these
three Bartonella species. When the same DIG-based probes were used to screen Southern
blots containing B. bacilliformis DNA, no significant banding patterns were observed. The
only probe to give a positive hybridization result was a B. quintana-specific virB11 sequence,
which showed the presence of multiple bands. This result may be due to the presence of
sequences within the B. bacilliformis genome that are similar enough to the virB11 probe to
produce a limited level of hybridization. While these sequences have yet to be determined, it
is unlikely that they represent a complete virB11 gene.
In January 2007 the genome of B. bacilliformis KC583 was released (GenBank
Accession CP000524.1). Like the results of the studies presented here with B. bacilliformis
KC584, sequence analysis of the KC583 strain did not reveal the presence of a virB operon.
While our studies were with a different strain, it is reasonable to surmise that B. bacilliformis
KC584 also lacks the virB operon. Detailed analysis of accession CP000524.1 shows that
not only is B. bacilliformis KC583 lacking the virB operon but also the tra and bep operons
found in several other Bartonella species that are involved in apoptosis and virulence,
respectively. While the role of the tra operon has not been studied in Bartonella, studies
with E. coli indicate that the tra operon codes for a TFSS that is required for some
Escherichia species DNA conjugation (Wu et al., 1987). Previous work with B. henselae
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and B. quintana has shown that bepA plays a role in the vascular cell anti-apoptotic effect
seen during infection by these Bartonella species, and is able to prevent apoptosis by
cytotoxic T cells as well (Schmid et al., 2006).
Collectively, these data suggest that the virB operon is not responsible for B.
bacilliformis-induced formation of verruga peruana in Carrion’s Disease. We have
demonstrated that B. quintana and B. clarridgeiae along with several other Bartonella
species do contain a virB operon homologue. However, our search for a corresponding
operon in B. bacilliformis was negative. Our results, combined with the recently published
sequence for B. bacilliformis KC583 and previous studies of the 17kDa antigen, suggest that
B. bacilliformis does not contain a virB operon and, further, that VirB homologues are not
involved in the B. bacilliformis-induced formation of verruga peruana in Carrion’s Disease
(Sweger et al., 2000). There is some anecdotal evidence suggesting that Bartonella species
that do contain the virB operon tend to become less virulent after multiple passages, and
investigators have speculated that this decrease in virulence might be connected to the loss of
VirB proteins on the bacterial surface (Padmalayam, personal communication). However,
this is clearly not the case for B. bacilliformis. The virulence and angiogenic properties of B.
bacilliformis must be the result of other factor(s).

67

Chapter II – Analysis of HMEC-1 Gene Expression during B. bacilliformis Infection
Introduction
Bartonella bacilliformis, the causative agent of Carrion’s Disease, produces
proliferative angiogenic lesions in human hosts during the later phase of infection. These
lesions, which may be due to the infiltration of B. bacilliformis into both cutaneous and
subcutaneous epithelial tissues, show histopathology similar to those of Kaposi’s Sarcoma
(KS) (Garcia et al., 1990; Nayler et al., 1999; Ramirez et al., 1996; Ramirez Ramirez et al.,
1996).
Kaposi’s Sarcoma of the AIDS-associated variety presents itself on the head, neck
and trunk of the host after co-infection with HIV and the normally benign KS-associated
herpesvirus (KSHV) or Human Herpes Virus 8 (HHV-8). In immunocompromised patients,
it has been established that HIV-1 exacerbates HHV-8 pathogenesis via immunosupression,
by the alteration of the localized tissue microenvironment and by direct interaction of viral
proteins with host tissues (Barillari et al., 1999; Dourmishev et al., 2003; Sinkovics, 1991).
While both viruses (HIV and HHV-8) are sexually transmitted, there is evidence to support
an evolutionary link between HHV-8 and humans, as HHV-8 infection is often suppressed by
immunocompetent persons.
The similarities in histopathology seen with B. bacilliformis infection and HHV-8
infection include the involvement at the site of the lesion of several cell types, including
epithelial, endothelial and infiltrating inflammatory cells. Often “spindle” cells are involved.
Spindle cells express both endothelial and macrophage markers but their origin remains
undefined. During both B. bacilliformis and HHV-8 infection, localized aberrant
neoangiogenesis is seen, with the extent of neoangiogenesis being greater with Carrion’s

68
disease than with HHV-8 infection. During HHV-8 infection, elevated levels of many
cytokines, including bFGF, Interleukin-1 (IL-1), IL-6, IL-8, platelet-derived growth factor
(PDGF), tumor necrosis factor (TNF), gamma interferon (INF-#), vascular endothelial
growth factor (VEGF) and the transcription factor HIF1 (Hypoxia-inducible Factor-1), have
been reported (Catrina et al., 2006; Sinkovics, 1991; Sodhi et al., 2000). In HHV-8 lesions,
these cytokines are produced by infiltrating spindle cells. This is believed to allow for
continued growth and expansion of the lesion, as these cytokines are proangiogenic and
necessary for lesion viability (Fiorelli et al., 1995; Poole et al., 2002; Yang et al., 2000).
Interesting, while micro-environmental cytokine levels increase, there does not appear to be a
corresponding increase in cytokine levels in the host serum, and a correlation between HHV8 activity and serum cytokine levels has not been successfully established (Dourmishev et
al., 2003).
While the cells infected with HHV-8 have been found to express a wide variety of
markers, immunohistochemistry studies have shown that the presence of LANA-1 (latencyassociated nuclear antigen) marker cells increases during KS lesion progression; this has
been seen in multiple KSHV infected cell types (Dourmishev et al., 2003; Poole et al., 2002).
Studies of the histopathology of HIV-1 infected patients implicate the HIV- Tat protein as
inducing the KS-like lesions when over expressed in a bFGF rich environment (Mallery et
al., 2003). Ex vivo it has been demonstrated that extracellular Tat stimulates monocytederived macrophages to secrete IL-8 and Gro!, both of which are known proangiogenic
cytokines for endothelial cells (Poole et al., 2002; Samaniego et al., 1998). HIV-1 Tat has
also been shown to sustain growth of KS lesions in AIDS-associated KS by direct interaction
with host anti-apoptotic genes and activation of Akt kinase activity (Deregibus et al., 2002).

69
Tat functions are mediated by direct interaction with VEGF receptor 2 (VEGFR2) and
insulin growth hormone (IGF) receptor 1 (Catrina et al., 2005). Tat is also able to bind to
several host integrins which activate angiogenic and proliferative cascades (Dourmishev et
al., 2003; Poole et al., 2002).
To date, research into the interaction of B. bacilliformis with host cells is limited by
the growth requirements of the bacterium. Garcia et al. (1990) have shown that B.
bacilliformis is able to induce proliferation when live bacteria are co-cultured with
endothelial cells. Concurrent with proliferation induction, there is an increase in host tissue
plasminogen antigen (t-PA) production. Further studies by this group implicated a 12-14
kDa protein produced by B. bacilliformis in endothelial cell proliferation (Garcia et al., 1990;
Garcia et al., 1992). Studies have also shown that the infection of endothelial cells by B.
bacilliformis decreases cellular mobility by interfering with the host’s ability to form new
actin-based tubules while increasing cytoskeletal rearrangement (Verma et al., 2001).
Cerimele et al. (2003) have shown that proteins produced by B. bacilliformis interact with
both the VEGF receptor 1 and VEGF receptor 2 and that this results in the production of
angiopoietin-2 by epithelial cells. By using co-cultures of epithelial and endothelial cells, the
authors demonstrated a cell-signaling link between these cell types as the endothelial cells
responded to the angiopoietin-2 produced by the epithelial cells (Cerimele et al., 2003).
Finally, in a series of experiments, Minnick et al. (2003) implicated B. bacilliformis GroEL
as a mitogen acting directly on host endothelial cells. A mechanism for this interaction has
yet to be established.
In this study, we report the global gene expression analysis of B.
bacilliformis/HMEC-1 utilizing microarray technology. HMEC-1 cells were infected with B.
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bacilliformis and total RNA was extracted after six and thirty-six hours post-infection. The
RNA was hybridized to Affymetrix HG-U133 gene chips to evaluate the host transcriptional
response to infection. In order to place these responses into context, the information was
further analyzed against published HHV-8 infected endothelial cell microarray data (Wang,
2004).
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Materials and Methods
Bacterial Growth and Culture. B. bacilliformis KC584 was obtained from the ATCC and
only passages 2-6 were used. B. bacilliformis was grown on BHI agar supplemented with
10% sheep’s blood at 25°C for 5-7 days. Growth was monitored by visual inspection; once
confluent colonies were observed the bacteria were harvested by the addition of 15 ml of
sterile PBS, pH 7.4, and the plate was gently scraped using a cell scraper (Fisher). The PBSB. bacilliformis mixture was removed by aspiration and added to a sterile 15 ml tube
(Falcon). Unused B. bacilliformis was placed in a 50% PBS/50% glycerol mixture and stored
at -80C until needed.
Human Cell Growth and Culture. HMEC-1 cells were obtained as a generous gift from
Dr. Thomas Lawley of Emory University and the Centers for Disease Control and Prevention
(Ades et al., 1992). HMEC-1 cells from passages 19-27 were grown in a 15 ml mixture of
50% M199 (Cambrex) supplemented with 15% FBS, 2% penicillin-streptomycin and 50%
EGM-2 (Cambrex). This medium was changed every 2-3 days until 70-80% confluence was
reached. After they became confluent, the cells were released from the flask by decanting
the growth media and adding 15mL of CellStripper (Cellgro). The cells were allowed to
incubate at room temperature for 10 minutes to facilitate cell release. The cells were then
gently scraped with a CellScraper (Sarstedt). The cell mixture was aspirated into a 15 ml
tube (Falcon) and centrifuged at 700xg for 10 minutes at room temperature. The liquid was
decanted and the pellet was resuspended in 1mL of sterile PBS, pH 7.4. Cells not intended
for use immediately were resuspended in DMSO Cryoprotectant (Cellgro), stored at -80oC
overnight, and subsequently moved to liquid nitrogen for long term storage.
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Infection of HMEC-1 with Live B. bacilliformis. HMEC-1 were grown in T150 flasks
containing 30 ml of a mixture of 50% M199 supplemented with 15% FBS, 2% penicillinstreptomycin) and 50% EGM-2 media. Cells were incubated at 37oC in 5% CO2 and
saturated humidity. The cells were grown to 90% confluence, as verified by visual
inspection. The medium was aspirated and replaced with 30 ml of M199 with 5% FBS, and
the HMEC-1 were allowed to incubate for 24 hours at 37°C and 5% CO2 in saturated
humidity. A single flask of HMEC-1 was then counted to give an approximation of the
growth in the remaining flasks. Live B. bacilliformis, at an MOI of 100:1 in 100 µL, was
added to each experimental flask, while 100 µL of sterile PBS, pH 7.4, was added to each
control flask. At the appropriate time points (6 and 36 hours post-infection), the media were
aspirated and the HMEC-1 cells were detached from the flasks, as described above. The
cells were then centrifuged at 700xg for 10 minutes at 4oC. The cells were immediately
processed for total RNA.
Preparation of HMEC-1 Total RNA. Extraction of total RNA from HMEC-1 cells was
accomplished using the Qiagen RNeasy column (Qiagen). Briefly, the HMEC-1 were
harvested as stated previously, but the pellet was resuspended by flicking the tube after
adding 600 µL of RTL buffer with "-mercaptoethanol. The lysate was pipetted into a
QIAShredder spin column (Qiagen) for homogenization, and centrifuged at 14,000xg for 2
minutes. To the spin column, 700 µL of 70% ethanol was added, and the sample was mixed
well with a pipette. Into an RNeasy spin column, 700 µL of the lysate-ethanol mixture was
added and the column was centrifuged at 14,000xg for 24 seconds. The procedure was
repeated until the entire mixture had been processed through the spin column, while the flowthrough was discarded. Into the spin column, 700 µL of RW1 buffer was added, the spin
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column was again centrifuged at 14,000xg for 24 seconds, and the flow-through was again
discarded. Next, two rounds of 500 µL of RPE buffer was added to the spin column and
centrifuged at 14,000xg for 24 seconds for the first round, and 2 minutes for the second
round of centrifugation. Finally, 30 µL of RNase-free water was added to the spin column,
which was then placed into a fresh 1.5 ml RNase-free microcentrifuge tube (USA Scientific).
The spin column was held at room temperature for five minutes, then centrifuged at 14,000xg
for one minute. The eluate was placed back into the spin column and allowed to incubate for
30 minutes at room temperature, after which the spin column was centrifuged again at
14,000xg for one minute. The samples were placed in a BioPhotometer (Eppendorf) to
determine the RNA concentrations, and the total HMEC-1 RNA was stored at -80°C until
needed.
Microarray Analysis of B. bacilliformis Infected HMEC-1. Purified total HMEC-1 RNA
was used for microarray studies with the HG-U133A and HG-U133B Chip Sets
(Affymetrix). The manufacturer’s protocol was followed for the entire process, as follows.
Briefly, cDNA for each sample was synthesized from 8 µg of total HMEC-1 RNA per
reaction using the Affymetrix-supplied SuperScript II first strand synthesis kit. This firststrand cDNA was then used for the synthesis of second-strand cDNA. The second-strand
cDNA was then placed in Phase-lock gel tubes (Eppendorf) and extracted with 25:24:1
phenol:chloroform:isoamyl alcohol (Boehringer Mannheim). Next, the second-strand cDNA
was used to synthesize Biotin-labeled RNA using the Enzo BioArray High Yield RNA
Transcription Labeling Kit, as suggested by Affymetrix. After synthesis, the labeled RNA
was cleaned using the Qiagen RNeasy columns, as recommended by Affymetrix. The cRNA
was quantified via the included IVT Product calculations, and once it was determined that the
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concentration and purity of the cRNA were within the manufacturer’s recommendations the
cRNA was fragmented using the supplied fragmentation buffer. The fragmented cRNA was
then spiked with the supplied Affymetrix controls, including the B2 Oligonucleotide and
Eukaryotic Hybridization Controls. The spiked cRNA from each sample was subsequently
hybridized onto the HG-U133A chip for 16 hours at 45°C rotating at 60 rpm. After HGU133A hybridization, the spiked cRNA was removed and added to the HG-U133B chip,
which was hybridized as described above. The hybridized chips were then washed and
stained, as per the supplied Affymetrix protocols, using the GeneChip Fluidics Station for
automated washing and staining. The chips were subsequently scanned using the GeneArray
scanner operating with GeneChip Operating System (GCOS) 5.; normalized values for each
gene spot were given via normalization from 0.1 to 1 as compared to spiked-in endogenous
chip controls. Raw data from the GCOS analysis were then used for microarray analysis by
GeneSpring v7.3 (Agilent).
GeneSpring Analysis of Human Microarray Data. GeneSpring v7.3 (Agilent) was used
for the analysis of the microarray data. All data were initially preprocessed using the CHP
file preprocessor. Following file preprocessing, all data were normalized by setting raw
signal values below 0.01 to 0.01. The 50.0th percentile of all measurements in that sample
divided each measurement. Each gene was divided by the median of its measurements in all
samples. If the median of the raw values was below 10, then each measurement for that gene
was divided by 10 if the numerator was above 10; otherwise, the measurement was thrown
out. Genes selected for pathway and further analysis were identified by Fold-Change
analysis. The significantly differentially expressed genes from the fold-change data were
built by comparing "Timed Control" with "Timed Experimental" using all normalized genes.
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Statistical analysis was conducted using the parametric test, assuming unequal variances.
Genes that were differentially expressed passed this testing method defined by Fold
Difference: 2 and a P-value Cutoff: 0.1.
Data from Human Herpes Virus-8 (HHV-8) infected human Blood Endothelial Cells
(BEC) were used in various microarray-based comparison studies to B. bacilliformis infected
HMEC-1. Microarray data generated by Wang, et al. (2004) from HHV-8 cells were
obtained from the Array Express public microarray database and subjected to the same
statistical and sorting methodology as noted above for the HMEC-1 microarray data
RT-PCR Verification of Selected HMEC-1 Genes. Further analysis of fold-change data
from the HG-U133A and HG-U133B (Affymetrix) microarray data was done via RT-PCR
analysis of selected genes at each time point as follows. Previously collected B.
bacilliformis-infected HMEC-1 total RNA was used for first strand cDNA synthesis using
the SuperScript III Platinum Two-Step qRT-PCR kit (Invitrogen) containing 500 ng of total
RNA in RT reaction mix, RT enzyme mix, and DEPC-treated water. These reagents were
then gently mixed and incubated at 25°C for 10 minutes, then 42°C for 50 minutes per
manufacturer’s instructions. The reaction was terminated by heating the mixture at 85°C for
5 minutes, and the sample was then chilled on ice. After termination, 1 µL of E. coli RNase
H was added and incubated with the reaction mixture at 37°C for 20 minutes. This reaction
mix was stored at -20°C, and used for second-step RT-PCR as needed. The second step RTPCR reactions were completed using the TaqMan& Universal PCR Master Mix (Applied
Biosystems, Inc.). An endogenous control, peptidylpropyl isomerase A (PPIA), was chosen
as an mRNA housekeeping gene using the TaqMan Endogenous Control Array kit (Applied
Biosystems, Inc.) In brief, each reaction was prepared in triplicate with 100 ng of the above
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prepared cDNA, a target-gene specific TaqMan Gene Expression Assay Primer pair (Applied
Biosystems Inc.) for HIF1! (Hs00936368_m1), CASP3 (Hs00234387_m1) and CASP8
(Hs00154256_m1) and the TaqMan two-step RT-PCR Master Mix reagent kit (Applied
Biosystems, Inc.) The cycling parameters for the Applied Biosystems 7500 sequence
detection system were RT at 48°C for 30 minutes, AmpliTaq activation at 95°C for 10
minutes, denaturation at 95°C for 15 seconds, and annealing-extension at 60°C for 1 minute
(repeated 40 times). The generated triplicate Ct values were analyzed using Excel
(Microsoft) by the comparative Ct (''Ct) method, per Applied Biosystems, Inc. instructions.
The amount of target, calculated using the formula RQ =2-''Ct, or –''Ct = log2(RQ), was
determined by normalization to the endogenous control (PPIA) and expression relative to a
calibrator (uninfected, same time point HMEC-1 sample). Relative quantification between
microarray and RT-PCR data was done using previously normalized values for control
(uninfected) and experimental (infected) data from microarray data, obtained by dividing the
experimental data by the control data. From the normalized ratio (NR), the log 2-based foldchange calculations were performed using Excel.
Fold-Change Calculations. Fold-change calculations were completed using both the
Normalized Ratio (NR), derived from microarray analysis, and RQ values, derived from the
comparative Ct (''Ct) method for RT-PCR analysis, with the following formula: IF(NR or
RQ<1,-1/NR or RQ) (Ingenuity™). A NR greater than 1.0 represents fold-change directly
and no calculation was required. According to this formula if the NR is more than 1, then
this value represents a positive fold change or gene up-regulation, however if the NR is less
than one, then the values are divided by -1 to give a negative integer representative of gene
down-regulation. Finally, if normalized ratio is 1, then this value represents no change in
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gene expression. RT-PCR data was processed in a similar manner, once RQ values were
obtained, using the RQ value as a substitute for the normalized ratio, thus producing foldchange data for RT-PCR RQ values.
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Results
Scatter plot analysis of HG-U133A Microarray chips.
Scatter plot analysis based on control versus experimental gene expression profiles
was conducted on the HG-U133A chip following hybridization with HMEC-1 mRNA. As
shown in Figure 2.1, HG-U133A microarray data exhibit expected expression variability at
both time points with B. bacilliformis-infected HMEC-1 cells. As the plot indicates, blue
dots represent a down-regulation and orange/red dots represent an up-regulation of the
experimental samples relative to the controls. Panel A, the scatter plot generated from host
cell gene expression levels 6 hours post infection, reveals 2.3% of the host genes to be upregulated (as indicated by the orange/red dots), and 6.7% to be down-regulated (as indicated
by the blue dots). Panel B, the scatter plot obtained with RNA isolated 36 hours postinfection, shows a similar overall effect on gene expression levels, with 2.6% of the genes
being up-regulated and 7.6% being down-regulated.
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Figure 2.1 – Scatter plot analysis of Affymetrix HG-U133A Microarray chips at various time
points.
HMEC-1 cells were infected with B. bacilliformis at a MOI of 100:1 at 37° C. Host mRNA
was harvested at six and thirty-six hours post-infection. Cellular total mRNA was isolated
post-infection and hybridized to Affymetrix HG-U133A microarray chips containing
approximately 54,681 human transcripts. The two panels above indicate the time point data
used to generate gene expression profiles from two replicate samples, as follows: Panel A: 6
hours post-infection; and Panel B: 36 hours post-infection. Each data point above represents
the relative mean hybridization intensity of one of the mRNA transcripts purified from the
infected cells, represented on the y-axis, versus a PBS-mock infected control, represented on
the x-axis. Genes whose expression was unchanged in the infected cells compared to controls
are shown as yellow dots; genes whose expression was down-regulated as compared to
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control are represented as blue dots; and genes whose expression was up-regulated compared
to controls are represented as orange/red dots. The green bars indicate the two-fold change
range for each chip hybridized.

81
Scatter plot Analysis of HG-U133B Microarray chips.
Scatter plot analysis of the HG-U133B microarray chips reveals a level of variability
of gene expression distribution similar to that shown in the HG-U133A microarray chips. As
shown in Figure 2.2, Panel A, which plots data obtained at the 6-hour time point, shows that
2.0% of genes are up-regulated, while 6.8% are down-regulated. Panel B, which
incorporates data from the 36-hour time point, shows percentages of up- and down-regulated
genes at 2.5% and 8.4%, respectively.
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Figure 2.2 – Scatter plot analysis of Affymetrix HG-U133B Microarray chips at various time
points.
Analysis was conducted as described in Figure 2.1
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Fold Change Analysis of Highly Differentially Expressed Functional HMEC-1 Genes.
Analysis of the most highly differentially expressed functional HMEC-1 genes was
conducted utilizing data from the fold change ratios prepared from signal intensity data
obtained by hybridization of B. bacilliformis-infected and mock-infected HMEC-1 cellular
RNA onto HG-U133A and HG-U133B (Affymetrix). The fold change data shown in Tables
2.1a and 2.1b represent approximately 40 of the mostly highly differentially-expressed
functional genes at each monitored time point, as organized by highest fold change ratios.
These genes were selected due both to their high level of fold change versus the mockinfected control and their role as functional proteins in the host cell. Putative or hypothetical
genes were eliminated from this analysis. For example, at 6 hours post-infection, the highlevel up-regulation of catalase (a 9-fold increase) may indicate an altered immune response
mechanism for B. bacilliformis clearance, while the down-regulation of IL-17 and IL-26
precursors may indicate a bacterial mechanism by which infiltration of immune cells is
temporally reduced (Table 2.1a). Furthermore, up-regulation of epidermal growth factor
receptor(s) and IL-22 binding proteins may indicate an increased responsiveness to microenvironmental growth factors and inflammatory response. The down-regulation of several
CDC42-related genes may further indicate the effect B. bacilliformis infection has on cellular
polarity and alteration of actin fibers (Table 2.1b)
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Table 2.1a – Highly differentially expressed functional HMEC-1 genes 6 hours after B. bacilliformis infection.
Fold change analysis for the top selected functional genes, via GeneSpring comparison of mock-infected control HMEC-1 cells versus
HMEC-1 cells infected B. bacilliformis. Total RNA extracted from mock and infected cells was hybridized to HG-U133A and HGU133B (Affymetrix) microarray chips. Hybridization data were then used to determine the fold change of the highly differentially
expressed HMEC-1 genes.
Accession
Gene product
No.
Up-regulated Gene Products
SET and MYND domain
AW074336
containing 3
Polycystic kidney disease
AF182034
2-like 2
UV excision repair protein
T93562
RAD23 homolog B
F-box only protein 3
AL162053
isoform 1&2
Basic helix-loop-helix
domain containing, class B,
3

Fold
Change
16.04
14.69
14.26
13.68

R93946

13.65

Spermatogenesis
associated 1

NM_022354

12.41

Synaptopodin 2-like

NM_024875

12.04

AB044807

11.47

AF007137

11.19

Inad-like protein; inad-like
protein isoform 4
Glutamate receptor,
ionotropic, AMPA 1

Accession
Gene product
No.
Down-regulated Gene Products

Fold
Change

Interleukin 17A precursor

-19.763

Z58820

Potassium inwardlyBG542347
rectifying channel J15
RAP2B, member of RAS
NM_002886
oncogene family
Cardiomyopathy associated
AI800785
4 isoform 1&2
Myeloid/lymphoid or
mixed-lineage leukemia
N64035
translocated to, 10 isoform
A&B
N-methyl-D-aspartate
T65537
receptor subunit 2A
precursor
Mitochondrial ribosomal
AW007410
protein S31
Hepatocyte nuclear factor
AI916600
4, gamma
Ras homolog gene family,
AW173151
member A

-14.535
-12.887
-12.837

-12.837

-11.198
-10.627
-10.593
-10.194

85
Accession
Gene product (con’t)
No.
Down-regulated Gene Products
Nude nuclear distribution
AI963104
gene E homolog like 1 (A.
Nidulans) isoform A&B
Replication protein A3,
AI022132
14kda

Fold
Change

10.67

Jun D proto-oncogene

AI339541

-9.524

AI640145

10.11

AL122039

-9.346

Muts homolog 6

D89646

10.05

AF152509

-9.259

Mohawk homeobox

R59304

10.04

CDC42 small effector 2
Protocadherin gamma
subfamily A, 3 isoform
1&2 precursor
Adaptor-related protein
complex 1 sigma 2 subunit

N74507

-9.259

AI829170

9.983

Polymerase (DNA
directed), beta

S69873

-9.009

NM_000750

9.63

Epidermal retinal
dehydrogenase 2

AI440266

-8.850

AF070647

9.276

Retinoic acid receptor, beta
NM_015854
isoform 1&2

-8.696

U32500

9.217

Interleukin 26 precursor

NM_018402

-8.547

AU147084

9.162

Inhibitor of Bruton's
tyrosine kinase

AB037838

-8.403

Gene product (con’t)
Up-regulated Gene Products
CD24 antigen precursor
Regulator of G-protein
signaling 1
Cerebellar degenerationrelated protein 1, 34kda
Spartin

Golgin-67; golgi
autoantigen, golgin
subfamily a, 8A
Cholinergic receptor,
nicotinic, beta polypeptide
4
Actin related protein 2/3
complex subunit 1A
Neuropeptide Y receptor
Y2
Catalase

Accession
No.

Fold
Change

BG327863

11.03

NM_002922

10.88

NM_004065

-10.173
-9.901

86

Gene product (con’t)
Up-regulated Gene Products
Homeodomain interacting
protein kinase 3
Alpha 1 type XI collagen
isoform A,B&C
preproprotein
Cytochrome c oxidase
subunit 8C
Low density lipoproteinrelated protein 2
RAS-like, estrogenregulated, growth inhibitor
Tropomodulin 2 (neuronal)
Protocadherin beta 14
precursor

Accession
No.

Fold
Change

AI640624

9.004

BG028597

8.967

AW269746

8.827

R73030

8.817

AW668616

8.679

NM_014548

8.48

NM_018934

8.332

Accession
Gene product (con’t)
No.
Down-regulated Gene Products
Solute carrier family 13
NM_022444
(sodium/sulfate
symporters), member 1

Fold
Change

Homeobox B6

-8.065

AI125255

-8.333
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Table 2.1b – Highly differentially expressed functional HMEC-1 genes 36 hours after B. bacilliformis infection.
Fold change analysis for the top selected functional genes, via GeneSpring comparison of mock-infected control HMEC-1 cells versus
HMEC-1 cells infected B. bacilliformis. Total RNA extracted from mock and infected cells was hybridized to HG-U133A and HGU133B (Affymetrix) microarray chips. Hybridization data were then used to determine the fold change of the highly differentially
expressed HMEC-1 genes.
Accession
No.

Fold
Change

Progesterone receptor

AI378893

15.02

G protein-coupled receptor
98 precursor

AL136541

12.89

Glutamate-rich 1

AA767385

12.27

Delta-sarcoglycan isoform
1&2

U58331

11.27

Cathepsin S preproprotein

BC002642

10.8

AI492860

10.53

AJ012370

10.5

AL080170

10.49

R38712

10.46

Gene product
Up-regulated Gene Products

Tachykinin receptor 1
isoform long
N-acetylated alpha-linked
acidic dipeptidase 2
Tripartite motif-containing
58
Sidekick homolog 1

Accession
Gene product
No.
Down-regulated Gene Products
Fumarylacetoacetate
AA700567
hydrolase
Phosphodiesterase 3B,
AW974995
cgmp-inhibited
Sulfotransferase family,
AF026303
cytosolic, 1C, member 1
isoform A&B

Fold
Change

Diaphanous 2 isoform 156

AA778894

-13.263

L35848

-12.690

R49412

-11.765

AW135765

-11.534

AA758116

-10.449

AW293826

-10.417

Membrane-spanning 4domains, subfamily A,
member 3 isoform A,B&C
Dystrobrevin alpha isoform
1-8
Isoleucine-tRNA
synthetase
Cell cycle related kinase
isoform 1&3
Tetratricopeptide repeat
domain 8 isoform A,B&C

-17.065
-13.986
-13.947
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Accession
No.

Accession
Gene product (con’t)
No.
Down-regulated Gene Products
IQ motif containing H
NM_022784
isoform 1&2

Fold
Change

10.23

R7 binding protein

H05023

-9.434

10.18

CDC42 small effector 2

AI535736

-9.259

NM_022066

10.06

XK, Kell blood group
complex subunit-related,
Y-linked 2

NM_004677

-9.091

AI344149

9.853

Deoxyribonuclease I
precursor

AA720770

-8.929

AA608964

9.802

CDC42 small effector 2

AL117571

-8.850

Calcitonin receptor

AB022177

9.763

AI732427

-8.475

Sodium potassium chloride
cotransporter 2

AI632015

9.537

AK026344

-8.403

AK025026

9.411

AI912122

-8.403

R20529

9.4

AB044556

-8.403

AL560266

9.179

AA126642

-8.264

Gene product (con’t)
Up-regulated Gene Products
ZXD family zinc finger C
AA702187
isoform 2
Family with sequence
AI650599
similarity 9, member C
Leucine rich repeat
H07100
containing 7
Ubiquitin-conjugating
enzyme E2O
Epidermal growth factor
receptor pathway substrate
8
Glutamate receptor,
metabotropic 3 precursor

Phosphoinositide-3-kinase,
regulatory subunit 4, p150
Latrophilin 3 precursor
Fc receptor-like and
mucin-like 1

Fold
Change
10.4

Protocadherin 11 Y-linked
isoform a, b & c
Pleckstrin homology
domain containing, family
A member 5
Calcium-dependent cellcell adhesion
PAR-6 gamma protein
Brain-specific protein p25
alpha

-9.524
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Accession
No.

Gene product (con’t)
Up-regulated Gene Products
Similar to FERM domaincontaining protein 4B
AK000244
(GRP1-binding protein
GRSP1) isoform 1
Interleukin 22-binding
BE348657
protein isoform 1, 2 & 3

Fold
Change

9.164

9.076

Accession
Gene product (con’t)
No.
Down-regulated Gene Products

Fold
Change

Zinc finger protein 750

NM_024702

-7.874

AF116689

-7.813

AI052441

-7.692

Calcium binding protein
P22
Protein phosphatase 2
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Differential regulation of selected HMEC-1 genes during B. bacilliformis infection.
The infection of HMEC-1 by B. bacilliformis alters the global gene expression profile
in several ways. Table 2.2 shows the alteration of selected genes, which are grouped into
specific host cell functions. Infection of B. bacilliformis alters the expression patterns of
several angiogenesis-related genes throughout its infection cycle from 30 minutes1 to 36
hours. Analysis of early infection gene regulation from 30 minutes to 3 hours indicates an
overall change in hypoxia factors and plasminogen factors as well as VEGF production. The
infection of HMEC-1 cells by B. bacilliformis induces a down-regulation, by almost fourfold, in hypoxia inducible factor 1 alpha (HIF1!) gene expression at 30 minutes of infection.
This down-regulation in HIF1! production diminishes but is still evident by 3 hours, where
the levels of gene expression are almost two-fold lower than those of the control. However,
the early infection cycle also reveals an increase of hypoxia inducible factor 3 (HIF3!)
expression at both one hour, with an almost seven-fold up-regulation, and at 3 hours, with a
three-fold up-regulation. In addition, there is an increased expression of microvascular
endothelial differentiation gene(s), plasminogen activators, and VEGF and VEGF-C. By 36
hours, these increases are no longer apparent. There is a slight increase in IL-8 expression of
about two-fold over that of the control, and a two-fold decrease in VEGF-A expression at 36
hours.
Differential analysis of anti-apoptotic proteins during B. bacilliformis infection of
HMEC-1 cells shows an alteration in host gene expression of selected anti-apoptotic genes at
the early stages of infection. The data in Table 2.2 reveal a striking increase in anti-apoptotic

1

Raw microarray hybridization signal data from 30 minutes, 1 hour and 3 hours post-B.
bacilliformis infection provided by T. Soni, following the same infection protocol as noted
above.
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gene expression at 30 minutes post infection. This increase can be seen most dramatically in
the almost 8.5-fold increase in expression of the Id2 (Inhibitor of DNA-binding 2) gene as
well as the four-fold up-regulation in the BAG-family molecular chaperone regulator. Other
genes whose expression is increased include those controlling the B cell lymphoma and
myeloid cell leukemia sequences.
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Table 2.2 - Selected dynamically regulated host genes of infected HMEC-1 cells during
B. bacilliformis infection.
The follow table shows an analysis of selected dynamically regulated host genes of infected
HMEC-1 cells during B. bacilliformis infection. Genes discussed in the text are indicated in
red.
Fold change at h post-infection
Gene name and
function
Angiogenesis
Angiopoetin-2
bFGF2
Ephrin B2
Ephrin B4
Fms-related tyrosine
kinase
Hypoxia-inducible
factor 1, alpha
subunit
Hypoxia-inducible
factor 2, alpha
subunit
Hypoxia-inducible
factor 3, alpha
subunit
ICAM1
IL-8 C terminal
variant
Inhibitor of DNA
binding 3
Insulin-like Growth
Factor
Insulin-like Growth
Factor Receptor 1
Matrix
metalloproteinase 1
Microvascular
endothelial
differentiation gene 1
Plasminogen activator
inhibitor 2
Plasminogen
activator, tissue

Accession no.

30mins

1hr

3hrs

6hrs

36hrs

NM_001147
AW592991
AF025304
NM_004444

-1.092
2.076
2.596
1.234

3.391
2.484
1.032
1.185

1.313
2.408
-1.355
-1.057

2.292
1.107
1.065
1.081

1.062
2.308
-1.163
-1.368

AA058828

-1.431

1.336

1.818

-1.553

1.263

AA777349

-3.922

-1.138

-2.301

1.763

1.359

AA913703

-1.172

2.036

8.001

3.398

-1.350

AK021881

-1.321

7.329

2.776

-1.109

-1.274

AA284705

1.696

2.612

2.86

-2.070

-2.198

AF043337

-1.122

-1.59

-1.706

-1.634

2.249

NM_002167

1.276

1.383

1.32

-1.276

1.208

M37484

1.858

4.893

2.548

-1.776

-6.757

H05812

3.634

2.221

-3.521

1.198

1.485

NM_002421

1.789

-1.976

-1.3

-1.127

-1.062

NM_012328

3.446

1.232

-1.081

1.099

1.881

NM_002575

1.046

2.356

-1.116

-1.605

1.318

NM_000930

1.729

-1.196

1.013

1.01

-1.321

93
Gene name and
function (cont’t)
Platelet-derived
Growth Factor
Receptor 1
PPAR (gamma)
angiopoietin related
protein 4
Stanniocalcin
Thrombomodulin
Tissue inhibitor of
metalloproteinase 1
Urokinase
plasminogen activator
receptor precursor
Urokinase-type
plasminogen activator
receptor
Vascular endothelial
growth factor C
(VEGFC)
Vascular permeability
factor VEGF
(VEGFA)
VEGF
Antiapoptotic
BAG-family
molecular chaperone
regulator-2
Basic helix-loop-helix
domain containing,
class B, 2
B-cell lymphoma 6
BCL2-related protein
A1
Cyclin-dependent
kinase inhibitor 1A
Fas-interacting
serinethreonine
kinase 3
Human IAP
homologue C

Accession no.

30mins

1hr

3hrs

6hrs

36hrs

M22734

1.514

3.538

4.482

2.285

5.307

NM_016109

-1.667

-2.257

-1.957

-1.016

-1.802

AI300520
NM_000361

1.146
1.761

-1.58
-1.068

-1.139
-1.205

-1.192
1.083

1.353
-1.647

NM_003254

1.259

-1.248

-1.073

-1.181

-1.176

AY029180.1

1.857

1.405

1.04

-1.164

1.128

U08839.1

1.496

1.303

-1.088

-1.236

1.038

U58111.1

3.451

-1.592

1.031

1.256

1.287

M27281.1

-1.174

-1.109

1.454

-1.667

-2.066

AF022375.1

4.595

-1.401

-1.104

-1.008

1.276

AF095192.1

4.193

-1.244

-1.393

1.125

1.037

BG326045

3.663

-1.114

-4.525

-1.58

-1.156

NM_001706

2.025

-1.538

1.013

1.043

-1.377

NM_004049

-1.25

-1.003

1.172

-1.379

-1.403

NM_000389

1.517

-1.88

-1.149

-1.121

-1.129

AF305239.1

1.652

1.339

1.144

-1.03

-1.156

U37546.1

1.433

-1.071

1.385

3.529

-1.456
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Gene name and
function (cont’t)
Inhibitor of DNA
binding 2 (Id2)
Leukemia inhibitory
factor
Myeloid cell
leukemia sequence 1
Phospholipid
scramblase 4
TNF alpha-induced
protein 3
TNF-induced protein
(GG2-1)
Cancer signatures
Absent in melanoma
1
Insulin-induced gene
1
N-myc downstream
regulated
Nucleoside
phosphorylase
Potential tumor
suppressor (ST7)
Snail 1 (Drosophila
homologue)
Uridine
phosphorylase

Accession no.

30mins

1hr

3hrs

6hrs

36hrs

NM_002166

8.495

1.044

1.191

-1.08

1.303

NM_002309

-1.773

-3.215

1.511

-1.408

-1.761

AI275690

2.085

-1.634

-1.742

-1.269

-1.014

NM_020353

1.63

1.171

-1.11

-1.259

-1.199

NM_006290

1.004

-1.536

-1.016

-1.185

1.314

BC005352

-1.024

-1.111

-1.211

-1.287

-1.239

U83115.1

1.463

-1.637

-1.186

1.007

1.014

NM_005542

2.322

-1.067

-1.196

-1.376

1.062

NM_006096

1.618

-1.19

-1.233

-1.053

-1.351

NM_000270

1.848

-1.381

-1.181

-1.172

1.152

NM_013437

-2.053

-2.89

-1.25

1.068

-2.179

NM_005985

3.413

1.447

1.081

1.39

1.43

NM_003364

1.103

-1.761

1.001

1.415

-1.372

2.101
-1.104
-6.211

-1.009
1.065
-2.747

-1.279
1.024
1.718

1.006
1.103
-2

-1.25
-1.05
1.259

1.024

2.35

-1.089

-2.165

-1.658

1.454

-1.202

-1.433

-1.292

1.152

Cell and structural dynamics
Cytovillin 2 (ezrin)
J05021.1
Integrin, alpha 2
NM_002203
Nephropontin
M83248.1
Plectin, intermediate
Z54367
filament binding
protein
Protein kinase-related
M24779.1
oncogene (PIM1)
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Gene name and
function (cont’t)
Cytokines
Cytokine gro-ß
Cytokine, Cys-X-Cys,
member 10
GRO1 oncogene
GRO3 oncogene
(GRO-gamma)
Interleukin 1 ß
Interleukin 4 receptor
Interleukin 6
(interferon, ß 2)
Macrophage-specific
CSF-1
Monocyte
chemotactic protein
MCP1
Pre-B-cell colonyenhancing factor
Prostate
differentiation factor
RAFTK
STAT-induced STAT
inhibitor 3
IFN responsive
2-5oligoadenylate
synthetase 2 (OAS2)
IFN-inducible, 67kD
guanylate binding
protein 1
IFN-stimulated T-cell
alpha chemoattractant
Interferon regulatory
factor 1
Interferon regulatory
factor 2
Interferon regulatory
factor 2 Binding
Protein
Interferon regulatory
factor 4

Accession no.

30mins

1hr

3hrs

6hrs

36hrs

M57731

-1.908

-2.959

1.12

1.036

1.111

NM_001565

3.231

1.522

-1.008

-1.664

-1.488

NM_001511

-1.14

-1.314

1.01

1.074

1

NM_002090

1.056

1.198

-1.431

-1.247

-4.065

M15330
NM_000418

-1.224
3.176

1.305
-1.241

-1.458
1.052

-1.186
1.188

1.673
-1.274

NM_000600

-1.186

1.182

-1.515

-1.318

-1.247

M37435.1

2.753

-1.196

1.094

1.043

-1.565

S69738.1

2.832

1.373

-1.297

-1.548

2.062

BF575514

1.151

-1.126

-1.122

1.064

-1.58

AF003934

1.042

-1.795

1.241

-1.012

-1.047

NM_004103

-2.653

-2.294

-2.667

1.667

1.18

NM_003955

5.037

-2.841

1.605

-1.567

1.405

NM_016817

3.835

-1.215

1.385

1.213

1.101

BC002666

1.338

-1.353

1.237

-1.142

-1.311

AF030514

-12.21

-1.626

3.137

3.639

5.249

NM_002198

-1.018

1

1.564

1.135

1.188

AW968775

-1.019

5.385

2.848

-1.316

-2.632

BF968057

5.727

-1.025

-1.832

1.408

-1.422

D78261

-6.250

4.23

2.701

2.541

-4.082
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Gene name and
function (cont’t)
Interferon regulatory
factor 5
Interferon regulatory
factor 7, transcript
variant c
Interferon-stimulated
protein, 15 kDa
ISGF-3
Mx resistance 1, IFNinducible protein p78
Metabolism
Carnitine
octanoyltransferase
Glutamine-fructose6-phosphate
transaminase 2
GTP cyclohydrolase
1
Prostaglandinendoperoxide
synthase 2 (Cox2)
Tryptophanyl-tRNA
synthetase
Hexokinase 1
Phosphofructokinase,
liver
Phosphofructokinase,
platelet
Molecular
chaperons
DnaJ-like heat shock
protein 40
Superoxide dismutase
2
Zinc finger protein
133
Zinc finger protein
238

Accession no.

30mins

1hr

3hrs

6hrs

36hrs

BF223643

4.777

-2.336

-3.984

-1.323

1.263

NM_004030

1.691

-1.224

-1.054

1.409

-1.52

NM_005101

1.099

-1.199

-1.122

-1.155

1.132

BC002704

3.352

-1.054

1.21

-1.188

-1.471

NM_002462

1.763

-1.481

1.19

1.053

-1.527

NM_021151

2.823

1.023

-1.389

-1.333

-1.508

NM_005110

1.131

-1.437

1.078

1.056

-1.524

NM_000161

1.085

-1.664

-1.034

1.007

-1.377

NM_000963

-1.379

1.018

-3.096

2.743

-3.115

NM_004184

1.416

-1.013

-1.508

-1.006

1.076

NM_000188

1.412

-1.183

-1.024

1.13

-1.205

NM_002626

2.201

1.418

-1.035

-1.232

-1.342

NM_002627

1.69

1.287

-1.25

1.014

1.099

NM_007034

1.204

1.496

-1.435

-1.335

1.613

X15132.1

1.754

-1.119

1.042

-1.852

-1.186

U09366

-1.263

1.223

1.003

1.233

-1.279

AJ223321

1.541

-1.043

-1.453

-1.171

-1.151
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Gene name and
Accession no.
function (cont’t)
Proteolysis/protein processing
Secretory granule,
NM_003020
neuroendocrine
protein 1
Ubiquitin-conjugating
AL545760
enzyme E2D 1
Signal transduction
A kinase (cAMP)
anchor protein 13
ADP-ribosylation
factor-like 7
Diphtheria toxin
receptor
Dual specificity
phosphatase 1
Dual specificity
phosphatase 5
Dual specificity
phosphatase 6
Heparin-binding
EGF-like growth
factor
Immediate early
response 3
Inositol 1,4,5triphosphate receptor,
type 1
Mitogen-activated
protein kinase 3
Phospholipase A2,
group IVA
Phospholipid
scramblase 1
Phosphoprotein
regulated by MAPK
pathways
Preprourokinase
Protein kinase C,
delta

30mins

1hr

3hrs

6hrs

36hrs

-1.148

1.006

1.553

1.141

1.478

1.657

1.62

1.18

1.13

1.436

AK022014

-4.386

5.275

-4.348

1.185

1.44

BG435404

1.36

-1.012

-1.056

1.055

1.077

NM_001945

1.854

-1.161

-1.318

-1.012

1.139

NM_004417

1.406

-2.114

-1.795

-1.157

1.065

U16996

2.579

-1.224

-1.013

1.111

-1.145

BC005047

-3.367

-2.02

-1.224

2.079

-1.675

M60278

1.948

-1.203

-1.949

-1.047

-1.235

NM_003897

1.815

-1.323

-1.577

1.044

1.062

NM_002222

-1.049

-2.208

1.738

1.33

-1.381

AA780381

1.549

-1.066

-1.117

1.344

-1.066

M68874

1.857

1.029

1.458

1.486

1.092

NM_021105

3.443

-1.034

1.039

-1.193

-1.101

NM_025195

-1.182

-2.632

-1.149

1.244

1.11

K03226.1

1.331

1.013

-1.193

-1.196

-1.03

NM_006254

2.377

2.129

1.013

-1.403

-2.387
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Gene name and
function (cont’t)
Regulator of Gprotein signaling 16
Serum-inducible
kinase
SMAD7
Sprouty (Drosophila)
homologue 2
Sprouty (Drosophila)
homologue 4

Accession no.

30mins

1hr

3hrs

6hrs

36hrs

U94829.1

-2.262

-2.667

-1.134

1.098

-1.1

NM_006622

1.432

1.056

-1.28

1.048

1.151

NM_005904

1.354

-1.374

1.7

1.418

-1.143

NM_005842

1.609

-1.61

-1.147

-1.151

-1.174

W48843

-1.13

-1.189

2.184

1.328

-1.517

-1.099
-1.014

-1.701
-1.104

1.287
-1.106

1.274
-1.134

-1.022
-1.233

1.263

1.16

1.174

1.306

1.078

2.315

-1.001

-1.101

1.311

-1.025

1.06

1.085

1.02

1.519

-1.036

1.909

1.099

1.076

1.135

1.029

1.461

1.312

-1.183

-1.037

-1.481

1.418

-1.174

-1.271

1.237

-1.258

-3.745

-1.142

1.022

-1.07

1.309

1.115

2.087

1.065

1.037

1.135

-1.292

2.021

-1.067

1.128

-1.294

-1.185

1.205

-1.044

-1.156

-1.031

1.749

-1.548

-1.195

1.036

1.041

Small molecular/vesicle transport
Aquaporin
N74607
Importin alpha 3
U93240.1
Niemann-Pick
NM_000271
disease, type C1
RAB31, member
BE789881
RAS oncogene family
Ral guanine
nucleotide
AI421559
dissociation
stimulator
RAN binding protein
AL043571
2-like 1
Solute carrier family
NM_006931
2
Solute carrier family
NM_005415
20, member 1
Solute carrier family
AF047033.1
4, NaHC03
cotransporter 3
Transcription factors/proto-oncogenes
B-cell CLL
AI829875
lymphoma 3
Cas-Br-M, retroviral
transforming
U26710.1
sequence-b
CCAAT enhancer
NM_005195
binding protein
(CEBP), delta
CCAAT enhancer
AL564683
binding protein, ß
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Gene name and
function (cont’t)
DNA-binding zinc
finger
Early growth
response 1
Early growth
response 3
ELL-related RNA pol
II elongation factor
Estrogen-responsive
B box protein
Forkhead box O1A
FOS-like antigen 2
FOS-like antigen-1
Glucocorticoid
receptor alpha-2
HIV-1 enhancerbinding protein 2
jun B
NF- kappa B
enhancer in B cells 1
(p105)
NF-kappa B enhancer
in B-cells 2
(p49p100)
Nf-kappa B enhancer
in B-cells inhibitor,
alpha
Nuclear factor,
interleukin 3
regulated
Nuclear receptor
subfamily 2, group F,
member 2
p54 (EGR binding
protein 1)
Pleckstrin homologylike domain, family
A,1
ß-Glucocorticoid
receptor
TGFB-inducible early
growth response

Accession no.

30mins

1hr

3hrs

6hrs

36hrs

AB017493

1.155

1.228

1.067

-1.33

1.077

NM_001964

-1.443

-1.623

-1.05

-1.292

2.033

NM_004430

-2.083

1.232

3.765

1.02

1.092

NM_012081

1.515

1.071

-1.064

-1.235

-1.013

NM_006470

1.455

1.206

-1.393

-1.065

-1.149

NM_002015
NM_024530
BG251266

1.056
3.272
2.183

-1.136
1.434
-1.106

-1.661
-1.024
1.001

-1.007
-2.096
1.215

-1.074
-1.016
1.439

U01351.1

1.157

1.154

-1.351

-1.233

-1.174

AL023584

-1.142

4.605

-1.565

-1.264

-2.865

NM_002229

4.503

-1.783

-2.674

1.143

-1.309

M55643.1

1.056

-1.458

1.018

1.184

-1.174

NM_002502

1.13

1.508

1.911

-1.379

-1.161

AI078167

2.305

-1.072

-1.126

1.817

1.255

NM_005384

2.103

-1.282

-1.218

1.011

-1.079

AL554245

3.262

1.051

-1.053

1.037

-1.095

AF045451.1

1.698

1.075

-1.054

-1.294

1.05

NM_007350

1.36

-1.832

1.3

-1.34

1.159

X03348.1

2.126

-1.277

-1.359

-1.282

-1.142

NM_005655

2.098

-1.33

1.026

1.009

-1.111
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Gene name and
function (cont’t)
Transcription factor 8
(represses IL2
expression)
Transcriptional
coactivator with
PDZ-binding motif
v-ets homologue 2
v-maf, oncogene
family, protein F
Zinc finger protein
homologous to Zfp36
Others
IFN-induced
transmembrane
protein 1
Progesterone
membrane binding
protein

Accession no.

30mins

1hr

3hrs

6hrs

36hrs

NM_030751

-1.359

-1.404

-3.077

-1.908

-1.529

AA081084

1.162

-1.29

-1.314

-1.063

-1.004

NM_005239

1.44

1.167

1.007

1.007

-1.49

AL021977

2.237

-1.582

-1.471

-1.284

-1.035

NM_003407

-1.076

-1.048

1.279

-1.312

-1.212

AA749101

1.299

-1.106

1.279

-1.427

-1.116

NM_006320

1.246

-1.018

-1.004

1.088

1.011
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Real Time RT-PCR Validation of Microarray Data.
In order to validate the microarray data obtained from the hybridization of total
mRNA onto the HG-U133A and HG-U133B (Affymetrix) microarray chips, a series of real
time RT-PCR reactions were completed for genes coding for the transcription factor HIF1!
(AA913703), and the apoptotic enzymes caspase-3 (CASP3; NM_004346) and caspase-8
(CASP8; NM_001228). For each reaction (Figure 2.3), pre-validated RT-PCR primers (ABI)
corresponding to each gene selected were used and the results were compared to an internal
control, PPIA (cyclophilin A, CAG32988), which has been shown to have little significant
regulation changes throughout the experimental time points (Soni, personal communication).
Every RT-PCR primer set gave products of the expected size. As shown in Table 2.3, all
three genes examined agreed 100% between the RT-PCR and microarray fold change values,
as defined by falling within 2.5 fold of one another with overall regulation agreement (Gao et
al., 2004; Stintzi, 2003). While the data presented here fall within our correlation scheme, as
with any microarray study we can expect some discordance between RT-PCR and microarray
fold change analysis. We have noted this discordance with other genes at earlier infection
time points including: 30 minutes, 1 hour and 3 hours post-infection (Soni, personal
communication). When correlation analysis includes these time points, with the same genes,
the RT-PCR and microarray fold change correlation decreases to 73%, which remains
acceptable for microarray validation (Draghici, 2002; Nadon et al., 2002).
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Table 2.3 – Validation of Microarray Experiment via RT-PCR 6 and 36 hours post-infection.
Validation of the HG-U133A&B (Affymetrix) microarray chips was completed via RT-PCR
of selected HMEC-1 host genes. Raw RT-PCR data analysis was completed with respect to a
PPIA internal control and uninfected HMEC-1 cells to give the relative gene expression
value (RQ) versus GeneSpring fold change value at each time point. Correlation is noted by
values within ±2.5-fold change of GeneSpring analysis value.
Selected
Gene
HIF1!

Entrez ID
AA913703

Time Point
6hrs
36hrs

RT-PCR
Fold
Change
1.35
1.91

GeneSpring Fold
Change Analysis
1.76
1.36

Correlate
Correlate

CASP3

NM_004346

6hrs
36hrs

0.00
2.91

0.87
0.79

Correlate
Correlate

CASP8

NM_001228

6hrs
36hrs

1.06
1.61

0.34
1.25

Correlate
Correlate
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Comparative gene expression analysis of 36 hour post-infection HMEC-1 infected with
B. bacilliformis and two-day post-infection BEC infected with HHV-8.
Venn diagram analysis was carried out on data from B. bacilliformis-infected HMEC1 cells 36 hours post-infection versus two-day post-infection HHV-8 infected primary blood
endothelial cells (BEC) (Table 2.4). Analysis of B. bacilliformis-infected HMEC-1 cells
versus HHV-8 infected BEC cells was conducted because of the functional similarities
between the two endothelial cell lines. Genes showing a two-fold change or greater were
selected for comparison and then these genes were grouped by pathway/function
commonalities. Groupings included angiogenic, apoptotic, cell adhesion, cell signaling, and
immune response factors. Analysis shows a dramatic increase in the expression of
angiogenic genes in HHV-8 infected cells relative to B. bacilliformis-infected cells. For
example, infection with HHV-8 results in a 15-fold up-regulation in IL-8 production with an
increase in IL-8 in B. bacilliformis-infected cells of two fold. Platelet derived growth factor
(PDGF) is up-regulated during B. bacilliformis infection by almost two fold, while in HHV-8
infected cells PDGF gene production is down-regulated almost 2.5-fold. Examination of
apoptosis/cell death functional genes indicates that HHV-8 infection of BEC cells results in
an increase of chemokine ligand 2 (CCL2) expression that is almost four-fold higher than
HMEC-1 cells infected by B. bacilliformis (6.4-fold vs. 2.1-fold increase, respectively).
Also, TNF superfamily receptor 21 is down-regulated almost six-fold in B. bacilliformis
infected HMEC-1 cells while its gene expression is up-regulated almost five-fold in HHV-8
infected BEC cells. Cell adhesion and mobility regulated genes show almost universal
down-regulation during infection with B. bacilliformis, as opposed to those infected by
HHV-8. This includes the down- regulation of Claudin 1 (CLDN1), epithelial V-like antigen
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(EVA1), Alpha 5-integrin (PLTP) and laminin gamma 2 (LAMC2), all of which are downregulated during the infection of B. bacilliformis but are up-regulated during the infection by
HHV-8. It should be noted that thrombospondin 3 (THBS3) is down-regulated almost three
fold in B. bacilliformis infected cells, while it is up-regulated two fold in HHV-8 infected
cells. Cell signaling genes show similar gene expression patterns between HHV-8 infected
cells and B. bacilliformis infected cells; however, HHV-8 infected cells exhibit an increased
cytokine receptor 7 (CMKOR1) expression of eight fold, whereas B. bacilliformis infected
HMEC-1 cells CMKOR1 expression increases by 2.5-fold. Ficolin (FCN3) gene expression
is up-regulated almost three-fold in B. bacilliformis infected HMEC-1 cells, but is downregulated 2.5-fold in HHV-8 infected cells. The immune response is also differentially
regulated in Bartonella infected cells and HHV-8 infected cells. For example, CD69 is upregulated almost 5.5-fold by HHV-8 infected cells, but is down-regulated over three-fold in
B. bacilliformis infected cells, while B. bacilliformis infection increases chemokine ligand 11
(CXCL11) production over five-fold versus a 3.5-fold increase by HHV-8 infected cells.
HHV-8 infection induces production of IL-2 receptor and IL-32 greater than B. bacilliformis,
showing almost a seven-fold increase in the production of IL-32 versus B. bacilliformis
infected cells. B. bacilliformis, however, induces an up-regulation of IL-6 signal transducer
production with a 2.6-fold increase versus a two-fold decrease in HHV-8 infected cells. B.
bacilliformis also induces the increased expression of G-protein signaling regulator genes
(RGS1) by a four-fold greater rate than that of HHV-8 infected cells, while HHV-8 infected
cells appear to induce the production of Selectin E (SELE) over five-fold greater than that of
B. bacilliformis. Host cell metabolism gene expression patterns are very similar between B.
bacilliformis infected cells and HHV-8 infected cells. The only exception is the expression
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of the carboxypeptidase E gene (CPE), which shows a two-fold decrease during B.
bacilliformis infection and a two-fold increase during HHV-8 infection. Lastly, analysis of
proliferation-related genes in B. bacilliformis infected HMEC-1 indicates a down-regulation
of almost three-fold for Cyclin D2 (CCND2), while HHV-8 infected cells up-regulate
CCND2 expression two-fold. Breast cancer marker 2 (BRCA2) gene expression shows a
modest difference between HHV-8 and B. bacilliformis infected cells, increasing about fourfold during B. bacilliformis infection and two fold following infection with HHV-8.

106
Table 2.4 – Venn Diagram Analysis comparing genes overlapping between 36hrs B.
bacilliformis-infected HMEC-1 Cells and 2 day HHV-8 infected Primary Blood Endothelial
Cells.
Venn diagram analysis was conducted comparing HMEC-1 36 hour post-infection with B.
bacilliformis versus HHV-8 two-day infected BEC; genes were selected by two-fold or more
change over control and those which overlapped between both infective conditions. Genes
discussed in the text are highlighted in red.

Gene name and function
Angiogenesis
EPH receptor B2
Interleukin 8
Interleukin 8 receptor beta
Platelet-derived growth factor
alpha polypeptide
Apoptosis/Cell Death
Chemokine (C-C motif) ligand
2
GULP, engulfment adaptor
PTB domain containing 1
Interferon induced with
helicase C domain 1
Tumor necrosis factor receptor
superfamily, member 21
Tumor necrosis factor receptor
superfamily, member 9
Cell Adhesion & Mobility
BH-protocadherin (brainheart)
Cadherin-like 22
Claudin 1
Epithelial V-like antigen 1
Extracellular link domain
containing 1
Gelsolin (amyloidosis, Finnish
type)
Heparan sulfate proteoglycan
2 (perlecan)
Integrin, alpha V
Laminin, gamma 2

Accession no.

B.
bacilliformisInfected Fold
Change

2 day HHV-8
Infected Fold
Change

D31661
AF043337
NM_001557

-2.392
2.249
3.828

2.481
15.500
2.198

X03795

2.173

-2.519

S69738

2.062

6.417

AK023668

-4.000

-2.252

NM_022168

2.133

2.188

NM_016629

-5.780

4.258

BC006196

2.992

2.020

NM_002589
AF035300
NM_021101
NM_005797

2.105
-4.926
-5.525
-4.808

2.054
-2.037
2.035
2.649

NM_016164

-2.283

-3.077

BE675337

-2.381

-2.262

AI991033
NM_006227
NM_005562

5.000
-3.106
-2.646

2.863
2.275
3.967
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Gene name and function
(con’t)
PDZ domain containing 2
Thrombospondin 3
Cell Signaling
Chemokine (C-X-C motif)
receptor 7
Ficolin
G protein-coupled receptor 37
(endothelin receptor type Blike)
G protein-coupled receptor 4
PDZ domain containing 1
Immune Response
CD69 molecule
Chemokine (C-X-C motif)
ligand 11
Interleukin 1 receptor
antagonist
Interleukin 2 receptor, gamma
Interleukin 32
Interleukin 6 signal transducer
RAB7, member RAS
oncogene family
Regulator of G-protein
signaling 1
Selectin E (endothelial
adhesion molecule 1)
Serine proteinase inhibitor
Tachykinin
Metabolism
Carboxypeptidase E
Glutamate-ammonia ligase
(glutamine synthase) domain
containing 1
Klotho
Phosphatidylinositol glycan,
class C
Proliferation
Cyclin D2

Accession no.
AF338650
L38969

B. bacilliformisInfected Fold
Change
2.961
-3.049

2 day HHV-8
Infected Fold
Change
2.123
2.059

AI817041
NM_003665

2.477
2.892

8.148
-4.566

T16257
NM_005282
NM_002614

2.836
-2.037
-2.336

2.321
-2.262
2.059

L07555

-3.115

5.426

AF030514

5.249

3.855

BE563442
NM_000206
NM_004221
BE856546

3.346
-2.096
2.101
2.681

2.190
2.253
7.348
-2.033

AK024417

2.192

2.031

NM_002922

8.016

2.028

NM_000450
AB046400
NM_003182

3.813
-3.597
3.469

18.500
-9.009
2.001

NM_001873

-2.179

2.182

NM_016571
NM_004795

2.965
2.600

2.483
2.091

AL035301

2.141

2.201

AI635187

-3.367

2.043
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Gene name and function
(con’t)
Breast cancer 2, early onset

Accession no.
NM_000059

B. bacilliformisInfected Fold
Change
3.834

2 day HHV-8
Infected Fold
Change
2.038
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Comparative gene expression analysis of 36 hour post-infection HMEC-1 infected with
B. bacilliformis and seven-day post-infection BEC infected with HHV-8.
Venn diagram analysis was conducted comparing gene expression in B. bacilliformis
infected HMEC-1 36 hours post-infection with that observed in HHV-8 infected BEC seven
days post-infection. Groups of genes were selected as noted above (Table 2.5). This analysis
was completed in order to determine the expression of genes during both infected conditions
to establish commonalities of expression during both infective conditions. Analysis of cell
adhesion and mobility differentially regulated genes indicates B. bacilliformis infection at 36
hours is down regulated (-5.2 fold) versus up regulation (2.1 fold) in HHV-8 infected cells
after seven-days. Cell signaling Venn analysis of overlapping regulated genes indicates B.
bacilliformis infection down-regulates the production of Aquaporin 8 (AQP8) (2.3 fold), as
opposed to a two-fold increase of AQP8 (2.1 fold) during HHV-8 infection. A three-fold
decrease in somatostatin receptor (SSTR2) expression levels is seen in B. bacilliformis
infected cells (-3.0 fold) versus a two-fold increase (2.0 fold) in HHV-8 infected cells.
Immune response gene regulation between B. bacilliformis infected cells and HHV-8
infected BEC cells indicate similar expression patterns. However, B. bacilliformis upregulates the expression of cytotoxic and regulatory T cell molecules (CRTAM) to a fourfold greater extent than HHV-8 (8.1 fold vs. 2.0 fold). Also, CD 28 gene (CD28) expression
is up-regulated two-fold during B. bacilliformis infection (4.0 fold) when compared to HHV8 infection (2.1 fold). Interestingly, both IgE fragments (FCER1A) and serpin peptidase
inhibitor (SERPINF2) show a down-regulation during B. bacilliformis infection (-3.3 fold
and -2.6 fold versus 2.2 fold and 2.3 fold, respectively) while infection with HHV-8 shows
an increase in the expression of both of these genes. Finally, analysis of genes which are
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differentially regulated regarding metabolism reveals a three-fold down-regulation in
fucosyltransferase 9 (FUT9) and almost a four-fold down regulation of SMA4 (SMA4)
expression in B. bacilliformis infected HMEC-1 cells, while both of these genes are upregulated in HHV-8 infected cells (2.0 fold and 2.2 fold).

111
Table 2.5 – Venn Diagram Analysis comparing genes overlapping between 36 hrs B.
bacilliformis-infected HMEC-1 Cells and 7 day HHV-8 infected Primary Blood Endothelial
Cells.
Venn diagram analysis was conducted comparing B. bacilliformis-infected HMEC-1 36 hour
post-infection with HHV-8 infected BEC 7 days post-infection. Genes with 2-fold change
over control were selected and those which overlapped between both infective conditions.
Genes referred to in the text are highlighted in red.

Gene name and function
Cell Adhesion & Mobility
Dynein, axonemal, HC3
Formyl peptide receptor-like 1
K-cadherin
Leucine rich repeat neuronal 5
Cell Signaling
Aquaporin 8
Interleukin 5 receptor, alpha
Phosphodiesterase 6C, cGMPspecific, cone, alpha prime
Somatostatin receptor 2
Tetraspanin 7
Immune Response
Apolipoprotein H
CD28 molecule
Chemokine (C-X-C motif)
ligand 14
Cytotoxic and regulatory T cell
molecule
Dedicator of cytokinesis 2
Fc fragment of IgE
Myelin basic protein
Serpin peptidase inhibitor
Urotensin 2
Metabolism
Fucosyltransferase 9
Proline dehydrogenase
(oxidase) 2
SMA4

Accession no.

B. bacilliformisInfected Fold
Change

7 day HHV-8
Infected Fold
Change

AK026793
U81501
NM_004932
AK024867

2.901
-5.208
-3.472
2.430

2.288
2.129
2.107
2.064

NM_001169
M96651

-2.398
3.743

2.134
2.023

U31973
BC000256
NM_004615

3.057
-3.086
-2.294

2.047
2.062
-2.045

NM_000042
AF222343

3.811
4.015

2.120
2.177

NM_004887

2.462

2.193

NM_019604
D86964
BC005912
M13577
NM_000934
NM_021995

8.193
3.174
-3.367
2.426
-2.667
2.794

2.086
2.130
2.244
2.116
2.308
2.041

BC001879

-3.096

2.048

U95090
X83300

2.284
-4.274

2.363
2.208
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Gene name and function
(con’t)
UDP-Gal:betaGlcNAc beta 1,3galactosyltransferase 2

Accession no.
Y15014

B. bacilliformisInfected Fold
Change

2 day HHV-8
Infected Fold
Change

2.094

2.120
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Comparative gene expression analysis of 36 hour post-infection HMEC-1 infected with
B. bacilliformis versus two-day and seven-day post-infection BEC infected with HHV-8.
A final Venn diagram analysis was completed comparing B. bacilliformis infected
HMEC-1 36 hour post-infection with HHV-8 infected BEC two- and seven-day postinfection. Genes were selected as noted above (Table 2.6). One major outcome of this
analysis as it relates to angiogenesis genes concerns the differential response of the cells with
respect to the expression of IL-8. In HHV-8 infected cells, there is an up-regulation in IL-8
expression at both time points, while the gene is two-fold down-regulated in cells infected
with B. bacilliformis Overall, the immune response genes show similar expression patterns
following infection with either B. bacilliformis or HHV-8, with the exception of the Fc
fragment of IgA and the von Hippel-Lindau tumor suppressor, both of which are downregulated in B. bacilliformis infected cells and up-regulated in HHV-8 infected cells. Cell
Adhesion-related genes exhibit a dissimilar gene regulatory pattern between B. bacilliformis
and HHV-8 infected cells, with the most dramatic differences seen with the Epithelial V-like
antigen 1 gene, which is 2-fold down-regulated in B. bacilliformis infected cells but 7-fold
up-regulated at the two-day post HHV-8 infection BECs. The up-regulation of Pappalysin in
B. bacilliformis-infection HMEC-1 cells does not correlate with the down-regulation of this
gene by HHV-8 infection. Finally, analysis of the expression changes in Transport-related
genes reveals differences in the expression of the glutamate receptor, which is downregulated 7.5 fold in B. bacilliformis-infected cells, but up-regulated in HHV-8 infected cells
at both time points.
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Table 2.6 – Venn Diagram Analysis comparing genes overlapping between 36hrs B.
bacilliformis-infected HMEC-1 Cells and 2 & 7 day HHV-8 infected Primary Blood
Endothelial Cells.
Venn diagram analysis was completed comparing HMEC-1 36 hour post-infection with B.
bacilliformis versus HHV-8 day-two and seven-day infected BEC; genes were selected due
to their two-fold change over control and those which overlapped between all three infective
conditions. Genes discussed in the text are highlighted in red.

Gene name and
function
Angiogenesis
Interleukin 8
Aminopeptidase A
Kruppel-like factor 5
Endothelin receptor
type A
Immune Response
Immunoglobulin
lambda locus
Immunoglobulin
heavy constant g1
Major
Histocompatibility
Complex, class II, DR
beta 1
T cell receptor alpha
locus
Fc fragment of IgA
Interleukin 26
von Hippel-Lindau
tumor suppressor
Cell Adhesion
CD1c molecule
Epithelial V-like
antigen 1
Embryonal Fynassociated substrate
Neurofibromin 2

Accession no.

B.
bacilliformisInfected Fold
Change

2 day HHV-8
Infected Fold
Change

7 day HHV-8
Infected Fold
Change

X77737
NM_001977
AF132818

2.249
2.342
4.193

15.500
2.235
2.214

2.579
2.191
2.112

AU118882

7.052

2.221

2.311

D01059

2.137

2.129

2.131

AJ275383

2.375

-3.175

-2.404

AJ297586

-2.212

-2.994

-2.283

AE000659
U56237
NM_018402

2.452
-3.096
2.211

2.414
2.250
2.090

2.311
2.350
2.082

NM_000551

-2.041

2.297

2.064

NM_001765

2.371

-2.762

-2.174

AF275945

-2.320

7.489

2.121

NM_005864
BC003112

-2.294
3.939

2.328
2.106

2.056
2.246
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Gene name and
function

Accession no.

B.
bacilliformisInfected Fold
Change

Cell Cycle Regulation
Pappalysin 2
fyn-related kinase

BF435151
NM_002031

7.014
5.549

-4.049
2.130

-3.205
2.054

AU156204
NM_014111

-7.519
2.112

2.161
2.424

2.113
2.375

W60595

7.713

2.172

2.128

AF260824
M98399

-2.825
2.879

2.029
3.774

2.051
3.103

Transport
Glutamate receptor
Transferrin
Cystic Fibrosis
transmembrane
conductance regulator
Solute carrier family
13 m1
CD36 molecule

2 day HHV-8
Infected Fold
Change

7 day HHV-8
Infected Fold
Change
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Discussion
The infection of host endothelial cells by B. bacilliformis results in the alteration of
numerous gene regulation profiles. To date, little research has been done to analyze these
regulatory changes. The experiments described herein were undertaken to provide
information about the global regulation of host genes in response to infection with B.
bacilliformis KC584. Genes analyzed were divided into several key categories, depending on
their roles in angiogenesis, apoptosis, the immune response and signal transduction. A
comparison of gene regulatory patterns induced by B. bacilliformis infection with those
observed following infection by HHV-8, the etiological agent of Kaposi’s Sarcoma (Naranatt
et al., 2004; Wang, 2004) was also carried out due to the striking histopathological
similarities between the clinical presentation of Kaposi’s Sarcoma and that of verruga
peruana.
Microarray analysis of cellular gene expression in response to infection by B.
bacilliformis
Work in our laboratory has focused on the response of HMEC-1 cells during early
(within 3 hours) and late (36 hours) B. bacilliformis infection, as determined by microarray
analysis. Early host response has shown the expression of several key host genes relating to
angiogenesis, apoptosis and immune response (Soni, personal communication). Early
infection, within 30 minutes, of B. bacilliformis shows the highest degree of change in
overall gene expression change (21.9%), with 7.9% of the genes being up-regulated and
14.0% being down-regulated. Those genes relating to angiogenesis that are up-regulated
through the first three hours of infection include bFGF, ICAM-1, Insulin-like growth factor
(IGF), and Platelet-derived Growth Factor Receptor 1 (PDGFR-1). While bFGF and IGF
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have been clearly associated with angiogenesis and blood vessel formation, PDGFR1 upregulation may indicate that infected endothelial cells are priming not only for angiogenesis,
but also involvement of the immune system in clearance of the B. bacilliformis infection. Upregulation of ICAM-1, a cellular adherence factor, may indicate the restructuring and
increased attachment of endothelial cells as they begin priming for the angiogenic cascade.
Several angiogenesis-related genes, including HIF2! and HIF3!, Insulin-like Growth Factor
receptor I (IGFR-1), Microvascular endothelial differentiation gene I and VEGF, are only
transiently up-regulated early in infection. While HIF2! gene expression is a known
response to hypoxia and able to induce angiogenesis via the VEGF pathway, recent research
suggests that HIF3! may actually be involved in a destruction of tubules by a yet unknown
method (Hirota et al., 2006). HHV-8 has been found to contain genetic elements which are
activated in hypoxic environments (HRE); these genetic elements have not been found in B.
bacilliformis (Haque et al., 2003). HIF1! expression has also been implicated in the
infective cycle of HHV-8; its accumulation is believed to be due to the presence of upregulated IGF-I and the subsequent induction of VEGF (Catrina et al., 2006). Research into
the role of HIF1! has shown that B. henselae infection actively increases HIF1! expression
and decreases ATP stores. Interestingly, this study suggests that B. henselae strains which
are pilus negative do not induce HIF1! or VEGF expression, thus indicating the role of the
pilus in HIF1! activation. However, to date the role and presence of a B. bacilliformis pilus
homologue has not been established in HIF1! induction (Kempf et al., 2005). Our data,
however, show a constant down-regulation of the transcription factor HIF1! throughout
early B. bacilliformis infection. The down-regulation of HIF1! upon B. bacilliformis
infection is unexpected, since HIF1! plays a significant role in mediating VEGF expression
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during HHV-8 infection. Under these conditions, HIF1! activation is achieved through
phosphorylation by p38 and proteins in the MAPK signal pathways (Sodhi et al., 2000).
HHV-8 induced tumors express the gene coding for the IGF-I receptor, suggesting an
autocrine role during angiogenesis. The 3.6-fold increase in IGF-1 gene expression seen
early in B. bacilliformis infection may indicate that this protein is also involved in the
formation of verruga peruana (Catrina et al., 2005).
Expression of anti-apoptotic genes during early B. bacilliformis infection reveals the
transient up-regulation of several genes. Of these, the Id2 (Inhibitor of DNA binding-2)
gene, whose expression is increased 8-fold 30 minutes post-infection, is the most highly upregulated. ID2 is able to inhibit cellular differentiation and may actually act as a tumor
suppressor (Lavarone et al., 1994). In a manner similar to that of HHV-8 infection, the host
response in the early stages of B. bacilliformis infection exhibits an interferon-based immune
response (Dourmishev et al., 2003; Naranatt et al., 2004). Transiently up-regulated genes
include CXC10, MCP-1, MS-CSF and STAT-induced stat inhibitor 3 (SSI-3) which are
involved in the recruitment and chemotaxis of immune cells to sites of inflammation and
infection (Poole et al., 2002). Consistently down-regulated during early B. bacilliformis
infection, RAFTK, a focal adhesion kinase, is expressed in cells infected by HHV-8 and acts
as a coordinator of cytokine, integrin receptor, cytoskeletal and actin processes by direct
activation of JNK (Liu et al., 1997). While RAFTK activation can be induced by bFGF, IL-6
or VEGF in B. bacilliformis infection, RAFTK down-regulation may indicate that B.
bacilliformis is bypassing this kinase while still able to alter the angiogenic cascade. Several
transcription factors are also activated during early infection by B. bacilliformis, including
the activation of multiple NF-kB factors. The role of NF-kB as a downstream gene
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transcription factor and its involvement in pathogenesis has been established by the work by
Fuhrmann et al. (2001). These authors report that B. henselae is able to activate NF-"B,
thereby increasing PMN rolling and adhesion to infected endothelial cells during infection.
During the later phase of infection (6 and 36 hours post infection) far fewer genes
show altered expression as compared with their earlier time point levels. Those that are upregulated include the Interferon-inducible T Cell Alpha Chemoattractant (I-TAC) gene and
the gene coding for Chemoattractant Protein-1 (MCP-1). Both I-TAC and MCP-1, an
activator protein of monocytes, are able to induce monocyte influx into the site of infection.
At six hours post-infection an up-regulation of the gene coding for IAP homologue C, a
known inhibitor of apoptosis via the TRAF pathway, is also seen. This gene product may
play a role in the established anti-apoptosis strategy of many Bartonella species (Dehio,
2003; Kirby et al., 2002; Liberto et al., 2004). This continued depression of the apoptosis
pathway suggests a mode and methodology of continued survival not only for infected
endothelial cells, but also a way by which B. bacilliformis can avoid the immune response.
A wider examination of the regulation patterns indicates several up and downregulatory trends over the 36 hour infection period studied. For example, the bFGF gene
shows an overall up-regulation, and therefore could act as a stimulant for angiogenesis
throughout the 36 hours of B. bacilliformis infection. However, this is in contrast to the
overall down regulation of the IL-8, one of the primary inducers of angiogenesis, which may
indicate that the angiogenesis seen during B. bacilliformis infection does not involve the IL-8
signaling pathway. Also down-regulated throughout the time period under investigation are
the tissue inhibitors of MMP-1, a protein involved in the degradation of extracellular matrix.
This is an essential prelude to the migration of endothelial cells and tubule formation. An
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overall decrease in this inhibitor would therefore result in a higher potential activity for
MMP-1 activity in the localized area surrounding infected tissues. Several anti-apoptosis
genes were also down-regulated throughout the monitored 36 hour infective cycle studied;
including BCL-2, and the leukocyte inhibitory factor. Down-regulation of these genes is
probably due to the influx of immune response cells and follows the up-regulation trend of
these genes at earlier time periods, which was discussed previously. These observations
suggest that there is a robust interferon-dominated immune response and an alteration of host
cell apoptosis during B. bacilliformis infection. It should also be noted that there is an
overall down-regulation of the TNF induced genes, an indication that TNF is not involved in
infection during B. bacilliformis. Since TNF expression is closely linked to LPS infectivity,
B. bacilliformis LPS may not play a role in the infection or in the immune response of the
cell to B. bacilliformis infection. The analysis of known cancer signatures reveals an overall
down-regulation of tumor suppressor genes during the infection of HMEC-1 cells by B.
bacilliformis and may indicate similarities between tumorgenesis and B. bacilliformis
infection. Interestingly, there is an overall down-regulation of IL-6 gene expression during
B. bacilliformis infection, which may be counteracted by the influx of highly activated
immune cells. These cells are able to produce IL-6, which could potentially act in an
autocrine manner, affecting the immune cells themselves in addition to infected and
uninfected endothelial cells. As expected, metabolism genes such as phosphofructokinase
are up-regulated throughout the entire 36-hour infective cycle. It has previously been
established that HIF1! expression increases several glycolytic enzymes (Greijer et al., 2005).
While our 36 hour microarray-based infection study of HMEC-1 cells infected by B.
bacilliformis does not seem to provide a clear-cut model by which B. bacilliformis is
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inducing angiogenesis, there are several key points that can be taken away from this study.
We suggest that a high number of genes are up-regulated within 30 minutes of B.
bacilliformis infection of HMEC-1 cells. This high level of gene up-regulation may result in
the expression of genes that are directly involved in angiogenesis or are involved in the
pathways which lead to the angiogenesis cascade. Next, our data have shown that hypoxia
factors HIF1!, HIF2! and HIF3! are clearly involved at several different stages of B.
bacilliformis infection. While HIF1! and HIF2! are known to be involved in VEGF
expression, HIF3! may actually be involved in the degradation of newly formed and preexisting endothelial tubules which are created during periods of high oxygen consumption.
This may in fact be a key element in the poor tubule formation during B. bacilliformis
infection (discussed in Chapter 3). The resulting expression of HIF1! and HIF2! may result
in the induction of the angiogenic cascade through both VEGF and other factors, including
the constitutively up-regulated bFGF. However, due to the presence of up-regulated HIF3!,
the tubules formed are weak and/or highly permeable. This could result in the pooling of
blood in the subcutaneous location of B. bacilliformis infection, producing the clinical
presentation of verruga peruana formation (Hirota et al., 2006). Also, the transient rather
than continual increase in ICAM-1 expression may indicate that while endothelial cells are
able to migrate and form tubules, cell-to-cell contact is not properly reinforced. Therefore,
the tubules that are formed are highly permeable, establishing another route of blood leakage
into the localized subcutaneous environment. Our microarray studies also suggest a role for
the interferon dominated immune response during the infection of B. bacilliformis. During
the 36 hour time window, several chemoattractant genes regulated by interferon-# are upregulated, and may be involved in the chemoattraction of monocytes, macrophages and
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activated T cells into the localized infective environment. These cells in turn could produce
several factors involved in endothelial cell migration and tubule formation.
The study presented here of the gene regulation pattern of B. bacilliformis infected
HMEC-1 cells is similar to the results seen by Dehio et al. (2005) during their study of B.
henselae infection of HUVEC cells, with a few key differences. As with our studies, Dehio
and his coauthors used the Affymetrix HG-U133 human microarray set to study the global
gene regulation pattern of infected endothelial cells. They chose to harvest RNA for analysis
at 6 and 30 hours post infection, and to use HUVEC cells rather than HMEC-1 hosts. Their
findings indicate a significant increase in interferon-dependent gene transcription factors,
which is also seen during the B. bacilliformis infection. Similarly, Dehio et al. (2005)
suggest that interferon (IFN) is involved in the immune response during B. henselae
infection, even though its expression was not found via ELISA detection from infected
HUVEC cells. Although our study did not seek to determine if IFN was produced by
HMEC-1 cells during B. bacilliformis infection, we would expect the results to be similar to
those reported by Dehio et al. (2005). . The authors are also able to show the involvement of
the NF-kB transcriptional factor in B. henselae infection, as we have in our studies, which
relates to the up-regulation of IL-6, IL-8, ICAM-1 and CXC cytokine family members. Our
study shows the involvement of these and several other NF-"B -induced gene products.
While Dehio et al. (2005) suggest a role for the virB/Bep operon in the induction of NF-"B,
research in our lab, as well as the published B. bacilliformis KC583 genome, indicates that
the virB operon is not present in B. bacilliformis (see Chapter 1). Therefore, the induction of
NF-"B during B. bacilliformis infection must be mediated by some other factor(s). Lastly,
Dehio et al. (2005) examined the genes related to angioproliferation, and were able to show
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that 22% of the 100 most highly differentially regulated genes were related to angiogenesis.
These results correlate well with our own studies of B. bacilliformis infection. While
infection by the two Bartonella species resulted in the up-regulation of several similar
angioproliferative genes, infection by B. henselae did not show an increase in Hypoxiainducible factors (HIF) of any kind, while our results reveal differential regulation patterns
consistent with a key role for these factors in the on-going angiogenesis seen in verruga
peruana formation during Carrion’s disease.
Real-time RT-PCR analysis was also conducted on three genes as a way to verify the
microarray data (Table 2.3). The RT-PCR data and the microarray fold-change analysis
show a 73% correlation when both early and late time points are included in the validation
analysis. Most successful microarray studies prefer a fold-change range of no more than a 2.5
fold difference between microarray and RT-PCR data (Draghici, 2002; Firestein et al., 2002;
Gao et al., 2004; Nadon et al., 2002; Stintzi, 2003). Differences between RT-PCR and
microarray data are commonly ascribed to several factors, including the different microarray
hybridization probes used for each technique. Even a slight difference in binding locations
can result in differential fold-change data. Also, the required use of microarray imaging
software, such as GCOS, can result in analysis of microarray data with different
hybridization intensity levels. While intensity levels were adjusted to be as close to one
another as possible, slight gene spot intensity differences will lead software-based analysis to
different fold change results. While we did not obtain the expected correlation between
microarray and RT-PCR data at all time points, we are confident that these studies will
provide the necessary tools for further research into the interaction of Bartonella species with
their hosts.
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Venn diagram-based analysis of B. bacilliformis infected HMEC-1 cells versus Kaposi's
sarcoma BEC infected cells.
Due to the histopathological similarities between B. bacilliformis infected endothelial
cells and HHV-8 infected blood endothelial cells, a Venn diagram-based comparison was
conducted utilizing microarray data from B. bacilliformis-infected HMEC-1 cells 36 hours
post-infection versus HHV-8 infected blood endothelial cells (BEC) after two and seven days
post-infection. Microarray data from HHV-8 infected cells was generated by Wang, et al.
(2004) and published to the ArrayExpress database (www.ebi.ac.uk) accession number EMEXP-66. These data were treated in the same manner as B. bacilliformis data with regard
to software-based analysis. Gene regulation analysis of genes with at least a two-fold change
from mock infected cells was completed on several basic categories of host gene pathways
including angiogenesis, apoptosis, cell adhesion, and immune response. Table 2.3 shows the
comparison between B. bacilliformis-infected cells and two-day HHV-8 infected BECs. The
first striking difference between Bartonella infected cells and HHV-8 infected cells is the
expression of IL-8, a hallmark of angiogenesis. Expression of the IL-8 cytokine is upregulated by 15-fold in HHV-8 infected but only by two-fold in B. bacilliformis infected
cells. These data suggest that HHV-8 infected cells are more responsive to and produce
higher levels of IL-8, thus indicating its role in infection by the virus, while suggesting that
IL-8 may play only a small role in angiogenesis seen in B. bacilliformis-infected cells. This
difference in IL-8 expression raises the possibility that the role of IL-8 may be offset in B.
bacilliformis-infected cells by the up-regulation of Platelet-derived Growth Factor (PDGF),
as compared to the down-regulation of the same gene in HHV-8 infected cells. PDGF is a
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known vascular growth factor able to induce proliferation while acting as a chemoattractant
for a wide variety of immune cells. Upon examination of apoptosis-related genes, it is
interesting to note the down-regulation of GULP in both infective conditions, as this gene is
responsible for an increase in the engulfment of cells which have undergone apoptosis via
phagocytes. This observation may indicate a survival strategy for both infective conditions,
since it will decrease uptake by host cells that are actively undergoing apoptosis or have
recently undergone apoptosis, thereby allowing B. bacilliformis a protected location for
continued growth. Interestingly, a five-fold down-regulation of tumor necrosis factor
receptor 21 (TNFR21) is seen in B. bacilliformis infected cells while up-regulation of fourfold of this gene is observed in HHV-8 infected cells. This may indicate that TNF plays a
less important role in B. bacilliformis infection as compared with HHV-8 infection. Analysis
of genes involved in cell adhesion and mobility again indicates differences between
Bartonella infection and HHV-8 infection. The up-regulation of Perlecan in both infective
conditions indicates yet another possible mode of survival. Induction of this gene results in
the inhibition of apoptosis in fibroblasts following the initiation of apoptosis in nearby
endothelial cells. Perlecan binds to the fibroblast !2$1 integrin, and may inhibit apoptosis
via integrin activation. Interestingly, this analysis shows the down-regulation of several
genes that are directly involved in endothelial cell maintenance, including Claudin 1,
Laminin and Thrombospondin 3. All three are involved in binding of the extracellular matrix
and have been implicated in endothelial cell permeability in vivo. The down-regulation of
each of these genes may provide deeper clues into the overall effect that B. bacilliformis
infection has on endothelial cells and their ability to form tight junctions and maintain tubule
integrity during infection. The analysis of cell signaling molecules, a category which shows
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the highest difference in gene regulation between B. bacilliformis-infected and HHV-8
infected cells, reveals the different possible roles the immune system plays in clearance of
both infective conditions. HHV-8 infected cells show a higher level of up-regulation of
chemokine receptor 7, a B cell binding site and attractant, and a greater down-regulation of
Ficolin, a protein functioning in the clearance of non-self foreign material from the host. The
weaker levels of chemokine receptor 7 up-regulation in B. bacilliformis-infected cells may
indicate that the B cell response does not play as important a role in B. bacilliformis infection
as it does in HHV-8 infection. The up-regulation of Ficolin expression may indicate that
phagocytosis or other direct uptake methods for infective clearance are more important
during B. bacilliformis infection than during HHV-8 infection. The immune response gene
regulation patterns indicate a high similarity of regulatory patterns between B. bacilliformisinfected cells and HHV-8 infected cells. The down regulation of CD69 expression following
B. bacilliformis infection may further indicate the lack of a TNF-! response, as CD69
expression is induced by TNF-! expression in endothelial cells. The eight-fold up regulation
of G-protein signaling involved in Rho/rac proteins suggests that these proteins play a role
during infection (Verma et al., 2000; Verma et al., 2002).
Venn diagram analysis was also used to compare the overall gene expression profiles
between B. bacilliformis-infected HMEC-1 and seven-day HHV-8 infected BEC, using the
same methodology as described above (Table 2.4). Most interesting is the overall similarity
of immune response gene regulatory patterns between the two infective conditions. An
example of this similarity is the up-regulation of the cytotoxic and regulatory T cell molecule
which, while up-regulated more during B. bacilliformis infection than HHV-8 infection, still
reveals the immune response similarities between the two infective conditions. This again
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suggests a role for INF-# in both infective conditions, with a possible higher immune
response in B. bacilliformis infection of HMEC-1.
A final analysis was completed using 36 hour B. bacilliformis-infected HMEC-1 cells
and two- and seven-day HHV-8 infected BECs via a Venn diagram analysis (Table 2.5).
These data overall show the striking similarity by which B. bacilliformis infection and HHV
infection alter endothelial cell gene profiles, as indicated by the 50% overall similarity in
gene expressions. Interestingly, several genes involved in B. bacilliformis infection are
indicative of the slightly difference host responses to B. bacilliformis infection versus HHV-8
infection. An example of this is the up-regulation of angiogenesis-related endothelium
receptor type A (ET1RA) expression, ET1RA is a mitogen involved in the escape from
apoptosis and the induction of angiogenesis via a pathway mediated by ILK, an integrin
linked kinase involving !2$1 and !3$1 integrins. The up-regulation of this factor indicates a
continued strategy of B. bacilliformis to alter host apoptosis while implicating various
integrins in the induction of angiogenesis. This analysis shows an almost four-fold increase
of Neurofibromin 2, a protein that is able recruit rac proteins, which in turn promote
mitogenesis of host cells. This protein up-regulation provides further evidence for the
proposed survival strategy used by B. bacilliformis: by inducing cell proliferation, B.
bacilliformis gains increasing numbers of host cells that can support bacterial proliferation
and provide a place to avoid host immune responses. Finally, we note the up-regulation of
two genes involved in cell cycle regulation, Pappalysin 2 and fyn-related kinase. Pappalysin
2 interacts with the localized matrix metalloproteins, while fyn-related kinase is an inducer of
cell proliferation via insulin receptors.
This comparative analysis between B. bacilliformis-infected HMEC-1 cells and
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HHV-8 infected BEC reveals the striking commonality of endothelial cell host response to
both of these infective conditions. While individual commonalities may be difficult to
determine, it is clear that with over 50% similarity in the up- or down-regulation of the
various genes examined, the infective condition of both B. bacilliformis and HHV-8 do
induce similar gene regulation profiles in the host cells. These similar host gene regulation
profiles may provide vital insights into the formation of both verruga peruana and Kaposi's
Sarcoma lesions while providing key information about the commonalities in the
histopathology between both infective states. It should be noted that the cell lines used for
these studies do differ in function and localization. HMEC-1 cells consist of an established
immortalized microdermal endothelial cell line which would be commonly found lining
vessels, while BEC are a progenitor cell line which can differentiate into lymphatic or other
endothelial cells as necessary. This contrast may account for the slight difference in degrees
of fold-change seen during different infective conditions.
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Chapter III – Bacterial Components & Secreted Protein(s)
Introduction
Bartonella bacilliformis is the causative agent of Carrion’s disease, a serious infection
that exhibits a biphasic disease progression. The first phase, Oroya fever, is characterized by
colonization of red blood cells followed by a severe hemolytic anemia (>80% untreated
fatality rate). The disease can then progress into the second phase, termed verruga peruana,
which is marked by cutaneous and subcutaneous eruptions of angiogenic lesions (Anderson,
1997). Verruga peruana resembles a similar condition called Bacillary Angiomatosis (BA),
that is observed in immunocompromised individuals infected with B. henselae or B. quintana
(Berger et al., 1993; Cockerell, 1992). In both cases, the lesions are the result of
uncontrolled angiogenesis involving host endothelial and epithelial cells with a
histopathology similar to the lesions resulting from HHV-8 (Human Herpesvirus 8) infection
that are seen in patients with Kaposi’s Sarcoma (Dourmishev et al., 2003; Nayler et al.,
1999). Several attempts have been made to identify the factor(s) from B. henselae that are
responsible for BA; however, to date no definitive factor has been found (Dehio, 1999;
Kirby, 2004; McCord et al., 2005; Resto-Ruiz et al., 2002; Schmidt, 1998; Schulte et al.,
2006). Similarly, research into the angiogenic factor(s) encoded by B. bacilliformis has
provided relatively few insights.
When applied to vascular endothelial cells, a soluble fraction of a B. bacilliformis cell
homogenate has been reported to produce a mitogenic effect approximately threefold greater
than that of control cells (Garcia et al., 1990). The mitogenic factor(s) has been shown to be
angiogenic in a rat model. The authors were able to eliminate lipopolysaccharide (LPS) as
the mitogen in these studies, and also tentatively identified the factor as a protein based on its

130
heat lability (Garcia et al., 1990). Additional studies have demonstrated that live B.
bacilliformis is able to produce these proliferate lesions when co-cultured with human
umbilical vascular endothelial cells (HUVEC cells) (Garcia et al., 1992). Knobloch, et al.
have shown that serum from Carrion’s disease positive patients exhibits reactivity to a 65kDa
B. bacilliformis produced protein, which could implicate this antigenic protein in lesion
formation (Knobloch et al., 1990). Recently, the suggestion was made that this 65kDa
protein is a homologue of GroEL, a stress-induced molecular chaperone that is highly
conserved among prokaryotes (Chatellier et al., 1998; Keskin et al., 2002; Zeaiter et al.,
2002). The assignment of a role in angiogenesis for B. bacilliformis GroEL is based on
several findings. First, a study in which HUVEC cells were infected with a strain of B.
bacilliformis that overproduces GroEL revealed that the secretion of GroEL was
accompanied by a 6- to 20- fold increase in endothelial cell growth (Minnick et al., 2003). A
positive correlation between GroEL levels and the degree of mitogenesis supported a role for
GroEL in this increase. In addition, mitogenesis was found to be significantly inhibited in
the presence of anti-GroEL antiserum.
GroEL is a highly conserved Type I chaperone, with non-specific substrate-binding
requirements. In the cell, the GroE system consists of two proteins which function together
to aid in conformational changes of both nascent and mature proteins, by hydrolyzing ATP
and possibly providing a protected environment for protein rearrangement (Amir et al., 2004;
Poso et al., 2004). Structurally, the GroE system consists of two proteins: GroES, a sevenmember ring composed of 10kDa GroES subunits; and GroEL, a cylinder of 14 identical
57kDa GroEL subunits arranged back-to-back in a seven-member ring (Gomez-Puertas et al.,
2004; Grallert et al., 2001; Wong et al., 2004). When functional, the stacked GroEL rings
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are capped by GroES, which provides an ATP-binding site. The GroEL rings are open in the
absence of ATP, and have a high affinity for unfolded or misfolded substrates. With the
binding of ATP, the cavity of the ring structure closes and protein re-folding can take place
with the hydrolysis of ATP. Once the ATP has been hydrolyzed, the GroEL ring cavity reopens and the folded substrate is released (Amir et al., 2004; Poso et al., 2004; Wong et al.,
2004).
While the role of the GroE system in protein folding has been known for some time,
it is only recently that researchers have considered GroEL to be a protein with pathological
implications. Upon infection, bacterial GroEL can be exposed to host immune machinery by
lysis or by active bacterial secretion. During M. tuberculosis infections, for example,
populations of T cells show reactivity to chaperone 60.2 (the GroEL homologue) and the
active secretion of two populations of M. tuberculosis GroEL homologues are seen inside
macrophages (Ranford et al., 2000). GroEL production from E. coli has been seen to
correlate with the increase of numerous signaling molecules with as little as 1ug/ml of GroEL
in co-culture with HUVEC cells (Galdiero et al., 1997; Ranford et al., 2000; Retzlaff et al.,
1994). Several other bacteria, including Helicobacter, Legionella, and Actinobacillus, have
all been shown to use GroEL as a factor in their pathology (Garduno et al., 1998; Ranford et
al., 2000; Zhang et al., 2004). These data, combined with previous research into the role of
B. bacilliformis GroEL as a mitogen, raises the possibility that GroEL might play an
important part in the eruption of verruga peruana lesions during the B. bacilliformis infective
cycle. In order to determine the role of GroEL in angiogenesis, we have isolated GroEL
from low-passage number B. bacilliformis cultures and examined its angiogenic potential
using purified GroEL co-cultured with Human Microdermal Endothelial Cells (HMEC-1).
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We report here an increase in HMEC-tubule formation in the presence of purified B.
bacilliformis GroEL.
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Materials and Methods
Bacterial Growth and Culture. B. bacilliformis KC584 was grown as previously described
in Chapter I (page 30). Unused B. bacilliformis was placed in a 50% PBS/50% glycerol
mixture and stored at -80°C until needed.
Human Cell Growth and Culture. HMEC-1 cells were obtained as a generous gift from
Dr. Thomas Lawley, of Emory University and the Centers for Disease Control and
Prevention (Ades et al., 1992). HMEC-1 cells were grown and cultured as previously
described in Chapter II (page 70). Cells not intended for use immediately were resuspended
in DMSO Cryoprotectant (Cellgro) and stored at -80oC overnight, then moved to liquid
nitrogen for long term storage.
The HUVEC cells (Cambrex) were prepared via growth of the first passage HUVEC
cells in EGM-2 media (Cambrex) until 70-80% confluent in a T-75 flask (Starsdt). Upon
reaching confluency, the EGM-2 media was aspirated and 15 ml of trypsin-EDTA (CellGro)
solution was added and incubated until the cells began to round up and detach from the flask.
The trypsin solution was neutralized with the addition of 15 ml of EGM-2 media (Cambrex)
and the cell slurry was aspirated and transferred to a 50 ml conical tube (Falcon). The T-75
flask was then washed with 5 ml of HBSS (CellGro) and this was added to the conical tube
cell slurry. The HUVEC cells were then centrifuged for 8 minutes at 200xg, the supernatant
was decanted and the cells were resuspended in 5 ml of EGM-2 media. Aliquots of these
primary cells were made and those not intended for immediate use were resuspended in
DMSO Cryoprotectant (CellGro) and stored at -80oC overnight, then moved to liquid
nitrogen for long-term storage. Due to the unique nature of the primary HUVEC cell line,
only cells passaged 2-6 were used for experimental purposes.
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The epithelial cell line HEp-2 (ATCC) was maintained in T-75 flasks containing
M199 media (CellGro) replaced every 2-3 days depending on confluence. Upon reaching
75-80% confluency, the cells were released using 15 ml of Trypsin-EDTA (CellGro), after
aspiration of the M199 media. After allowing the cells time to round up, M199 with 5% FBS
was added to neutralize the trypsin and the detached cells were decanted into a 50 ml conical
tube (Fisher). The T-75 flask was rinsed with 5 ml of HBSS, which was also transferred into
the 50 ml tube. The cells were then pelleted by centrifugation at 200xg for 8 minutes. The
supernatant was then decanted and the HEp-2 cells were resuspended in 5 ml of M199 media.
Aliquots of these cells were made and those not intended for immediate use were
resuspended in DMSO Cryoprotectant (CellGro) and stored at -80oC overnight, then moved
to liquid nitrogen for long-term storage.
Host Cross-talk Analysis via Corning TransWell System. Analysis of cross-talk between
B. bacilliformis infected endothelial (HUVEC) and epithelial (HEp-2) cells, and uninfected
endothelial (HUVEC) cells, was done using the Corning TransWell Insert system. Briefly,
24-wells cell culture plates (Corning) were coated with Matrigel™ (BD BioSciences) and
after drying 750ul of M199 media was added. The wells were inoculated with 2x106 cell/ml
of PBS-washed HUVEC cells (Cambrex) (lower chamber). The HUVEC cells were then
allowed to grow at 37°C, 5% CO2 in a humidified incubator for 24 hours. After 24 hours of
incubation unused wells were filled with 1 ml of M199 media, to which a single TransWell
Insert was added. Into the TransWell insert chamber 300 µL of M199 media and HUVEC
cells (2 x 106 cells/ml) added into the TransWell Insert (upper chamber). The cell culture
plates were allowed to incubate for 24 hours at 37°C, 5% CO2 in a humidified incubator.
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B. bacilliformis KC584 were grown and harvested as previously described in Chapter
I (page 30). Bacteria were diluted in PBS to a MOI of 100:1 for the infection of upper
chamber HUVEC cells. The TransWell inserts were gently removed from their well and
placed into the wells containing previously grown HUVEC cells with Matrigel™ (lower
chamber), after fresh M199 media was added to both wells and inserts. To the TransWell
inserts (upper chamber), 10 µL of previously diluted B. bacilliformis was added and the plate
was incubated at 37°C, 5% CO2 in a humidified incubator. At each time point,
photomicrographs were taken of the lower uninfected HUVEC cells for angiogenic potential
analysis.
Analysis of cross-talk between infected epithelial (HEp-2) and uninfected (HUVEC)
cells was accomplished using similar methods. Again, after HUVEC cells had incubated for
24 hours on Matrigel™, unused wells were filled with 1 ml of M199 media. A single
TransWell Insert was added to the well followed by 300 µL of M199 media (upper chamber)
and HEp-2 cells (4x105 cells/ml) were added into the TransWell Insert directly (upper
chamber). The cell culture plates were allowed to incubate for 24 hours at 37°C, 5% CO2 in
a humidified incubator. Infection and photomicrograph monitoring were carried out as
described above, except that HEp-2 cells were infected with B. bacilliformis after 24 hours of
growth in the upper chamber.
Separation of B. bacilliformis Membranes. B. bacilliformis inner and outer membranes
were separated via sucrose gradient (Minnick, 1994) as follows. Previously harvested B.
bacilliformis was prepared in 5 ml of ice-cold 0.2M Tris-1mM MgSO4 (pH 8.0), and
centrifuged at 6000xg for 5 minutes at 4oC. The B. bacilliformis pellet was then re-suspended
in 5 ml of 0.2M Tris pH8.0. The suspension was mixed sequentially with 5 ml of 1M
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sucrose in 0.2M Tris (pH8.0), 10 !L of 0.5M EDTA and 75 !L of freshly prepared lysozyme
(25mg/ml stock), then incubated on ice for three hours. After the three-hour incubation, 10
ml of ice-cold deionized H2O was forcefully added to the mixture and the incubation was
continued for 30 minutes on ice; then 20 ml of 0.2M dithiothreitol (DTT) was added. To
break the cells completely, the mixture was passed through a French press at least twice.
Cell debris was removed by centrifuging at 10,000xg for 15 minutes at 4oC. The supernatant
was collected into ultracentrifuge tubes and diluted with one volume of deionized H2O. The
supernatant was then centrifuged at 240,000xg for 2 hours at 4oC to isolate the total
membrane fraction. The total membrane pellet was re-suspended in 0.5 ml of 20% sucrose1mM EDTA-2mM DTT. The sample was then layered onto a two-step sucrose gradient of
53%-70% sucrose-1mM EDTA and centrifuged at 160,000xg, for 16-18 hours at 4oC. The
inner membrane was isolated between the 20% and 53% interphase and the outer membrane
between the 53% and 70% interphase. The two membranes were carefully aspirated and
placed in separate ultracentrifuge tubes. The remaining proteins were precipitated from the
membrane fractions with four volumes of 5% (wt/vol) trichloroacetic acid for 16 hours at
4oC, and then centrifuged at 16,000xg for 15 minutes. The isolated membranes were resuspended in 0.2 volume of Laemmli sample buffer (100mM Tris-HCl, pH6.8, 200 mM
dithiothreitol, 4% SDS, 0.2% bromophenol blue and 20% glycerol) and stored at -20°C until
needed.
Proliferation and Cytokine Production Analysis of HMEC-1 in the presence of B.
bacilliformis Membranes. HMEC-1 were detached as described previously, and diluted in
sterile PBS, pH 7.4, to a concentration of 5x105 cells/ml. 100 µL of the HMEC-1 cell
dilution was added to a low-fluorescence 96-well plate(s) (Fisher) containing 100 µL of pre-
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warmed M199 (Cambrex) containing 15% FBS and 2% penicillin-streptomycin. The
dilution was calculated to provide each well with 50,000 cells total. The 96-well plate was
gently shaken to distribute the cells and then incubated at 37°C in 5% CO2 for 24 hours.
After 24 hours’ incubation, the medium was aspirated and replaced with pre-warmed M199
containing 5% FBS. The incubation was continued for 24 hours in the same conditions. For
the testing of inner and outer membranes, extracted as described above, 50uL (50mg/ml) of
purified inner and outer membranes were added to each well containing growing HMEC-1.
Controls were included for each test condition by adding equivalent volumes of sterile PBS,
pH 7.4. After incubation for the prescribed time period, the medium was removed and
replaced with 50 µL of 1x CyQuant Proliferation mix (Invitrogen), and the cells were
allowed to incubate at 37oC, 5% CO2 for 45 minutes. The 96-well plate was then read using
the Typhoon Variable Imaging System (GE/Amersham) set at 600V using the 520-nm blue
laser filter. The data were subsequently transferred to the ImageQuant Analysis software
(Amersham) and the pixel values were calculated for each well following the 96-well
template. Raw pixel data were then transferred to Excel and cell numbers were calculated
from a previously prepared HMEC-1 specific standard curve. ELISA analysis was
conducted on collected testing media for each time point noted and ELISA analysis was
conducted for each cytokine noted. Each ELISA was done with the manufacturer’s standards
and completed with a single control media and two experimental media. The plates were
read on a SPECTRAmax plate reader (Molecular Devices) at OD405. Raw data were
collected and correlated to a best-fit of the given cytokine standard per manufacturer’s
instructions. Control and experimental data were averaged to give a final result noted in
cytokine concentration (pg/ml).
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Proliferation Analysis by Infection of HMEC-1 with Live and Dead B. bacilliformis.
HMEC-1 were detached as described previously, and diluted in sterile PBS, pH 7.4, to a
concentration of 5x105 cells/ml. 100 µL of the HMEC-1 cell dilution was added to a lowfluorescence 96-well plate(s) (Fisher) containing 100 µL of pre-warmed M199 (Cambrex)
containing 15% FBS and 2% penicillin-streptomycin. The dilution was calculated to provide
each well with 50,000 cells total. The 96-well plate was gently shaken to distribute the cells
and then incubated at 37°C in 5% CO2 for 24 hours. After 24 hours’ incubation, the medium
was aspirated and replaced with pre-warmed M199 containing 5% FBS. The incubation was
continued for 24 hours in the same conditions. For the testing of live bacteria, B.
bacilliformis (passage 2-4) was added at a MOI of 100:1, and the cells were washed three
times in sterile PBS, pH 7.4. For the testing of dead bacteria, formalin-killed B. bacilliformis
(passage 2-4) was added at a MOI of 100:1, and the cells were washed three times in sterile
PBS, pH 7.4. Negative growth controls were prepared by adding 25-50 uL of sterile PBS,
pH 7.4, which had been incubated on BHI plates containing 10% sheep’s blood for eight
days at 25°C under conditions of saturated humidity. Controls were included for each test
condition by adding equivalent volumes of sterile PBS, pH 7.4. After incubation for the
prescribed time period, the medium was removed and replaced with 50 µL of 1x CyQuant
Proliferation mix (Invitrogen), and the cells were allowed to incubate at 37oC, 5% CO2 for 45
minutes. The 96-well plate was then read using the Typhoon Variable Imaging System
(GE/Amersham) set at 600V using the 520-nm blue laser filter. The data were subsequently
transferred to the ImageQuant Analysis software (Amersham) and the pixel values were
calculated for each well following the 96-well template. Raw pixel data were then
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transferred to Excel and cell numbers were calculated from a previously prepared HMEC-1
specific standard curve.
HMEC-1 growth on Matrigel. Angiogenesis analysis was conducted with HMEC-1 cells
grown on Matrigel% (BD BioSciences). Briefly, HMEC-1 cells were grown in T75 flasks
(Starsted) as noted above. Following cell pellet re-suspension in sterile PBS, the cells were
counted via hemocytometer and diluted to 1x106 cells/ml in sterile PBS. 100 µl of the
HMEC-1 dilution was added to each well containing a 1ml mixture of 50% M199 (Cambrex)
(15% FBS and 2% penicillin-streptomycin) and 50% EGM-2 (Cambrex), along with 100 µl
of pre-warmed, solidified Matrigel%. The cells were then incubated for 24 hours in 5% CO2
at 37°C. After 24 hours, the medium was aspirated and replaced with pre-warmed M199
with 5% FBS (Cambrex), and the cells were allowed to incubate in 5% CO2 at 37°C for
either 24 hours for “Newly-formed Vessels” or 48 hours for “Pre-formed Vessels,”
depending on the testing to be completed.
Angiogenesis Analysis of HMEC-1 Infection by Live and Dead B. bacilliformis.
HMEC-1 were grown as previous stated on Matrigel until “Newly-Formed and Pre-formed
Vessels” were present for testing. Live B. bacilliformis or formalin-killed B. bacilliformis,
prepared as described above and diluted in 100 µL of sterile PBS, pH 7.4, to give an MOI of
100:1, were added to each well. At the time of infection (time zero), two randomly chosen
areas in each well were marked and microphotographs were taken. At each prescribed time
point, the same field of view was photographed again. Once all time points had been
captured, the microphotographs were compiled and printed using a color laser printer. Each
microphotograph was analyzed for the number of angiogenic nodes, defined as the
convergence point of three vessels. These raw data were averaged for each well per time
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point in Excel (Microsoft) and graphed as needed. Each of these experiments was completed
in triplicate.
Growth of B. bacilliformis for Enhanced GroEL Production. B. bacilliformis KC584
(passage 2) were grown by the inoculation of 100 µL of bacteria stock onto 10 BHI plates
supplemented with 10% sheep’s blood and a subsequent incubation at 25°C with saturated
humidity for 96 hours. After 96 hours, 15 ml of sterile PBS, pH 7.4, was added to each of
the B. bacilliformis-containing plates and the plates were incubated at 25°C with saturated
humidity for another 96 hours. The B. bacilliformis was gently harvested as described above,
and the PBS/B. bacilliformis mixture was placed in 50-ml (Falcon) tubes. The bacteria were
centrifuged at 2000xg for 15 minutes at room temperature and stored at 4°C until needed.
Crude Purification of B. bacilliformis GroEL from Culture Supernatants. B.
bacilliformis GroEL was harvested immediately from B. bacilliformis culture supernatants.
To precipitate the proteins, ammonium sulfate was added to the culture supernatants to give a
50% saturated solution, and the samples were equilibrated for 1 hour at 4°C. The mixture
was then centrifuged at 12000xg for 30 minutes. The precipitated proteins were resuspended in 5 ml of Equilibration Buffer (50mM Tris-HCl, 0.5mM KCl, 0.5mM NaCl,
0.2mM PMSF and 5mM MgCl2, pH 7.5), which was then measured for protein concentration
using the Bradford method (Bradford, 1976). The presence of GroEL was determined by
SDS-PAGE on a 4-12% Bis-Tris gel (Invitrogen) and Western blot analysis.
Purification of B. bacilliformis GroEL via FPLC. Crude B. bacilliformis GroEL fractions
were further purified by FPLC. Briefly, an ATP-agarose column (Kamireddi et al., 1997;
Kandekar et al., 1993) was equilibrated with Equilibration Buffer (50mM Tris-HCl, 0.5mM
KCl, 0.5mM NaCl, 0.2mM PMSF and 5mM MgCl2, pH 8.2) at a flow rate of 0.2 ml/min for
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five column volumes. To the equilibrated column, 1 ml of the crude purification of B.
bacilliformis culture supernatants was added to the equilibrated ATP-agarose column; and
allowed to re-circulate for 12-16 hours at 4°C at 0.2mL/min. One column volume of
Equilibration Buffer was then allowed to move through the column before the Elution Buffer
(Equilibration Buffer containing 10mM ATP, pH 8.2) was added. Fractions of 2 ml were
collected and these were then subjected to SDS-PAGE to determine whether they contained a
band corresponding in size to that predicted for GroEL (65kDa). All fractions containing B.
bacilliformis GroEL were then concentrated further using an Amicon 30,000 dalton cutoff
membrane centrifuged for 10 minutes at 5000xg at 4°C. SDS-PAGE and Western blot
analysis were subsequently used to verify the presence and estimate the purity of B.
bacilliformis GroEL.
Proliferation Analysis of HMEC-1 Exposed to Purified B. bacilliformis GroEL with
HMEC-1. HMEC-1 were grown as previous stated and diluted to 5x105 cells/ml in sterile
PBS, pH 7.4. 100 µL of diluted cells were inoculated into each well of the low-florescence
96 well plate(s) containing 100 µL of pre-warmed M199 (Cambrex) (15% FBS and 2%
penicillin-streptomycin) to a final concentration of 50,000 cells per well. The cells were then
incubated at 37oC and 5% CO2. After 24 hours, the medium was aspirated and replaced with
100 µlLof M199 containing 5% FBS, and the cells were subsequently incubated at 37oC and
5% CO2. After 6 hours, 10 ng of GroEL was added to each well in a volume of 10 µL, while
10 µL of sterile PBS was added to each control well. Following an incubation for the
prescribed time period, the medium was removed and replaced with 50 µL of 1x CyQuant
Proliferation mix (Invitrogen) and allowed to incubate at 37°C and 5% CO2 for 45 minutes.
The 96-well plate was then read using the Typhoon Variable Imaging System
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(GE/Amersham) set at 600V and using the 520 nm blue laser filter. The data were then
transferred to the ImageQuant Analysis software (Amersham) and the pixel values were
calculated for each well following a 96-well template. Raw pixel data were then transferred
to Excel (Microsoft) and cell numbers were calculated from a previously prepared HMEC-1
specific standard curve.
Angiogenesis Analysis of HMEC-1 in the Presence of Purified B. bacilliformis GroEL.
HMEC-1 were grown on Matrigel as previously described until “Newly-Formed and Preformed Vessels” were present for testing. Ten ng of purified B. bacilliformis GroEL was
added to each experimental well in 10 µL of sterile PBS, pH 7.4. At the time of infection
(time zero) two randomly chosen areas in each well were marked and microphotographs
were taken. At each prescribed time point, the same field of view was photographed again.
Once all time points had been captured, the microphotographs were compiled and printed
using a color laser printer. Each microphotograph was analyzed for the number of
angiogenic nodes, defined as the point of convergence of three vessels. The raw data were
averaged for each well per time point and graphed as needed.
Angiogenesis Analysis of HMEC-1 in the Presence of Purified E. coli GroEL. HMEC-1
were grown and inoculated as previous stated, except that10 ng of purified E. coli GroEL in
10 µL of sterile PBS, pH 7.4, was added to each experimental well. Analysis of angiogenic
potential was completed as described above.
Angiogenesis Analysis of HMEC-1 in the Presence of Purified B. bacilliformis GroEL
and Rabbit E. coli Anti-GroEL antibodies. HMEC-1 were grown as previous described on
Matrigel until “Newly Formed Vessels” were present for testing. 10 ng of purified B.
bacilliformis GroEL (in 10 ml of sterile PBS, pH7.4) was added to each experimental well
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along with a 1:5000 dilution of Rabbit Anti-E. coli GroEL antibodies that had been
previously shown to react to purified B. bacilliformis GroEL. Analysis of angiogenic
potential was completed as described above.
Analysis of Cytokine Production by ELISA. Testing for the production of various
cytokines was done per the manufacturers’ recommendations. HMEC-1 cells were seeded in
96 well plates at 50,000 cells per well, and grown for 24 hours in pre-warmed EGM-2 media
(Cambrex). After 24 hours, the medium was decanted and replaced with pre-warmed M199
containing 5% FBS. After the addition of live B. bacilliformis, dead B. bacilliformis, or
purified B. bacilliformis GroEL, testing media were collected and ELISA analysis was
conducted for each cytokine noted. Each ELISA was done with the manufacturer’s standards
and completed with a single control media and two experimental media. The plates were
read on a SPECTRAmax plate reader (Molecular Devices) at OD405. Raw data were
collected and correlated to a best-fit of the given cytokine standard per manufacturer’s
instructions. Control and experimental data were averaged to give a final result noted in
cytokine concentration (pg/ml).
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Results
Effect of B. bacilliformis during infection of HMEC-1
HMEC-1 proliferation in the presence of B. bacilliformis.
HMEC-1 cells were analyzed for the induction of proliferation in the presence of live
and formalin-killed B. bacilliformis over a period of 48 hours. As shown in Figure 3.1, the
initial response by HMEC-1 cells to B. bacilliformis is indistinguishable from that of mockinfected control HMEC-1 cells. However, there is a dramatic 5.5-fold increase in HMEC-1
cell number at six hours post infection with live B. bacilliformis, with a continued
proliferative effect at 12 hours of almost 2.5-fold. This effect is also evident at 24 hours post
infection, with a 1.5-fold increase in HMEC-1 infected cells, but drops to less than
background levels at 36 hours post infection. Cell proliferation is not seen when HMEC-1
cells are infected with formalin-killed B. bacilliformis, as most time points are not
significantly different from those seen with mock-infected control cells.
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Figure 3.1 – HMEC-1 Proliferation during Infection with B. bacilliformis.
HMEC-1 cells were grown in EGM-2 media for 24 hours, then in M199 with 5% FBS for
another 12 hours. Live or formalin-killed B. bacilliformis, at an MOI of 100:1, were added to
the HMEC-1 cells and proliferation was assessed after various time points using CyQuant
(Invitrogen) dye, measured at 520 nm.
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HMEC-1 Tubule Formation in the Presence of B. bacilliformis.
Infection studies were conducted using HMEC-1 cells grown on Matrigel, an
environment that is optimized for tubule formation. HMEC-1 tubules allowed to grow for 48
hours before infection clearly showed a decrease in angiogenic vessels beginning at 24 hours
post infection with live B. bacilliformis. The maximum effect was observed at 72 and 96
hours, at which time there was nearly a 30-fold difference in nodule formation between the
infected and uninfected cultures (Figure 3.2). However, this effect was only observed
following infection with live bacteria: the presence of formalin-killed B. bacilliformis
produced no significant decrease in tubules relative to the uninfected control cells. HMEC-1
cells that were allowed to produce tubules for 24 hours prior to infection showed a slightly
decreased response as related to those that were allowed to grow for 48 hours before
infection; a decrease in vessel number of approximately 2.5 relative to the control is observed
after 72-96 hours (Figure 3.3). Again, the presence of dead Bartonella bacilliformis had no
overall effect on the angiogenic profile of these HMEC-1 cells.
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Figure 3.2 – Pre-formed HMEC-1 Tubule-formation in the presence of B. bacilliformis.
HMEC-1 cells were grown on Matrigel in EGM-2 media for 48 hours. The medium was
then changed to a low serum medium, M199 with 5% FBS, and the incubation was continued
for 12 additional hours before Bartonella was added at a MOI of 100:1. Photomicrographs
were taken at the time points noted above and each frame was analyzed for the presence of
blood vessel nodules. These were then used as a comparison from Time Point 0 (normalized
to 100%).
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Figure 3.3 – Newly-formed HMEC-1 Tubule formation in the presence of B. bacilliformis.
HMEC-1 cells were grown on Matrigel in EGM-2 medium for 24 hours. The medium was
then changed to a low serum media, M199 with 5% FBS, and the incubation was continued
for an additional 12 hours before Bartonella was added at a MOI of 100:1.
Photomicrographs were taken at the time points noted above and each frame was analyzed
for the presence of blood vessel nodules. These were then used as a comparison from Time
Point 0 (normalized to 100%).
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Analysis of Crosstalk between Infected and Uninfected Endothelial cells.
Cell to cell crosstalk studies were conducted using the Corning TransWell% system,
which allows for the movement of proteins across a membrane but does not allow the
crossing of live bacteria from one chamber to the next. Uninfected HUVEC cells were
allowed to grow in the lower chamber in a tubule-forming environment for 48 hours before
the upper layer of HUVEC cells was infected with B. bacilliformis at an MOI of 100:1.
Photomicrographs were taken at various time points over the subsequent 48-hour period.
While mock infected cells (data not shown) showed no appreciable degredation in tubules
formed over the 48 hour monitoring period, a dramatic decrease in tubules was noted after 24
hours of incubation in the lower chamber of uninfected HUVEC cells, which continues
through the monitored 48 hours (Figure 3.4). Further cell crosstalk studies were conducted
using infected HEp-2 cells, an epithelial cell line, in the top chamber of the Corning transwell system while uninfected HUVEC cells were grown in a tubule-forming environment in
the bottom. The photomicrographs reveal that within 8 hours there is a decrease in the
number of angiogenic vessels as compared to the previous time points measured (Figure 3.5),
while studies with mock infected cells showed no tubule degredation (data not shown).
These results indicate that the presence of live B. bacilliformis is not required for the
degradation of pre-formed tubules during the infection of endothelial and epithelial cells, and
suggests instead that a protein or some other soluble factor able to cross the TransWell
barrier promotes tubule degradation.
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Figure 3.4 – Cross-talk analysis of uninfected HUVEC cells in the presence of infected
HUVEC cells.
Cross-talk studies were conducted using the Corning TransWell% system allowing for the
diffusion of small molecules from the upper chamber, which contains B. bacilliformisinfected HUVEC cells, to the lower chamber, which contains uninfected HUVEC cells
growing in a tubule-forming environment. Photomicrographs were taken at the times noted
after addition of B. bacilliformis to the upper chamber (MOI 100:1).
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Figure 3.5 – Cross-talk analysis of uninfected HUVEC cells in the presence of infected HEp2 cells.
Cross-talk studies were conducted using the Corning TransWell% system allowing for the
diffusion of small molecules from the upper chamber, which contains B. bacilliformisinfected HEp-2 cells to the lower chamber, which contains HUVEC cells growing in a
tubule-forming environment. Photomicrographs were taken at the times noted after addition
of B. bacilliformis to the upper chamber (MOI 100:1).
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ELISA Analysis of HMEC-1 Cells in the Presence of B. bacilliformis.
ELISA analysis was conducted to determine the production of various cytokines over
the course of infection by B. bacilliformis of HMEC-1 cells growing in a non-tubule forming
environment. Initial studies were conducted with IL-2, IL-6 and TNF-alpha. IL-2 and TNFalpha showed no overall change from control conditions (Figures 3.6-3.8); however, at 24
hours post infection there was a slight decrease in IL-6 production in infected cells (Figure
3.7). Changes in the production of these cytokines was also monitored after infection with
formalin-killed bacteria. Again, there was no statistically significant change in production
(figure 3.9-3.11), with the single exception of a three-fold decrease in IL-6 after 36 hours of
infection (Figure 3.10).
Further studies were carried out with a larger battery of cytokines. IL-17 production
by HMEC-1 infected with live B. bacilliformis increased approximately 2.5-fold 48 hours
post infection (Figure 3.12). All other cytokines such as IGF-I (data not shown), IL-8
(Figure 3.13) and IL-18 (Figure 3.14) showed no overall change in production during
infection with live B. bacilliformis as compared with the uninfected control. However, there
were significant increases in the production of several cytokines in the presence of formalinkilled bacteria. Infection with formalin-killed B. bacilliformis showed an increase of IL-17
production at both six and 48 hours post infection, with a maximum increase of three-fold
after 48 hours (Figure 3.12). ELISA analysis of IL-8 production also showed increases at
six, 24 and 48 hours, with the largest increase (approximately seven-fold) occurring at 48
hours (Figure 3.13). Finally, the production of IL-18 in the presence of formalin-killed B.
bacilliformis with HMEC-1 cells showed an increase (relative to the control) of
approximately six fold at the 48 hour time point (Figure 3.14). It should be noted that in
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nearly all cases formalin-killed B. bacilliformis induced cytokine production at a higher rate
than live B. bacilliformis.
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Figure 3.6 – ELISA analysis of IL-2 production during infection with live B. bacilliformis.
IL-2 production by HMEC-1 cells was determined by ELISA analysis after the addition of B.
bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced
with M199 with 5% FBS and live B. bacilliformis was added at a MOI of 100:1. ELISA was
carried out per manufacturer’s instructions using a single control and two experimental
media. After the ELISA reaction was complete the 96-well plate was read using a
SPECTRAmax plate reader set at 450 nm.
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Figure 3.7 – ELISA analysis of IL-6 production during infection with live B. bacilliformis.
IL-6 production by HMEC-1 cells was determined by ELISA analysis after the addition of B.
bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced
with M199 with 5% FBS and live B. bacilliformis was added at a MOI of 100:1. ELISA was
carried out per the manufacturer’s instructions using a single control and two experimental
media. After the ELISA reaction was complete, the 96-well plate was read using a
SPECTRAmax plate reader set at 450 nm.
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Figure 3.8 – ELISA analysis of TNFa production during infection with live B. bacilliformis.
TNF-! production by HMEC-1 cells was determined by ELISA analysis after the addition of
B. bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was
replaced with M199 with 5% FBS and live B. bacilliformis was added at a MOI of 100:1.
ELISA was carried out per the manufacturer’s instructions using a single control and two
experimental media. After the ELISA reaction was complete, the 96-well plate was read
using a SPECTRAmax plate reader set at 450 nm.
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Figure 3.9 – ELISA analysis of IL-2 production during infection with formalin-killed B.
bacilliformis.
IL-2 HMEC-1 production was determined by ELISA analysis after the addition of formalinkilled B. bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was
replaced with M199 with 5% FBS and formalin-killed B. bacilliformis was added at a MOI
of 100:1. ELISA was carried out per the manufacturer’s instructions using a single control
and two experimental media. After the ELISA reaction was complete, the 96-well plate was
read using a SPECTRAmax plate reader set at 450 nm.
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Figure 3.10 – ELISA analysis of IL-6 production during infection with formalin-killed B.
bacilliformis.
IL-6 production of HMEC-1 was determined by ELISA analysis after the addition of
formalin-killed B. bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The
medium was replaced with M199 with 5% FBS and formalin-killed B. bacilliformis was
added at a MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a
single control and two experimental media. After the ELISA reaction was complete, the 96well plate was read using a SPECTRAmax plate reader at set 450 nm.
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Figure 3.11 – ELISA analysis of TNFa production during infection with formalin-killed B.
bacilliformis.
TNF-! production was determined by ELISA analysis after the addition of formalin-killed B.
bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced
with M199 with 5% FBS and formalin-killed B. bacilliformis was added at a MOI of 100:1.
ELISA was carried out per the manufacturer’s instructions using a single control and two
experimental media. After the ELISA reaction was complete, the 96-well plate was read
using a SPECTRAmax plate reader set at 450 nm.
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Figure 3.12 – ELISA Analysis of IL-17 Production in the presence of B. bacilliformis.
IL-17 production of HMEC-1 was determined by ELISA analysis after the addition of B.
bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced
with M199 with 5% FBS and live or formalin-killed B. bacilliformis was added at a MOI of
100:1. ELISA was carried out per the manufacturer’s instructions using a single control and
two experimental media. After the ELISA reaction was complete the 96-well plate was read
using a SPECTRAmax plate reader set at 450 nm. Analysis was completed based on per cell
number data obtained from proliferation assays in the presence of live and formalin-killed B.
bacilliformis.
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Figure 3.13 – ELISA Analysis of IL-8 Production in the presence of B. bacilliformis.
IL-8 production by HMEC-1 cells was determined by ELISA analysis after the addition of
B. bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was
replaced with M199 with 5% FBS and live or formalin-killed B. bacilliformis was added at a
MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a single
control and two experimental media. After the ELISA reaction was complete the 96-well
plate was read using a SPECTRAmax plate reader set at 450 nm. Analysis was completed
based on per cell number data obtained from proliferation assays in the presence of live and
formalin-killed B. bacilliformis.
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Figure 3.14 – ELISA Analysis of IL-18 Production in the presence of B. bacilliformis.
IL-18 production of HMEC-1 was determined by ELISA analysis after the addition of B.
bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced
with M199 with 5% FBS and live or formalin-killed B. bacilliformis was added at a MOI of
100:1. ELISA was carried out per the manufacturer’s instructions using a single control and
two experimental media. After the ELISA reaction was complete the 96-well plate was read
using a SPECTRAmax plate reader set at 450 nm. Analysis was completed based on per cell
number data obtained from proliferation assays in the presence of live and formalin-killed B.
bacilliformis.
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HMEC-1 proliferation in the presence of B. bacilliformis membranes.
HMEC-1 cells were studied for their proliferative response to the presence of inner
and outer B. bacilliformis membranes. As the data indicate (Figure 3.15), the presence of
inner membranes from B. bacilliformis induced an increase of approximately 1.5 fold in
HMEC-1 cell concentration at both 6 and 36 hours relative to the untreated control cells. In
contrast, the presence of B. bacilliformis outer membranes caused a four-fold decrease in cell
number at 36 hours post infection, with a similar but less dramatic decrease at six hours post
infection.
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Figure 3.15 – HMEC-1 Proliferation in the presence of B. bacilliformis membranes.
HMEC-1 cell proliferation was determined after the addition of B. bacilliformis inner (IM)
and outer (OM) membranes. HMEC-1 cells were grown in EGM-2 media for 24 hours, then
in M199 with 5% FBS for another 12 hours. Purified B. bacilliformis membranes, as noted,
were added to the HMEC-1 cells and proliferation was assessed after six and 36 hours using
CyQuant (Invitrogen) dye, as measured at 520 nm.
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ELISA analysis of HMEC-1 cells in the presence of B. bacilliformis cellular components
Production of IL-2, IL-6 and TNF&alpha by HMEC-1 cells was measured in the
presence of B. bacilliformis inner and outer membranes in order to determine the cytokine
response of HMEC-1 cells to these bacterial components. As shown in Figure 3.16, IL-2
production in the presence of either inner or outer membrane fractions decreased by
approximately 1.5 fold relative to the control at 36 hours post incubation. Analysis of IL-6
production shows an increase at both six and 36 hours in the presence of B. bacilliformis
outer membranes and at 36 hours in the presence of B. bacilliformis inner membranes (Figure
3.17). Finally, TNF-alpha production exhibits an overall decrease at 36 hours in the presence
of B. bacilliformis outer membranes (Figure 3.18).
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Figure 3.16 – ELISA analysis of IL-2 production in the presence of B. bacilliformis
membranes.
IL-2 production by HMEC-1 cells was determined by ELISA analysis after the addition of B.
bacilliformis inner (IM) and outer (OM) membranes. HMEC-1 cells were grown for 24
hours in EGM-2. The medium was replaced with M199 with 5% FBS and B. bacilliformis
membranes were added. ELISA was carried out per the manufacturer’s instructions using a
single control and two experimental media. After the ELISA reaction was complete the 96well plate was read using a SPECTRAmax plate reader set at 450 nm.
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Figure 3.17 – ELISA analysis of IL-6 production in the presence of B. bacilliformis
membranes.
IL-6 production by HMEC-1 cells was determined by ELISA analysis after the addition of B.
bacilliformis inner (IM) and outer (OM) membranes. HMEC-1 cells were grown for 24
hours in EGM-2. The medium was replaced with M199 with 5% FBS and B. bacilliformis
membranes were added. ELISA was carried out per the manufacturer’s instructions using a
single control and two experimental media. After the ELISA reaction was complete the 96well plate was read using a SPECTRAmax plate reader set at 450 nm.
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Figure 3.17 – ELISA analysis of TNF! production in the presence of B. bacilliformis
membranes.
TNF! production by HMEC-1 cells was determined by ELISA analysis after the addition of
B. bacilliformis inner (IM) and outer (OM) membranes. HMEC-1 cells were grown for 24
hours in EGM-2. The medium was replaced with M199 with 5% FBS and B. bacilliformis
membranes were added. ELISA was carried out per the manufacturer’s instructions using a
single control and two experimental media. After the ELISA reaction was complete the 96well plate was read using a SPECTRAmax plate reader set at 450 nm.
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Analysis of Production of B. bacilliformis GroEL.
Recent studies have shown that extracts containing the molecular chaperone GroEL
have a proliferative effect on B. bacilliformis-infected cells. To determine whether the
protein plays a direct role in cell proliferation, we purified GroEL and measured its
mitogenic abilities in culture. As a first step, we sought to optimize conditions for the
isolation and purification of B. bacilliformis GroEL.

Initial studies evaluated GroEL

production by both Bartonella bacilliformis KC584 and Bartonella bacilliformis JB584 on
BHI (Figure 3.19a) and TSA (Figure 3.19b) agar with a supplement of 10% sheep's blood.
After 10 days of growth on BHI agar (Figure 3.19a), the bacteria were physically removed
from the plate and and concentrated via centrifugation. The re-suspension was then
examined using SDS-PAGE and Western blot analysis for bacterial GroEL. After 10 days of
growth on solid media, no detectable amount of Bartonella GroEL was visualized via SDSPAGE or Western blot. Further studies were conducted with B. bacilliformis KC584 grown
on TSA with 10% sheep's blood (Figure 3.19b), and again the bacteria were physically
harvested and clarified using centrifugation. GroEL production was monitored at growth
days 1, 3, 5, 7 and 10 using SDS-PAGE and Western blot (data not shown). As shown in
Figure 3.19, bacterial GroEL was not obtained under these conditions either. Further studies
were conducted in liquid media consisting of Schaedler broth supplemented with 10%
sheep's blood. Bartonella bacilliformis KC584 was evaluated for the secretion of GroEL in
this liquid environment over a 10-day time course. At days 1, 3, 5, 7, and 10 the liquid was
clarified by centrifugation and the supernatant was subjected to both SDS-PAGE and
Western blot analysis (Figure 3.20). These conditions resulted in the identification of a
protein migrating at approximately 65 kilodaltons, the size predicted for B. bacilliformis
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GroEL. The 65-kilodalton protein was observed at high concentrations on both the SDSPAGE and Western blot starting at growth day four. The SDS-PAGE is further distinguished
by a characteristic double banding pattern produced in response to rabbit-produced E. coli
anti-GroEL antibodies. This additional band has been reported previously with purified
GroEL fractions from other Bartonella species (Haake et al., 1997), and has been attributed
to dimerization of GroEL or the presence of additional proteins bound to GroEL. Further
studies were conducted to verify the secretion of GroEL in the presence of both HUVEC
cells and HMEC-1 cells, and production of GroEL was evident in both tissue culture
environments (data not shown).
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Figure 3.19 – SDS & Western blot Analysis of B. bacilliformis Growth on Solid Media.
Figure A - B. bacilliformis KC584 (I) and JB584 (II) were grown on solid BHI and samples
taken after 10 days growth, Western blot analysis was done against GroEL using anti-E. coli
GroEL antibodies. Figure B - TSA agar (B) supplemented with 10% sheep’s blood over the
course of 10 days, with samples of B. bacilliformis taken every other day starting at Day 1
post inoculation (growth day indicated above lanes) . SDS-PAGE was conducted on each
sample, after clarification, as noted above, and Western blot analysis was completed (data not
shown).
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Figure 3.20 – SDS-PAGE and Western Blot Analysis of B. bacilliformis growth in liquid
media.
B. bacilliformis was grown in 100 ml bottles of Schaedler broth supplemented with 10%
sheep’s blood. Samples were taken, and after sample clarification and RBC lysis with double
distilled H2O each sample was run on SDS-PAGE (lanes indicate growth day 1, 3, 5, 7, 9 &
10). Western blot analysis was completed using rabbit-based E. coli Anti-GroEL antibodies.
The arrows indicate the position expected for GroEL (65 kDa) and the position of a possible
dimer (145 kDa).
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GroEL purification.
Purification of GroEL was carried out on extracts of Bartonella bacilliformis KC584
using both ammonium sulfate and ATP-agarose column purification (Figure 3.21 and 3.22).
At each step, the presence of an immunoreactive protein with the predicted molecular weight
of GroEL (65 KDa) was monitored by SDS-PAGE and Western blot analysis. Western blot
analysis (Figure 3.23) was conducted using rabbit-produced E. coli anti-GroEL antibodies.
Each positive Western blot shows a unique double banding, with immunoreactive proteins
migrating at approximately145kDa and 65kDa. This additional band has been reported
previously with purified GroEL fractions from other Bartonella species (Haake et al., 1997),
and has been attributed to GroEL dimerization or the presence of additional proteins bound to
GroEL.
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Figure 3.21 – SDS-PAGE analysis of B. bacilliformis GroEL purification after Ammonium
Sulfate Fractionation.
B. bacilliformis was grown on BHI with 10% sheep’s blood for 4 days followed by 4 days of
growth under PBS, then harvested by scraping. After clarification, the sample was mixed
with 50% ammonium sulfate and the proteins were allowed to precipitate. This mixture was
then centrifuged and re-suspended in buffer and a sample, shown in lane 2, was run on SDSPAGE. A Western blot was carried out (not shown) in order to verify the presence of the 65
kDa GroEL protein (indicated by the arrow). The position of a possible dimer migrating at
approximately 145 kDa is also shown.
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Figure 3.22 – SDS-PAGE Analysis of B. bacilliformis GroEL purification after ATP-Agarose
elution.
An ATP-agarose column was used to further purify B. bacilliformis GroEL, after ammonium
sulfate fractionation. The crude fraction believed to contain GroEL was added to the ATPcolumn and allowed to circulate for 16 hours, then eluted in 10mM ATP containing buffer.
The SDS-PAGE gel shows the fractions collected in lanes 2-7. The positions of proteins
reacting against anti-E. coli GroEL antibodies are indicated by the arrows (65 kDa and 145
kDa).
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Figure 3.23 – SDS-PAGE and Western Blot Analysis of B. bacilliformis GroEL purification
after Amicon Filtration.
After ATP-column purification the B. bacilliformis GroEL was polished using an Amicon
filter, MW Cutoff 30,000 kDa, as per the manufacturer’s instructions. The SDS-PAGE (A)
indicates purified GroEL (145kDa and 65kDa), lane 1 shows the protein marker (Bio-Rad,
All Blue), and lane 2 shows purified GroEL after Amicon polishing. Western blot analysis
(B) indicating the presence of purified GroEL using anti-E. coli GroEL antibodies.
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Induction of HMEC-1 Proliferation by Purified Bartonella bacilliformis GroEL.
Purified B. bacilliformis GroEL was evaluated for its ability to induce proliferation of
HMEC-1 cells in 96-well plates. After a series of purified B. bacilliformis GroEL infection
studies were completed to determine the best possible proliferative dilutions (data not
shown), a range of 10 ng to 1 ng of purified GroEL was chosen as the optimal conditions for
the proliferation studies. Further experiments showed that GroEL at most of these
concentrations had no detectable effect on proliferation of HMEC-1 cells that were not in a
tubule-forming environment; only 10 ng of GroEL gave any consistent yet weak proliferative
effect (data not shown).
HMEC-1 Tubule Formation in the Presence of purified GroEL.
Purified B. bacilliformis GroEL was incubated with HMEC-1 cells that were allowed
to grow in a tubule-forming environment for either 24 or 48 hours prior to GroEL addition.
Incubation of cells with 5 ng of purified GroEL produced an overall increase in angiogenesis
as compared to controls, with a maximum increase of two fold at 48 hours with 24-hour,
“newly-formed” HMEC-1 tubules (data not shown). Studies using 10 ng of purified
Bartonella bacilliformis GroEL showed a dramatic increase in tubule formation across time
points from six to 96 hours (Figure 3.24). This angiogenic effect reached a maximum at 72
hours, where a five-fold increase in angiogenesis as compared to the control was observed.
Further studies were conducted to determine the effect of incubating HMEC-1 with both live
B. bacilliformis (MOI of 100:1) and 10 ng/ml of purified B. bacilliformis GroEL. The results
of these studies indicate that the presence of B. bacilliformis GroEL continues to induce
angiogenesis in HMEC-1 cells despite ongoing infection by B. bacilliformis. As shown in
Figure 3.25, there is a stable increase in angiogenesis seen after 24 hours of infection which
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continues throughout the 96 hour monitoring period. This increase in angiogenesis is seen
maximally at 48 hours as a two-fold increase relative to mock infected HMEC-1 cells, and
continues through the remaining time points. In order to ensure that the angiogenesis seen
was induced by B. bacilliformis GroEL and not by a minor contaminant of the GroEL protein
preparation, a series of control experiments was carried out in which HMEC-1 cells were
incubated with E. coli anti-GroEL antibodies in the presence of live B. bacilliformis, B.
bacilliformis GroEL, or E. coli GroEL (Figures 3.26-3.29). The results indicate that antiGroEL antibodies significantly reduce the angiogenic effect seen with purified B.
bacilliformis GroEL; furthermore, they show that neither E. coli GroEL nor anti-GroEL
antibodies themselves affect angiogenesis in HMEC-1 cells.
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Figure 3.24 – HMEC-1 Tubule-formation in the presence of purified B. bacilliformis GroEL.
Ten ng of purified B. bacilliformis GroEL was added to HMEC-1 cells that had been grown
for 36 hours in EGM-2 on Matrigel followed by 12 hours’ growth in M199 media containing
5% FBS. Photomicrographs were taken at the time points noted above and each frame was
analyzed for the presence of blood vessel nodules. The 0 time points for experimental and
control samples were each normalized to 100; subsequent time point values are expressed as
a percent of the initial time point.
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Figure 3.25 – HMEC-1 Tubule-formation in the presence of Live B. bacilliformis and GroEL.
Purified B. bacilliformis GroEL was added to HMEC-1 cells that had B. bacilliformis at an
MOI of 100:1 and 10 ng of purified GroEL were added to HMEC-1 cells that had been
grown for 36 hours in EGM-2 on Matrigel followed by 12 hours’ growth in a low serum
M199 medium containing 5% FBS. Photomicrographs were taken at the time points noted
above and each frame was analyzed for the presence of blood vessel nodules. The 0 time
points for experimental and control samples were each normalized to 100; subsequent time
point values are expressed as a percentage of the initial time point.
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Figure 3.26 – HMEC-1 Tubule-formation in the presence of E. coli GroEL Antibodies.
Rabbit-based E. coli Anti-GroEL antibodies (diluted 1:5000) were added to HMEC-1 cells
that had been grown for 36 hours in EGM-2 on Matrigel followed by 12 hours in a low serum
M199 medium containing 5% FBS. Photomicrographs were taken at the time points noted
above and each frame was analyzed for the presence of blood vessel nodules. The 0 time
points for experimental and control samples were each normalized to 100; subsequent time
point values are expressed as a percent of the initial time point.
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Figure 3.27 – HMEC-1 Tubule-formation in the presence of Live. B. bacilliformis and E. coli
Anti-GroEL Antibodies.
Live B. bacilliformis and anti-GroEL antibodies (diluted 1:5000) were added to HMEC-1
cells that had been grown for 36 hours in EGM-2 on Matrigel followed by growth for 12
hours in a low serum M199 medium containing 5% FBS. Photomicrographs were taken at
the time points noted above and each frame was analyzed for the presence of blood vessel
nodules. The 0 time points for experimental and control samples were each normalized to
100; subsequent time point values are expressed as a percent of the initial time point.
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Figure 3.28 – HMEC-1 Tubule-formation in the presence of B. bacilliformis GroEL and E.
coli GroEL antibodies.
Purified B. bacilliformis GroEL (10 ng) in the presence of E. coli anti-GroEL antibodies
(diluted 1:5000) were added to HMEC-1 cells that had been grown for 36 hours in EGM-2 on
Matrigel followed by 12 hours’ growth in a low serum, M199 with 5% FBS, media.
Photomicrographs were taken at the time points noted above and each frame was analyzed
for the presence of blood vessel nodules. These were then used as a comparison from Time
Point 0 to determine the up- or down-regulation of HMEC-1 tubule formation.
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Figure 3.29 – HMEC-1 Tubule-formation in the presence of purified E. coli GroEL and E.
coli Anti-GroEL antibodies.
Purified E. coli GroEL (10 ng) and Anti-GroEL antibodies (diluted 1:5000) were added to
HMEC-1 cells that had been grown for 36 hours in EGM-2 on Matrigel followed by 12
hours’ growth in a low serum M199 medium containing 5% FBS. Photomicrographs were
taken at the time points noted above and each frame was analyzed for the presence of blood
vessel nodules. The 0 time points for experimental and control samples were each
normalized to 100; subsequent time point values are expressed as a percent of the initial time
point.
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ELISA Analysis of HMEC-1 cells in the Presence of Purified B. bacilliformis GroEL.
ELISA analysis was carried out to determine the production of various cytokines by
HMEC-1 after incubation with 10 ng GroEL in a tubule-forming environment. Overall,
cytokine production of IL-2 and IL-6 showed a general increase relative to the control, while
IL-8, IL-17 and IL-18 showed little to no change. Specifically, IL-2 induction was seen after
24 hours, with a seven-fold increase in IL-2 production over that of the mock incubated
HMEC-1 (Figure 3.30). Unlike IL-2, IL-6 production showed an overall increase at all
measured time points, with the greatest increase (10-fold) noted at six hours (Figure 3.31).
Production of IL-8 showed a slight decrease relative to the control at all measured time
points, but none of statistical significance (Figure 3.32). IL-17 cytokine production (Figure
3.33) exhibited almost no change from control values. Production of IL-18 showed a slight
increase at 12 hours post incubation while other time points showed little change (Figure
3.34).
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Figure 3.30 – ELISA Analysis of IL-2 production in the presence of B. bacilliformis GroEL.
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; then the media was replaced
with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was added.
ELISA was carried out per the manufacturer’s instructions using a single control and two
experimental media. After the ELISA reaction was complete, the 96-well plate was read
using a SPECTRAmax plate reader set at 450 nm.
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Figure 3.31 – ELISA Analysis of IL-6 production in the presence of B. bacilliformis GroEL.
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the media was then replaced
with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was added.
ELISA was carried out per the manufacturer’s instructions using a single control and two
experimental media. After the ELISA reaction was complete, the 96-well plate was read
using a SPECTRAmax plate reader set at 450 nm.
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Figure 3.32 – ELISA Analysis of IL-8 production in the presence of B. bacilliformis GroEL.
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the medium was then
replaced with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was
added. ELISA was carried out per the manufacturer’s instructions using a single control and
two experimental media. After the ELISA reaction was complete, the 96-well plate was read
using a SPECTRAmax plate reader set at 450 nm.
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Figure 3.33 – ELISA Analysis of IL-17 production in the presence of B. bacilliformis GroEL.
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the medium was then was
replaced with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was
added. ELISA was carried out per the manufacturer’s instructions using a single control and
two experimental media. After the ELISA reaction was complete, the 96-well plate was read
using a SPECTRAmax plate reader set at 450 nm.
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Figure 3.34 – ELISA Analysis of IL-18 production in the presence of B. bacilliformis GroEL.
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the medium was then
replaced with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was
added. ELISA was carried out per the manufacturer’s instructions using a single control and
two experimental media. After the ELISA reaction was complete, the 96-well plate was read
using a SPECTRAmax plate reader set at 450 nm.
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Motif analysis of Bartonella bacilliformis KC584 GroEL.
DNA and protein sequence analyses were conducted on B. bacilliformis KC583
GroEL (Accession YP989430) in order to search for any unique motifs that may be present
in this protein. DNA sequence analysis using Vector NTI AlignX (Invitrogen) was
conducted to compare the GroEL open reading frame deduced from the published B.
bacilliformis KC583 with those of other bacterial species, as well as those coding for GroEL
proteins and homologues implicated in disease and immunosuppression (Table 3.1). B.
bacilliformis GroEL DNA shares high sequence identity to the GroEL open reading frames
of B. henselae (85.0%), B. quintana str Toulouse (84.7%) and a lower 45.5% identity to that
of B. tribocorum GroEL, with a similar degree of identity to homologues of other Bartonella
species and other members of the !-2 Proteobacteria family (data not shown). Comparison of
the gene encoding B. bacilliformis GroEL to bacterial DNA sequence(s) from other genera
shows high individual identity, with the highest being B. abortus (72.5%), followed by E.
coli K12 and M. loti, with 65.8% and 65.7% identity, respectively. The degree of identity
between DNA sequences coding for B. bacilliformis GroEL and GroEL proteins implicated
in disease states from 34% to 63.1%, with Human HSP70 and C. trachomatis GroEL
exhibiting the lowest and highest level of identity, respectively. Finally, a comparison of B.
bacilliformis GroEL DNA sequences of eukaryotic GroEL homologues exhibited little or no
sequence identity above random background, with the possible exception of Mouse HSP60.
Comparison of the predicted amino acid sequences of the GroEL open reading frames
reveals a high degree of identity, as well as functional similarity. Within the genus
Bartonella, the identity exceeded 90% for all species tested. When protein homology was
determined between B. bacilliformis and other common bacterial GroELs there was an 88.4%
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similarity between all sequences noted with the highest similarity to B. abortus (92.5%). As
with the DNA sequence comparisons, amino acid identity and functional similarity between
B. bacilliformis and disease implicated GroEL species are lower (ranging from 20.2% to
79.6%) and the comparison with two of the three immunosuppressive GroEL proteins reveals
no significant identity or similarity. The very low identity within this grouping is not
unexpected as these proteins are derived from eukaryotic sources.
Motif analysis (MotifScan) indicates that the B. bacilliformis GroEL amino acid
sequence contains an unusual sequence of amino acids at position 466-492. This sequence,
termed the staphylocoagulase binding motif, is found in several strains of Staphylococcus
aureus (Figure 3.35) and is known to be able to form complexes with prothrombin
(Kawabata et al., 1985). Interestingly, the GroEL proteins from B. henselae and B. quintana
also contain a similar staphylocoagulase motif site, with each differing from the B.
bacilliformis protein at five positions (Figure 3.35). Motif-based searches of other human, !2-proteobacterial and infective bacterial GroEL proteins do not reveal other organisms that
share this unique staphylocoagulase-binding site.
In order to determine the hydrophobicity and antigenicity of the B. bacilliformis
GroEL protein, a series of Kyte/Doolittle and Hopp/Woods plots were prepared based on the
published B. bacilliformis KC583 GroEL DNA sequence. Examination of the Kyte/Doolittle
hydrophobicity plot indicates that B. bacilliformis GroEL is hydrophilic overall, which is
expected of a cytosolic/extracellular protein (Figure 3.36). The Hopp/Woods antigenicity
plot of B. bacilliformis GroEL indicates that there are several acceptable epitope sites for
antibody production; the highest scores are observed for sites between amino acids 350-435,
a region located at a distance from the Staphylocoagulase-binding site motif. Further
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Kyte/Doolittle hydrophobicity analysis reveals that amino acids between 468 and 485 are
weakly scored as being buried inside the GroEL globular protein structure, while amino acids
486-500 are predicted to be on the outer surface of the protein (Figure 3.37). A detailed
Hopp/Woods antigenicity analysis of amino acids 460-500 indicates a mix of weak epitope
sites. This analysis shows amino acids 467-475 to be predicted epitope sites, whereas 475495 are unlikely to be epitopes.
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Table 3.1 - B. bacilliformis GroEL DNA and Protein Sequence Homology to Bacterial
GroELs/Eukaryotic HSP Homologues.
DNA and protein sequence homology analysis was completed via AlignX (Vector NTI)
between common bacterial GroEL proteins, GroEL-implicated disease factors and GroEL
homologues with known immunosuppressant roles in disease.
DNA
Protein Sequence
Sequence
Identity Identity Similarity
Bartonella GroEL Homologues
B. henselae
B. quintana str Toulouse
B. tribocorum
GroEL Homologues of Other Bacteria
M. loti
R. Prowazekii
E. coli K12
R. typhi
H. pylori
M. pneumonia
B. abortis
GroEL-Implicated Disease Factor
C. trachomatis
P. gingivalis
Human HSP60
Human HSP70
GroEL-Homologues with Known
Immunosupressant Roles
Rat HSP60
Human HSP10
Mouse HSP60

85.0%
84.7%
45.5%

91.6%
91.4%
90.9%

95.1%
95.1%
95.1%

65.7%
64.5%
65.8%
64.9%
60.7%
54.1%
72.5%

78.3%
64.9%
65.8%
64.9%
61.6%
44.3%
85.5%

87.9%
78.4%
78.3%
78.4%
75.1%
60.7%
92.5%

63.1%
61.7%
57.9%
34.0%

61.9%
65.1%
51.7%
11.4%

75.2%
77.9%
68.2%
20.2%

19.0%
10.0%
57.4%

7.3%
3.1%
51.7%

12.3%
5.0%
68.2%
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Figure 3.35 – Analysis of a possible staphylocoagulase motif site in B. bacilliformis GroEL.
AlignX (Invitrogen) was used to conduct a protein sequence-based alignment of the known
GroEL sequences for various Bartonella species, including B. henselae (BH), B. quintana
Toulouse (BQT) and B. bacilliformis (BB). This view of amino acids 451-500, shows the
predicted staphylocoagulase binding site of B. bacilliformis in red, with the unique amino
acid residues as compared to the other Bartonella species noted in blue. The remainder of
the protein sequence alignment can be found in Appendix I.
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Figure 3.36 – Hydrophilicity and antigenicity plots for B. bacilliformis GroEL. Panel A & B
above represent the hydrophilicity (A) and antigenicity (B) of the B. bacilliformis GroEL
protein as conducted via MacVector 9.5. The B. bacilliformis GroEL protein sequence was
used to complete both the Kyte/Doolittle (hydrophilicity) and Hopp/Woods (antigenicity)
plots using an analysis window of 7.
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Figure 3.37 – Hydrophilicity & antigenicity plots for aa 460-500 of B. bacilliformis GroEL.
Panels A and B above represent the hydrophilicity(A) and antigenicity (B) of the
approximate location of the established Staphylocoagulase binding-site motif of B.
bacilliformis GroEL protein as conducted via MacVector 9.5. The B. bacilliformis GroEL
protein sequence from amino acid 460-500 was used to complete both the Kyte/Doolittle
(Hydrophilicity) and Hopp/Woods (Antigenicity) plots using an analysis window of 7.
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Discussion
Carrion’s disease, the infection caused by B. bacilliformis, is marked in the latter
phase by the formation of verruga, which are known to be proliferative lesions brought about
by cutaneous uncontrolled angiogenesis. These lesions form after the migration of B.
bacilliformis from host RBCs to the endothelial cells lining blood vessels and the subsequent
invasion of these cells. Several studies have reported results implicating B. bacilliformis
supernatants and possible secreted factors in verruga formation, although none have yet
presented a cohesive model for how this could occur (Garcia et al., 1992; Minnick et al.,
2003; Smitherman et al., 2005). In this study we attempt to identify the role played by B.
bacilliformis and the highly antigenic BB65 protein, which has been previously determined
to be a potential virulence factor and has been tentatively identified as a GroEL homologue
(Garcia et al., 1990; Knobloch, 1988; Knobloch et al., 1990).
Inoculation of HMEC-1 cells with live B. bacilliformis resulted in a significant,
though transient, increase in cell number (relative to the mock infected control) at 6 and
12 hours post infection. These results are very similar to what has been noted previously by
Liberto et al. (2004) in their studies of B. quintana. These investigators reported that
between 8 and 24 hours post infection of HMEC-1 cells with B. quintana, p38 map kinase
and JNK/SAPK signaling is inhibited, resulting in the induction of anti-apoptotic factors and
an increase in cell proliferation due to the decrease in host cell apoptosis (Liberto et al.,
2004). Our data suggest that this effect may also be in play during B. bacilliformis infection.
The transient nature of the cell proliferation observed in our studies may be due to the
production of cells that are unable to attach properly and therefore become free-floating;
since HMEC-1 require polarity to live, these free-floating cells would subsequently die.
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Also, it should be noted that we only observed proliferation in the presence of live B.
bacilliformis, but not with formalin-killed bacteria. This could indicate that not only are live
bacteria required but also that they are producing a factor(s) that is inducing proliferation in
HMEC-1cells. Research with B. henselae suggests that the presence of the bacteria in coculture with HUVEC cells is all that is required for the cells to proliferate as long as the
bacteria are alive; direct cell-to-bacteria contact is not required. B. quintana have been
shown to increase the production of the anti-apoptotic factor Bcl-2 at approximately 10 hours
post infection. The resulting cell survival would have a positive effect on B. quintana
infection as well, since it would provide a larger number of host cells able to support
bacterial growth (Liberto et al., 2004).
Cytokine Production in the Presence of Bartonella bacilliformis
In order to assess the effect of B. bacilliformis infection on the cytokine profile of
HMEC-1 cells these host cells were infected with both live and formalin-killed B.
bacilliformis and monitored for alterations in the cytokine production. Infection with live B.
bacilliformis resulted in little or no change in IL-2, IL-6, or TNF alpha cytokine production.
IL-17 production, on the other hand, was increased by three fold during the time course.
This increase in IL-17 production could indicate the initiation of an angiogenesis cascade
that, due to the lack of proper environmental signals, was not completed. Interestingly, we
did not observe an increase in IL-8 or IL-18 production from the HMEC-1 cells during
incubation with B. bacilliformis. This observation contrasts with that of Resto-Ruiz, et al.
(2002), who reported an increase in IL-8 production by HMEC-1 cells following 6 hours of
incubation with B. henselae.
Our data suggest that formalin-killed B. bacilliformis is generally able to induce a
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higher cytokine response than live B. bacilliformis, exhibiting an increase in IL-6, IL-8, IL17 and IL-18 evident between 36 and 48 hours of incubation. This may be due to in
increased persistence of the killed bacteria in the extracellular environment.
Incubation of HMEC-1 cells with isolated membranes of B. bacilliformis generated
results that correlate more closely with those reported for other Bartonella species than the
results we observed with live bacteria. Incubation with fractionated inner or outer
membranes produced an increase of IL-6 production at the 6- and 36-hour time points. This
increase has also been seen with B. henselae during macrophage infection, and with B.
quintana infection of HUVECs (Capo et al., 2003; Musso et al., 2001). Also, we note a
decrease in the overall production of TNF alpha in the presence of B. bacilliformis outer
membranes, seen maximally at 36 hours. This could indicate that, much like B. quintana, the
LPS of B. bacilliformis is a poor inducer of inflammatory responses normally observed with
other Gram-negative bacteria (Liberto et al., 2003).
The addition of membrane components also had a demonstrable effect on the number
of HMEC-1 cells in culture. Inner membranes caused a slight (approximately 1.5 fold)
increase in cell number relative to the mock infected control after both 6 and 36 hours of
incubation. Conversely, outer membranes produced a four-fold decrease in cell number after
36 hours. These results raise the possibility that B. bacilliformis outer membranes contain a
factor(s) that negatively affects cell proliferation or viability.
B. bacilliformis Infection and Angiogenesis
Our results indicate that B. bacilliformis not only affects cell number, but also
promotes changes in the blood vessels that are the hallmark of angiogenesis. Live B.
bacilliformis was found to have a significant effect on the stability of tubules formed by
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endothelial cells, causing a 30-fold decrease in pre-formed tubules (relative to mock infected
controls) over a 96 hour time period. These data would appear to suggest that live B.
bacilliformis causes a decrease in angiogenesis, a finding that would conflict with the clinical
observations of increased angiogenesis during B. bacilliformis induced verruga peruana
formation. The degradation of tubules could be advantageous at early stages of infection as it
would increase the localized environment of red blood cells, thus allowing for a higher
concentration of hemin in the localized environment and providing at an additional
nutritional source for the infecting bacteria. Previous work by Verma et al. (2000) has shown
that B. bacilliformis is able to induce cytoskeletal rearrangement and therefore disrupts cellto-cell contacts. Their research also suggests that endothelial cell motility is decreased by B.
bacilliformis infection. This decrease in motility could therefore interfere with the
endothelial cells’ ability to form tubules, causing them to be unable to take part in further
angiogenesis (Verma et al., 2001; Verma et al., 2000; Verma et al., 2002). The degradative
effect on preexisting tubules, or the effect of infection itself, may also establish conditions
that promote a response by the cells that ultimately leads to new blood vessel formation. It is
interesting to note that the expression of genes coding for two subunits of hypoxia induced
growth factor (HIF), a protein that has been shown to promote angiogenesis, are significantly
upregulated following B. bacilliformis infection (Chapter II). Taken together, these
processes could result in the poorly formed blood vessels characteristic of verruga peruana.
Crosstalk analysis and angiogenesis
Our work with cell-signaling involved studies with both endothelial and epithelial cell
lines (HUVEC and HEp-2, respectively) using the Corning TransWell% System. This
system allows for the movement of proteins, but not bacteria, from the infected to uninfected
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chamber, thus facilitating the analysis of cell signaling molecules. Our data suggests that
components produced by infected endothelial or epithelial cells are able to decrease the
numbers of established tubules formed by uninfected HUVEC within approximately 24 hours
of exposure. These data suggest that the infection by B. bacilliformis can result in an
alteration of the angiogenic profile of cells which are uninfected, and raise the possibility that
cell-signaling events are occurring between infected and uninfected cells. This would not be
surprising as work with endothelial cells has suggested that the induction of cytokines and
the inflammatory response of cells can result in vascular injury of uninfected endothelial
cells over time (Waltenberger et al., 1999). Several other studies with B. henselae have
suggested that macrophages are called into sites of infection and act as effector cells on both
infected and uninfected endothelial cells to induce angiogenesis (Dehio, 1999; Dehio, 2003;
McCord et al., 2005; Resto-Ruiz et al., 2002). The results of our cell-signaling and cytokine
studies raise the possibility that the cytokines which are produced are allowing for the
infiltration of macrophages into the B. bacilliformis-infected area and that these effector cells
might also be altering the angiogenic profile of endothelial cells in the localized environment.
The Role of GroEL in Angiogenesis
The search for angiogenic and other virulence factors produced by B. bacilliformis
has been ongoing for several years. Research in this area was initiated by Garcia et al.
(1990), who reported that B. bacilliformis produces a factor between 12 and 14 kilodaltons
that is able to stimulate tissue plasminogen activator (t-PA), a thrombolytic protein
implicated in angiogenesis. Using immunoprecipitation, Knobloch et al. (1990) identified 24
antigens produced by B. bacilliformis, including Bb65, a highly immunogenic protein that is
now believed to be a homologue of GroEL.
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Classically GroEL, a molecular chaperone, is not considered a virulence factor in most
bacteria. Subsequent work, however, led to the proposal that GroEL may enhance the
virulence of numerous bacteria, including H. pylori (Phadnis et al, 1996), M. tuberculosis
(Ranford et al., 2002), and L. pneumophila (Garduno et al., 1998). Recently, B. bacilliformis
has been added to the list of bacteria that may use GroEL as a virulence factor. In 2003,
Minnick and coworkers reported the identification of a mitogenic and/or angiogenic factor
produced by B. bacilliformis (Minnick et al., 2003). The factor was found to be unaffected
by polymyxin B, indicating that it is not related to LPS, and was also shown to be heat and
trypsin sensitive, suggesting a proteinaceous nature. Further investigation by Minnick et al.
(2003) led to the proposal that this angiogenic factor is GroEL, based primarily on their
findings that a) a GroEL over-producing strain of B. bacilliformis enhances endothelial cell
growth by 6-20 fold and b) cell proliferation is inhibited by anti-GroEL antibodies. Our
results with purified B. bacilliformis GroEL are in agreement with Minnick’s observations.
Although we did not observe a direct proliferative effect on cell proliferation, we found that
addition of GroEL to endothelial cells stimulates the formation of the tubules that are
characteristic of angiogenesis. Moreover, this effect is abolished by the presence of antiGroEL antibodies, again implicating GroEL directly in the angiogenesis process. Unlike our
previous observations, where the addition of live B. bacilliformis led to tubule degradation,
exposure of cells to the bacteria in the presence of purified GroEL, actually increases
angiogenesis. This suggests that not only does GroEL play a role in angiogenesis but it is
actually protective against the effects of live B. bacilliformis infection on the angiogenic
process. The angiogenic effect was not observed with E. coli GroEL, suggesting that it is
due to amino acids unique to the B. bacilliformis homologue.
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DNA and protein analysis of B. bacilliformis GroEL suggests a high homology to
other Bartonella species GroEL, as would be expected since bacterial GroEL proteins are
highly conserved. Interestingly, motif analysis reveals suggests a staphylocoagulase binding
site between amino acids at positions 466-496. Hydrophobicity and antigenicity plots
suggest that this unique motif site is present on the outer surface of the B. bacilliformis
GroEL and is therefore expose the localized environment. The staphylocoagulase binding
site may play a role in the binding of prothrombin to the surface of the B. bacilliformis
GroEL. Given the repetitive nature of the GroEL subunits which make up the GroEL
structure, a maximum of 14 staphylocoagulase sites could be exposed for prothrombin
binding. This may produce in vivo a B. bacilliformis GroEL that is covered with
prothrombin in the interstitial environment. Studies have shown the role of prothrombin to
be vast. Prothrombin has been reported to interact directly with !5$3 integrin, one of a set
of cell surface receptors that have been implicated in adherence and invasion by pathogenic
bacteria. Prothrombin was shown to bind to the !5$3 integrin through the tripeptide RGD, a
motif that is recognized by integrins. The binding of prothrombin to the integrin is reported
to support increased adhesion of stimulated endothelial cells and smooth muscle, both in
suspension and cell monolayers. This activity is mediated by the protein kinase C and
calpain signaling pathways, as inhibition of those molecules prevented increased adhesion.
The authors of this study suggest that the maintenance of vascular homeostasis may be
related to the presence of prothrombin in limited quantities (Byzova et al., 1998). Further
studies indicate that the binding and activate of !5$3 integrin to higher concentrations of
localized prothrombin may result in a proliferation and focal adhesion formation effect on
smooth muscle cells due to the activation of JUN kinase-1 (Byzova et al., 1998; Stouffer et
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al., 2003). Thrombin has also been shown to interact with the PAF-1 receptor to induce
endothelial cell tube formation in vitro and to increase bFGF-induced angiogenesis in vivo
(Rhim et al., 1998). Taken together, the extracellular localized increase of prothrombin due
to its binding of B. bacilliformis GroEL could lead to the activation of integrin signaling
pathways which in turn could activate the angiogenesis cascade. In the case of B.
bacilliformis infected endothelial cells, however, the activation and angiogenic cycle of these
cells may be compromised by the volatile nature of extracellular protein degradation and a
general limitation on prothrombin availability. These limits could then manifest themselves
as the poorly formed and highly porous vessels seen in patients exhibiting verruga peruana.
To date there is no evidence for a staphylocoagulase binding site in GroEL
homologues from organisms other than Bartonella. The binding site seen in other Bartonella
GroEL proteins differs by five amino acids from that of B. bacilliformis. Further studies will
need to be conducted to determine whether the staphylocoagulase motif plays a role in
stimulating either the cell proliferation or angiogenesis.
Tests of B. bacilliformis purified GroEL for its ability to induce a change in the
cytokine profile in HMEC-1 cells revealed an IL-2 and IL-6 increase between six and 24
hours of incubation with a maximal increase for IL-2 and IL-6 of five fold at 24 hours. The
secretion of these cytokines may be the host cells’ initial response to invasion and would
bring about the infiltration of macrophages and other immune cells in order to begin fighting
off the Bartonella infection. These cytokines are also known to prime endothelial cells to
begin the angiogenesis cascade as other environmental signals become present. Interestingly,
there was an overall decrease in IL-8 production, the hallmark of angiogenesis, which may
indicate that IL-8 production is not necessary for the induction of angiogenesis in the
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formation of verruga peruana. This could be an interesting differentiation between the
infective profile of B. bacilliformis versus that of B. henselae, which has been shown to
increase IL-8 production in HUVEC cells (McCord et al., 2007). It is not uncommon for
various bacterial GroEL proteins to induce cytokine changes; incubation of E. coli GroEL
with monocytes shows increased IL-1$ and IL-6 production even under circumstances when
the E. coli GroEL has been partially degraded (Tabona et al., 1998). Work by Galdiero et al.
(1997) shows the increased production by monocytes of GM-CSF, IL-6, E-selectin, ICAM-1
and VCAM-1 in the presence of E. coli HSP60. This increase in ICAM-1 and VCAM-1 on
the outer surface of monocytes allows for migration by the cells into various regions and
increases the likelihood of cell-to-cell contact (Galdiero et al., 1997). If this characteristic is
also shared by B. bacilliformis GroEL, then it could also prime endothelial cells for migration
resulting in the production of tubules.
In conclusion, the localized environment of B. bacilliformis infected endothelial or
epithelial cells is likely to contain a mix of signals. We have shown cytokine induction under
conditions of exposure to bacteria or to GroEL that would be expected not only to aid in the
activation and priming of endothelial cells toward angiogenesis, but also to induce the
infiltration of effector macrophages. This in turn should produce a barrage of cytokines
including IL-8, the primary angiogenesis signal with probable VEGF involvement. This
along with the tubule-destructive nature of live B. bacilliformis should result in endothelial
cell proliferation and reduced endothelial cell migration, leading to poorly-formed and
degrading tubules. However, the addition of localized high concentrations of secreted B.
bacilliformis GroEL with its unique staphylocoagulase binding site, may activate !5$3
integrins, resulting in a boost to the angiogenic signaling in the localized environment. This
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may be the true hallmark of B. bacilliformis induced verruga peruana formation. The
infective cycle, which would result in host cell proliferation, infiltration of hemin and other
nutrients, would support the continued growth, invasion and immune evasion of B.
bacilliformis and give rise to the formation of verruga peruana in those with Carrion’s
disease.
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Concluding Remarks: A model for the formation of Verruga Peruana
The interaction of any bacteria with its host results in a variety of changes for both
organisms. The purpose of this project was to determine what role B. bacilliformis plays in
the formation of verruga peruana during Carrion’s disease. The data presented in Chapter II
and Chapter III provide the basis for our model of verruga peruana formation. According to
this model, once B. bacilliformis exits the RBCs it will migrate to and infect the endothelial
cells lining the subcutaneous capillary beds. The invasion of B. bacilliformis into the
endothelial cells and surrounding areas occurs within 30 minutes to 2 hours post-infection
followed by a rapid proliferation of endothelial cells at 6 hours post-infection. These new
endothelial cells provide an excellent location for the surrounding B. bacilliformis to hide
from the migrating effector macrophages. As infection progresses, active macrophages in the
area are able to kill some interstitial B. bacilliformis, resulting the presence of B.
bacilliformis membranes and whole dead B. bacilliformis in the localized environment. We
have found that the presence of these bacterial components and whole dead bacteria induces
the production of IL-6, IL-8, IL-17 and IL-18 cytokines from neighboring endothelial cells.
While the release of IL-6 can result in the increased migration of effector macrophages, the
other cytokines present are proangiogenic and able to prime endothelial cells into the
angiogenesis cascade. Also, during this time, infected cells increase transcription of
proangiogenic factors such as VEGF and hypoxia factors HIF1! and HIF2!. These factors
further prime endothelial cells to begin angiogenesis and increase localized tubule formation.
We have noted the degradation of pre-formed tubules by the presence of live B. bacilliformis
as infection continues, which could allow for greater numbers of host RBCs, hemin and
serum components to enter the infected interstitial spaces. Each of these components could
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contribute to bacterial growth and survival. Finally, our data show that infected endothelial
cells begin to transcribe greater quantities of HIF3!, which may aid in localized tubule
degradation. The persistent infection of B. bacilliformis may result in an increased localized
concentration of its unique, secreted GroEL. This GroEL has been shown to stabilize and
maintain tubule formation, and in some instances increase angiogenesis. As infection moves
from hours to days, the localized environment would be flooded with proangiogenic
cytokines and proteins, which along with the presence of a prothrombin-coated GroEL may
continue to push angiogenesis forward, resulting in the formation of incomplete, damaged
tubules. These would be unable to support proper blood flow, allowing the migration of host
RBCs into the area of infection and the formation of verruga.
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AP.1 - Bartonella quintana - virB Operon Sequence
1
41
81
121
161
201
241
281
321
361
401
441
481
521
561
601
641
681
721
761
801
841
881
921
961
1001
1041
1081
1121
1161
1201
1241
1281
1321
1361
1401
1441
1481
1521
1561
1601
1641
1681

TTTAAACCCA AAAATGACAG AGACTATATC CAGAAATATT
ATTTTTATCG TTATCGTGCT GCTGTTAACA GCACTTGTTG
TATCAAATCC CTCTTATGCT GCGAATAGTG CTAGTAGTCT
GGGAAACGTT GATAGTGTTT TACAGAATAT TGTTACGATG
ATGACGGGGA CAACAGCAAA GCTGATTGCA ATTATATGTG
TTGCAGCTGT GGGCATTGGT TGGATGTCCG GCTTTATTGA
TTTACGCAAA GCCGCTTATT GTATTCTCGG CATTGGGATT
GTTTTTGGTG CCCCCACTCT TGTTAGTACA TTAATGGGCT
CATCATAAAT GAATGAAGAT ACTCTTTTTC TTGCCTGTAC
GCGACCAGCT ACGTTTGCCG GTGTCACAAT GGAAGGAATG
GCCCTTAATG TCATGGCGAC ATCCATTCTC TTTATTTTGA
CCAGCAACTT TACAATGATT GGTCTTGGCA TTGGATTGCA
CTTTGTTTTG CGTGAAGTGA CAAAATACGA CCACAACCAG
TTTCGCGTAT TATTTGCTTG GCTCAACACA AGAGGAAAAC
AAAAAAACCT CACCAGATGG GGAGGAGGAT CTACATCTCC
CCTACGCCTT ATCCGTACTT ATAAGGAACT GAACAGATGT
CAATTATGAA ACGGGAGTCT TTACCTGAAG AATATATTCC
TTACATACGC CACGTCAACC AACACGTCAT TGCATTAAAT
TCACGCTGCT TAATGACTGT AATGGCTGTT GAGGGGGTGA
ATTTTGATAC TGCAGATATC AATCACTTAA ATTCCTTACA
CAACCAGTTA AACACTCTCT TGAGAAATAT CGCGGATGAA
CGTGTTGCTT TATATTCTCA CATCATTCGT CGGCGCGAAA
CGATCTATCC AGAGAGTCGT TTTTTTTCAT CTTTTGCAGC
AACACTAGAT GAAAATACAA AAAGAAAATG GTTTCGCAAG
AGCTGTATAG AAATGATCTC CTTCGTTTCA CTGCTGTGGA
ATCCAACATC GGGTAAGACT GAGCAACTCG CTTCATTTTT
TCAGCGCTTA ACAAAAGCGA AGAAAACACA ATCTGAACCA
GACATGGAAG CCATTCGTAA AATTGAAGAG TTAAGCCAAG
ATCTTATACA AGGGTTGGAG AGCTATGAAG CGCGCCTCTT
GTCAGTCTAT GCACATGAGG GCATTTTGTT TTCCGAACAA
AGTGAATTTC TACACCAGTT ATGGGAGGAA GGCGTGAGCG
GATTCCTCTC ACATTTGGTA CCCATTCCTT CAACGATTTA
CTCAGACCGT GTCATTTTTG GCAAAGAAAT GATCGAAATT
CGTCATGAAA GCAATGAACG CTTTGTTGGC ATGTTTGGCT
GGAAAGAATA TCCCTCTAAA ACACGCCCAG GTATGACAGA
TGGTTTACTC ACAGCACCGT TTGAATTTAT CTTAACACAA
TCCTTTGTCT TTAAGAGTAA AGCAGCTGCC AGGGTCATTA
TGGGCCGCAA ACAAAATCAG ATGATTAATG CAGCGGATCG
TGCTAGCTCG CAAATTGATG CACTTGATGA AGCGCTTGAT
GATTTAGAAT CAAACCGTTT TGTTTTGGGC GAACATCATC
TCTCTCTAGC CGTTTTTGCT GATCAACCAA AAACATTGGT
TGAATACCTC TCAAAAGCGC GCGCTCACTT AACCAATGGT
GGAGCGGTTA TCGCCAGAGA AGATCTAGGA TTAGAAGCTG
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1721
1761
1801
1841
1881
1921
1961
2001
2041
2081
2121
2161
2201
2241
2281
2321
2361
2401
2441
2481
2521
2561
2601
2641
2681
2721
2761
2801
2841
2881
2921
2961
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3041
3081
3121
3161
3201
3241
3281
3321
3361
3401
3441
3481
3521

CATGGTGGGC GCAACTGCCT GGAAATTTCA GCTATCGTGC
GCGATCTGGA GCCATTACCA GCAGAAATTT TGCAGCGTTA
TCGCCCTTCC ATTCCTTCCC CATTGGCAAA CTTGAAGGCA
ATGTTTGGGG AGCGGCTGTG GCATTGCTGA AAACACAAGC
TGGTTCACCT TATTATTTTA ATTTTCATTA TGGTGACCTT
GGCAACACTT TTGTTTGCGG TCCATCAGGA TCTGGTAAAA
CTGTGATTGT TAATTTCCTT CTCGCACAAT TACAAAAACA
TAACCCGACA ATGGTCTTTT TTGACAAAGA TCAAGGCGCA
GAGATTTTTG TGCGTGCTGG AGGTGGAAAA TATAAGCCTT
TGAAAAACGG ACAGCCCACG GGCATTGCTC CATTAAAGGG
CATGGAATAC ACTGAAAAAA ACAAAATCTT TCTTCGCAGT
TGGGTCTTGA AGCTGGTGAC AACTGAAGGG CAAACAGTGA
CAGAACAAGA GCGACAAGAT ATCGCCAAAG CCATAAATTC
CTTGGAAAGT CTTCCACATG CGCAACGCTC TCTTGGTGCC
CTTCAATTGT TTTTTGATAA CACATCAAAA GAAGGAATTG
CTATACGGTT ACAACGCTGG ATCAAAGGCA ATGACTTAGG
CTGGGTTTTT GACAACGATC AAGATGATCT CAATTTAGAC
TCACAATTCA TTGGTTATGA CATGACCGAT TTCTTAGACA
ATGAAGAAAT TCGGCGCCCC TTGATGATGT ATCTGTTTAA
CCGCATTCTC GATCTTATTG ATGGGCGGCG CATTATTATT
GTCATTGATG AATTCTGGAA AGCGCTTGAA GATGATTCCT
TTAAAGCTTT GCGCAAGCTC GCCTTAAGAC GATCCGTAAA
AAAATGGTAT GATGCTCTTT GCTACGCAAA GCCCAAAGAT
GCTTTGAACT CTACAATCGC ACACACGATT ATTGAGCAAT
GCCCTACCCA AATATTTTTT CCAAATCAAA AAGCAAATTA
CAAAGATTAT GTTGAAGATT TTAAACTGAC TGAGCGTGAA
TTTGAACTGA TACAGTCAGA ATTAAGCAGA GAATCTCGTC
GTTTTCTCAT AAAACAGGGA CAAAATTCGG TCGTTGCAGA
ACTCAATTTA CGTGGAATGA ACGATGAGAT CGCCATCTTA
AGCGGTACGA CCAAAAACAT CGAACTGGTG AACCAAATTA
TCAACGATTA TGGAGCAGAT CCCGATACAT GGCTGCCTAT
ATTTCACCAA AGGAGAGAAA ATCAATGAAA AAATATGGTT
TAGTCACACT TTTATCTTTA TCTTGCGTCT CTCATACAAT
AGCAGAAACT GCATTACTTG CTGATGAATA TTACAAAAGA
GCATTAGAAA ACACGCAAAA ATTAGATGCT GCAAAATCAG
AAACAGCGGA ATCTATTTAT GCATCTGCAA ATGAAATTAC
TAATAAAATT AAGGAAATAA ACGAGAAACT TAGAAAGGCT
CAGGCAGCTG AAAAAACCAA ACCTGAAGAA TTTCAGGCTC
TTCAAATAGA GCTGTCTCTT CTTCAAGCAC AGCTGCAAGC
AGATACTTTA AAAATTCAAT TCCTGTCTAT GATTCAAGCG
AAAAATACGA AAACAAAAGA AGACATCCGT GAAGAGCAAA
CACAAAAAAA GCATAAAGAT CTTCAAGAAA AATTAAAAGA
AAAACTTGGG AATTCTGATG TCCGACTTTA GTTTTTCCCC
GTAGTTTTTC CCCGTTTGAG AGCATTTCTG GATATATTTT
AAATCCACTC GAAAATGCAA TGAATACGAC AGTGAGTGGG
TTGTCTTCTG CTATTTCAGC ACCCTTAAAT CTTGCCTCGA

230
3561
3601
3641
3681
3721
3761
3801
3841
3881
3921
3961
4001
4041
4081
4121
4161
4201
4241
4281
4321
4361
4401
4441
4481
4521
4561
4601
4641
4681
4721
4761
4801
4841
4881
4921
4961
5001
5041
5081
5121
5161
5201
5241
5281
5321
5361

TCATTTTTAT CTTTCTGTAT GGCTATAATG TTATGACTGG
TCGTGTCTCC CTTTCGATGC ATAGCCTTCT CAACAATGTT
GTGAAAATCG TTGTTGTGAC GGCAATGGCA ACGAATGCGG
ATACATTTAA TACCTATGTC AAAGATATTT TCTTTGGTGA
TTTAGCAAAC GCTATTGGGA ATGCACTCAA CAGCAACCCC
GCTAGCGCAA ATGTTTTTGA TTATATTCTG TTAAAGACAA
GTGCCCGTTA TCAAGAAGTT TTAGCAGCTG CTTGGTTTCT
TGAAAAAATC ATGGTTGGTC TTCTTGGATC TTTAATGATT
ATGGCCGTTA TTGTCTTTTG TATAGGTGGT TTTATCGTAC
AAATGTTTGC ACAAGTTGCA CTTGTAATGA TTATAGGTCT
TGGTCCCCTC TTCATCAGCC TCTATTTGTT CAATGCAACC
AGAAAATTCA CCGATGCATG GATTACAACG CTGATTAATT
TTACCATTTT GCAAGTTTTA GTGATCATGC TTGGAACGAT
CATGTGCAAA ATTATCCTGC ATGTTCTCAA TGGCACCTAT
GATTCAATCT ATTTCCTTTT CCCACCTGTT GTCGTTATCT
CGATAGTGGG AGCTATTCTC TTCCGCGCAC TTCCTGGCAT
TGCCTCTGCA CTTTCTAGTG GAGGACCATA CTTTAACGCT
GGTATCTCTT CAGGAGGACA AATTTTTACA ATGCTTTCCA
GTGGCGCGAA AACGGGCAGA AACGCAGCCA AAAGCGCAGC
ATCAACTCTC TCTGGTACAG CAGGTGCCGC AGCCAAAGTT
GCAAAAATTG GAGATAGAGG CCGTGGTCGA TTTTAATGTC
AGATACCTCT TAAAAAGAAC GAGGGTTCTT GTTTTTGCAT
TGCGCGCGCT AGAGAGCGCG CAATGTACAT ATTGCGTGAA
ACAGTTGAGA TCTTTGATTT CATAAGACCA ATCAAAATGT
TTCATCGCAC GCTTTTGTGA AATTGTTCAA AGCAAGAGCC
CCACACCTCA CCTCTATGGG GTCATGCGGT TATGTGTTGT
ATTTTAAAGT ATTTGTGTGA GTTCAAAAAA TGAAACGAAA
AATAACTTTT TTTATGATCC TGATGATTGC CCTTACGGGT
TGTGCTTCTC TTAGTGGGCC CAAAAAACCA CCACGATGTA
ATGGCCAGTA TACGCGCGCT TTAAATAGAG ATAAGTGGGA
TTGGGACAAT AAAAACATCA TCATACAAAA AAAAATCGTA
AAACCTGTTA CAACCCCCAT CATCCTCAAC ACGCTGGAAA
GTGAAAAAGC AACAGCTGAC GTGACGCTTC ATCCAGCTTC
ATTGGATTCT ATAAATCATG AAAAATTCTC TGATCAAAAT
ACGGAAATCG CTCGTGAAAA GTGATGCATT TGATGAATAT
GTAAAAGAAG CACGCTCATT TGATATTGAT CGCATGCATA
GCCTACAACA GCGAATGAGA ATTGCCATGA CTTTGACAGT
GCTTTTTGGC TTGATGACAA TCGCCTTGGC TTTGGCTGTA
GCAGCATTAA CACCCTTAAA AACAGTAGAG CCCTTTGTTA
TCCGCGTTGA TAATTCAACA GGTATTATTG AGACAGTAAG
TGCCTTAAAA GAAACGCCAA ACAATTATGA TGAAGCAATA
ACACGTTATT TTGCTGGCAA ATATGTTCGT GCGCGCGAAG
GTTTTCAATT ATCAGAGGCG GAATACAATT TTCGCTTGAT
TTCTCTTTTA TCTTCACCAG AAGAACAAAA CCGTTTTGCA
AAATGGTATT CGGGCAACAA TCCAGAAAGT CCGCAAAATA
TCTATCACAA CATGACTGCT AAGGTCACAA TCAAGTCAAT
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5401
5441
5481
5521
5561
5601
5641
5681
5721
5761
5801
5841
5881
5921
5961
6001
6041
6081
6121
6161
6201
6241
6281
6321
6361
6401
6441
6481
6521
6561
6601
6641
6681
6721
6761
6801
6841
6881
6921
6961
7001
7041
7081
7121
7161
7201

CTCCTTTTTA AGCAAAGATC TTATTCAAGT GCGTTACTAT
AAAACGATCA GAGAATTGAA TGGAAAAGAA AATATTTCCC
ATTGGGTCTC GATCCTCAAT TTTTCCTACA TTAATGCACA
CATTTCAACA GAAGACCGAC TAATCAACCC GCTTGGTTTT
CAAGTGTCAG AATATCGATC TGATCCAGAG GTGATAAAAT
GATGAGATTT TCAAAAATAA TCTTTTTAGC TTTCCTTTTT
GCAATAAGCT GCCTGACAGT CCCGTTATTT GCTGAAACAG
CTCCTGTAAG TGCGCGCAAA GACAATCGCA TCAGATTTGT
CAATTATGAC CCATACAATG TCACACAAAT CATTGGATCT
ATTCGTTCTT CTGTTCAGCT TGAATTTGCC GATGATGAAG
AAGTGACCTA TGTGGGCATT GGCAATTCTG TTGCTTGGCA
AGTTGCACCA GCTGGACATT TTGTATTTCT CAAACCGCGC
GAAGTTCAAC CTGTGACCAA TTTACAAATT GTCACAAGCC
GTCAAGACGG GACAAAACGG TCCTATCAGT TTGAACTCAA
GTTCGTGAAG GCGACGTTTC ACCGCAGATA CTATTTCCTC
GTAAGTTTCG TTATCCAAAA GAACTTTGCG CAGAAATTAG
CCAAAGCAGC AGAAGCTGCA CAGCGTGAAG AAAATTTTGT
CAATGATGTT TTTAACATCC ATGAAAATTT TGGACCACGC
AATTGGGCTT ATGAAGCGCA AGGTTCATCC CTCATTGAAC
CTGCTTCTGT CTATGACAAC GGTAAAACAA CAACCTTTAC
ATTTTTGGGC AATACCGAAA TCCCTGCCAT TTATCTCGTA
TCGCTTGATG GGCAAGAATC TCTCGTTCCA AAATCAATTA
AAGGAAACAA GGTTATTGTT CATGCCATAG CTGCGCAATT
TACTTTGCGC CGCGGGAATG ACGTGCTGTG CATCTTTAAT
AAAAGATTTG TACCTGAAGG GATTAACCCT GAGACCGGTA
CGACATCACC ATCTGTACAA CGTAGAGTGA ACATAGGAAA
TGGTCATGAA GGATGAAATG GATGAAAACA ACATAAATGA
TCGCAGTACA ATAAAAGACG GTCAAGGAAA AAAACTGCAT
TCCAATACAA GTAAAGCAGT TGCTCTTCTC GTTCTTTTGG
GTGTTTGTGG TTATTTAGCG TATTCAACGC TTATCACAAA
CAAAAAACAG CCGGTTGAAC TTCCAAAAGA GGCGATTATT
AAGCAAACAG AGCGTTTCCG CCCTGCACAG CCCAAGCCTG
TACTCCTCGA GCCAACTGAA AAAAATAATC CGTCCTGTTG
CCCAAGGTCC TTTGAATTGC CAACGCCCAA AATAAACCTG
TTGAAAACAA ATGCTGATGA TTCACTCTTA GAAGCAGCAC
AAACAGAATG CTCCTGTCTT GCCTATGCCA GCCCACAAAA
AAGCCAAGCA ATGCAGAAAA AAATAACGAC ACTTCACCGA
ACCAACTCGA AAGAAAACCT GATGAAACAG CACAACGCTT
TAATCATCTT CTCAAACCGA CAAACCTTGA AGGTATTCAT
GCTTCAACAC TTACTAATCG AAATGCCAGC CCACAAAAAA
GCCAAGCAAA TGCAGAAAAA AATAACGACA CTTGACCGAA
CCAACTCGAA AGAAAACCTG ATGAAACAGC ACAACGCTTT
AATCATCTTC TCAAACCGAC AAACCTTGAA GGTATTCATG
CTTCAACACT TACTAATCGA AACTACATCA TCGCAAGGTG
CTTCCATTCC ATGTATTTTA GAAACGGCAA TCAGCAGTGA
CCAACAGGGA TTTACCAGTT GTATCGTTTC TAGAGATATC

232
7241
7281
7321
7361
7401
7441
7481
7521
7561
7601
7641
7681
7721
7761
7801
7841
7881
7921
7961
8001
8041
8081
8121
8161
8201
8241
8281
8321
8361
8401
8441
8481
8521
8561
8601
8641
8681
8721
8761
8801
8841
8881

TTGGTCAGAC AATGGTCGCG TTTGTCCTTC TTGACAAGGG
CACACAAATC GTTGGCGAAT ACCCGTTCCG GATTAAAAAA
GGGGCAAAAT CGTCTTTTTG TGTTATGGAA TAGAGCCAAA
ACCCAAGTGG GTATTATAAC ATTAGCCTCC CCGGCAACGG
ATGCCTTAGG GCGTTCTGGT GTTGATGGAG ATGTTGATAA
TCATTGGTTT GAGCGGATTG GATCTGCGCT TCTTGTATCG
ATTGTCAGAG ATGCAACCAA TTATGCGAGA AACCGGTTGC
CAAAAGATCA AGATAAGAAC AGTTCTGACA CAATCTCTTC
GGGACCAAAT ATTGCAAATA TTGTCGTGGA AAATTACGCC
AACATTCCTC CCACACTAAC AAAAAAACCA AGGGGAAAAT
GGTCAATGTT TTTTGTTGCC CCGCGATTTA GAATTTTTTC
CAGTGTTTAT AAATTGAAAG TGATCGAAGA CAAAAAACAG
ATTGTCAATC GATCCATTTC AAGAAACTTT TATAAAAATT
CTGCGGTGAT TTTGAAATGA ACCAAAACCT GCATAAATTG
AGCAATGAAA CTGTCGCGAT TGTTTTAACA AAACTTGAAC
CCATCAGTGC CTTTCTGAAA GATAAGAGCC TTTTTGAAAT
TGTCATCAAT AGTCCCTATC AAGTGATGAC AGAAGGTATT
GAGGGATGGA AACCAATAGA AGCACCAGCT CTTTCGTTTG
ATGAGCTTAT GGGAATTGCT AAAGTTGTCG CTTCCTATTC
TAAGCAAAAG ATATCCGACA AAAATCCAAT ATTATCGGCT
ACCCTACCGG GGAATGAACG TATTCAAATT GTCATTCCTC
CTGCAGTGGA AAAAGACACA ATCAGCATGA CAATTCGCAA
ACCATCATCG CGGAATTTTT CACTCGAAGA GCTGGCAAAT
AAAGGTCTCT TTTCTGTGTG TGAACAAGTG TCATTTACGC
CATTGAATGA TTATCAATCG CGTTTTAGTG AACTCAAACA
CATTGAGCAT AGCTTGGCAA CCGCTTATTC TAATAAGGAT
TTTGTCTCCT TTTTAAATCA AGCTGTAAAA TGCCAAAAAA
ATATTTTAAT TGCAGGGAAA ACGGGTTCTG GTAAAACACC
GCTATCAAAG GCATTAATCG CTAAAATTCC CGATAATGAG
CGTATTATCA CCATTGAAGA TACACCAGAA TTGGTCGTAC
CACAGCCCAA TTATGTCTCT ATGATCTATT CAAAAGATGG
TCAAGGCTTA GCCTCTGTTG GTCCAAAAGA ATTGCTTGAA
TCTGCTTTGC GCATGCGTCC TGATCGCATT CTTCTACAAG
AGCTTCGAGA TGGTACAGCC TTTTATTATA TCCGCAATAT
CAATTCAGGA CATCCAGGTT CAATTACCAC GGTTCATGCA
TCAACAGCAC TCGCTGCATT TGAGCAAATG ACCCTCTTGG
TCAAAGAAAG TGAAGGCGGA GGTGATTTAG AGCGTGATAT
TCGAGGGCTG TTGATTTAGA GCGTGATGAT ATTCGAGGGC
TGTTGATTTC AATGATTGAT ATCATTGTTC AATGCAAACG
GGTTGAAGGA AAATTTAAGG GTCACAGAAA TTTATTATGA
CCCGTTTAAA CAACGACACT TGGAGGATCT ACCGGATAAT
CGGGGCCACC GCGGTGGAGC TCCAGCTTTT TG
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1
41
81
121
161
201
241
281
321
361
401
441
481
521
561
601
641
681
721
761
801
841
881
921
961
1001
1041
1081
1121
1161
1201
1241
1281
1321
1361
1401
1441
1481
1521
1561

ATGACAGACA CTATATCCAG GAACATCATT TTTATCATCA
TCATGCTGCT GTTAACAGCG CTCGTTGTAT CAGACCCTTC
TTATGCTGCT GCTGCTACGG GTAGTGCCAG TAGTCTGGGA
AACGTTGATA ATGTTTTACA AAATATTGTT ACGATGATGA
CAGGAACAAC AGCAAAGCTG ATTGCAACAA TATGTGTTGC
AGCTGTGGGC ATTGGTTGGA TGTCCGGCTT TATTGATTTA
CGCAAAGCCG CTTATTGTAT TCTCGGCATT GGGATTGTTT
TTGGTGCCCC CACTCTTGTT AGTACATTAA TGGGCTCATC
ATAAATGAAT GAAGATACTC TTTTTCTTGC CTGTACGCGA
CCAGCTACGT TTGCCGGTGT CACAATGGAA GGAATGGCCC
TTAATGTCAT GGCGACATCC ATTCTCTTTA TTTTGACCAG
CAACTTTACA ATGATTGGTC TTGGCATTGG ATTGCACTTT
GTTTTGCGTG AAGTGACAAA ATACGACCAC AACCAGTTTC
GCGTATTATT TGCTTGGCTC AACACAAGAG GAAAACAAAA
AAACCTCACC AGATGGGGAG GAGGATCTAC ATCTCCCCTA
CGCCTTATCC GGTACTTATA AGGAACTGAA CAGGGGAAAC
AGATGTCAAT TATGAAAACG GGAGTCTTTA CCTGAAGAAT
ATATTCCTTA CATACGCCAC GTCAACCAAC ACGTCATTGC
ATTAAATTCA CGCTGCTTAA TGACTGTAAT GCGCGTGTTG
AGGGGGTGAA TTTTGATACT GCAGATATCA ATCACTTAAA
TTCCTTACAC AACCAGTTAA ACACTCTCTT GAGAAATATC
GCGGATGAAC GTGTTGCTTT ATATTCTCAC ATCATTCGTC
GGCGCGAAAC GATCTATCCA GAGAGTCGTT TTTTTTCATC
TTTTGCAGCA ACACTAGATG AAAAATACAA AAAGAAAATG
GTTTCGCAAG AGCTGTATAG AAATGATCTC TTCGTTTCAC
TGCTGTGGAA TCCAACATCG GGTAAGACTG AGCAACTCGC
TTCATTTTTT CAGCGCTTAA CAAAAGCGAA GAAAACACAA
TCTGAACCAG ACATGGAAGC CATTCGTAAA ATTGAAGAGT
TAAGCCAAGA TCTTATACAA GGGTTGGAGA GCTATGAAGC
GCGCCTCTTG TCAGTCTATG CACATGAGGG CATTTTGTTT
TCCGAACAAA GTGAATTTCT ACACCAGTTA GTGGGAGGAA
GGCGTGAGCG GATTCCTCTC ACATTTGGTA CCATTGCCTC
AACGATTTAC TCAGACCGTG TCATTTTTGG CAAAGAAATG
ATCGAAATTC GTCATGAAAG CAATGAACGC TTTGTTGGCA
TGTTTGGCTG GAAAGAATAT CCCTCTAAAA CACGCCCAGG
TATGACAGAT GGTTTACTCA CAGCACCGTT TGAATTTATC
TTAACACAAA CGTGTGGTCG ACGGCCCGGG CTGGTCTGCC
AGGGTCATTA TGGGCCGCAA ACAAAATCAG ATGATTAATG
CAGCGGATCG TGCTAGCTCG CAAATTGATG CACTTGATGA
AGCGCTTGAT GATTTAGAAT CAAACCGTTT TGTTTTGGGC
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1601
1641
1681
1721
1761
1801
1841
1881
1921
1961
2001
2041
2081
2121
2161
2201
2241
2281
2321
2361
2401
2441
2481
2521
2561
2601
2641
2681
2721
2761
2801
2841
2881
2921
2961
3001
3041
3081
3121
3161
3201
3241
3281

GAACATCATC TCTCTCTAGC CGTTTTTGCT GATCAACCAA
AAACATTGGT TGAATACCTC TCAAAAGCGC GCGCTCACTT
AACCAATGGT GGAGCGGTTA TCGCCAGAGA AGATCTAGGA
TTAGAAGCTG CATGGTGGGC GCAACTGCCT GGAAATTTCA
GCTATCGTGC GCGATCTGGA GCCATTACCA GCAGAAATTT
TGCAGCGTTA TCGCCCTTCC ATTCCTTCCC CATTGGCAAA
CTTGAAGGCA ATGTTTGGGG AGCGGCTGTG GCATTGCTGA
AAACACAAGC TGGTTCACCT TATTATTTTA ATTTTCATTA
TGGTGACCTT GGCAACACTT TTGTTTGCGG TCCATCAGGA
TCTGGTAAAA CTGTGATTGT TAATTTCCTT CTCGCACAAT
TACAAAAACA TAACCCGACA ATGGTCTTTT TTGACAAAGA
TCAAGGCGCA GAGATTTTTG TGCGTGCTGG AGGTGGAAAA
TATAAGCCTT TGAAAAACGG ACAGCCCACG GGCATTGCTC
CATTAAAGGG CATGGAATAC ACTGAAAAAA ACAAAATCTT
TCTTCGCAGT TGGGTCTTGA AGCTGGTGAC AACTGAAGGG
CAAACAGTGA CAGAACAAGA GCGACAAGAT ATCGCCCAAA
GCCCATAAAT TTCCCTTGGG AAAAGTTTTT TCCACCATGC
GCAAACGCTC TCTTGGTGCC CCTTCAATTG TTTTTTTGAT
ACCACATCAA AAGAAGGAAT TGCTATACGG TTACAACGCT
GGATCAAAGG CAATGACTTA GGCTGGGTTT TTGACAACGA
TCAAGATGAT CTCAATTTAG ACTCACAATT CATTGGTTAT
GACATGACCG ATTTCTTAGA CAATGAAGAA ATTCGGCGCC
CCTTGATGAT GTATCTGTTT AACCGCATTC TCGATCTTAT
TGATGGGCGG CGCATTATTA TTGTCATTGA TGAATTCTGG
AAAGCGCTTG AAGATGATTC CTTTAAAGCT TTTGCGCAAG
ATCGCCTTAA GACGATCCGT AAACAAAATG GTATGATGCT
CTTTGCTACG CAAAGCCCCA AAGATGCTTT GAACTCTACA
ATCGCACACA CGATTATTGA GCAATGCCCT ACCCAAATAT
TTTTTCCAAA TCAAAAAGCA AATTACAAAG ATTATGTTGA
AGATTTTAAA CTGACTGAGC GTGAATTTGA ACTGATACAG
TCAGAATTAA GCAGAGAATC TCGTCGTTTT CTCATAAAAC
AGGGACAAAA TTCGGTCGTT GCAGAACTCA ATTTACGTGG
AATGAACGAT GAGATCGCCA TCTTAAGCGG TACGACCAAA
AACATCGAAC TGGTGAACCA AATTATCAAC GATTATGGAG
CAGACCCAGA CATATGGCTG CCTATATTTC ATCAAAGGAG
AGAAAATCAA TGAAAAAATA TAGCTTAGTC ACATTGTTAT
CTTTATTTTG CATCTCTCAT GCAAAAGCAC AAACAGCACC
CCTTGCTGAT GAATATTATA AAAAAGCCTT AGAAAACAAG
CAACAATTAG ACGTTGCAAA ATCACAAACA GCTGAGTCTA
TTTATGAATC TGCAACACAA ACTGCAAATA AAATTAAGGA
CATAAACGAT CAACTTAAAA CTCTTAAAGC AGATACAAAG
ACTAAACCTG AACAATTGCA AACCCTGCAA ATAGAGCTCT
CTCTTCTCCA AGCGCAGTTG CAAGCGGATA CTTTAAAAGT

235

3321
3361
3401
3441
3481
3521
3561
3601
3641
3681
3721
3761
3801
3841
3881
3921
3961
4001
4041
4081
4121
4161
4201
4241
4281
4321
4361
4401
4441
4481
4521
4561
4601
4641
4681
4721
4761
4801
4841
4881
4921
4961
5001

TCAGTCTCTT GCTATGATTC AAGCAAAAGA TACAAAAACA
AAAGAAGAAC TGCGTGAAGA GCAAACACAA CAAAATCATA
AAAAAATTGA AGAAAAATTA AAAGAAAAAC TTGGAAAATC
TGATGTCCGA CTTTAGTTTT TCCCCGTTTG AGAGCATTTC
TGGATATATT TTAAAACCAC TCAAAAATGC AATGAACACA
ACAGTGAGTG GGTTGTCTTC TGCTATTTCA GCACCCTTAA
ATCTTGCCTC GATCATTTTT ATCTTTCTGT ATGGCTATAA
TGTTATGACC GGTCGCGTCG CCCTTTCGAT GAATAGCCTT
CTCAACAATG TTGTAAAAAT CGTCATTGTG ACGACAATGG
CAACCAACGC GGATACATTT AATACCTATG TCAAAAATAT
TTTCTTTGGC GATTTAGCAA ACGCTATTGG GAATGCACTC
AACAGCAACC CCGCTAGCGC AAATGTTTTT GATTATATTC
TGTTAAAGAC AAGTGCCCGC TATCAAGAAG TTTTAGCAGC
GGCTTGGTTC CTTGAAAAAA TCATGGTTGG TCTTCTTGGA
TCTTTAATGA TTATGGCCGT TATTGTCTTT TGTATAGGTG
GTTTTATCGT ACAAATGTTT GCACAAGTTG CACTTGTAAT
GATTATAGGT CTTGGACCCC TCTTCATCAG CCTCTATTTG
TTCAATGCAA CCAGAAAATT CACCGATGCA TGGATTACAA
CACTGATCAA TTTTACCATT TTGCAAGTTT TAGTGATCAT
GCTTGGAACG ATCATGTGCA AAATTATCCT GCATGTTCTC
AATGGAACAT ATGAGTCAAT CTATTTCCTG TTCCCACCTG
TCGTCGTTAT CTCCATAGTA GGAGCTATTC TCTTCCGCGC
ACTTCCTGGC ATTGCCTCTG CACTCTCCAG TGGAGGACCA
TACTTTAACG CTGGTATATC TTCAGGAGGA CAAATTTTCA
CAATGCTCTC CAGCGGCGCG AAAACGGGAA GAAACGCAGC
AAAAAGCGCA GCATCAACAC TCTCTGGTAC AGCAGGAACC
GCAACCAAAG CGGCAAAAAT AGGAGAGAAA GGCCGTGGTC
GATTTTAAAT GAAACGAAAA ATAACTTTTG TTATGATCCT
GATAATTGCC CTTACTGGCT GTGCTTCTCT TAGTGGCCCC
AAAAAACCAC CACGATGTAA TGGCAAAGAT ACGCGCGCTT
TAAATAGAGA TAAGTGGGAT TGGGACAATA AAAACATCAT
CCTACAAGAA AAAAGTGTAA AACCTGTTAC CACCCCCATC
ATCCTCAACA CGCTGGAAAG TGAAAAAGCA ACAGCTAACA
TCACCATATA CGCAAATTAA TTTAAGCCAT TCAGTCGTGA
ACCACACCGT GATAAAACTC TGGAGGTTAC GCGTGAAAAC
TGAATGTCCG ACTTTAGTTT TTCTCCGTTT GAGAGCATTT
CTGGATATAT TTTAGAACCA CTCATGAAAA ATTCTCTGAT
CAAAATACGG AAATCGCTCG TGAAAAGTGA TGCATTTGAT
GAATATGTAA AAGAAGCACG CTCATTTGAT ATTGATCGCA
TGCATAGCCT ACAACAGCGA ATGAGAATTG CCATGACTTT
GACAGTGCTT TTTGGCTTGA TGACAATCGC CTTGGCTTTG
GCTGTAGCAG CATTAACACC CTTAAAAACA GTAGAGCCCT
TTGTTATCCG CGTTGATAAT TCAACAGGTA TTATTGAGAC
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5041
5081
5121
5161
5201
5241
5281
5321
5361
5401
5441
5481
5521
5561
5601
5641
5681
5721
5761
5801
5841
5881
5921
5961
6001
6041
6081
6121
6161
6201
6241
6281
6321
6361
6401
6441
6481
6521
6561
6601
6641
6681
6721

AGTAAGTGCC TTAAAAGAAA CGCCAAACAA TTATGATGAA
GCAATAACAC GTTATTTTGC TGGCAAATAT GTTCGTGCGC
GCGAAGGTTT TCAATTATCA GAGGCGGAAT ACAATTTTCG
CTTGATTTCT CTTTTATCTT CACCAGAAGA ACAAAACCGT
TTTGCAAAAT GGTATTCGGG CAACAATCCA GAAAGTCCGC
AAAATATCTA TCACAACATG ACTGCTAAGG TCACAATCAA
GTCAATCTCC TTTTTAAGCA AAGATCTTAT TCAAGTGCGT
TACTATAAAA CGATCAGAGA ATTGAATGGA AAAGAAAATA
TTTCCCATTG GGTCTCGATC CTCAATTTTT CCTACATTAA
TGCACACATT TCAACAGAAG ACCGACTAAT CAACCCGCTT
GGTTTTCAAG TGTCAGAATA TCGATCTGAT CCAGAGGTGA
TAAAATGAAT GATGAGGATT TTAAAAACAC TCTTTTTAGC
TTTCATAGCT GCAATAAGTT GCTATACGAC CCCCTCATTT
GCTGAAACAG CACCTGTGAG TGCACGCAAA GACAATCGCA
TCAGATTTGT CAATTATGAC CCCTATAATG TGACAAAAAT
CATTGGCTCC ATTCGTTCTT CTGTTCAACT TGAATTTGCC
GATGATGAAG AAGTAACCTA TGTAGGGATT GGCAATTCCG
TTGCTTGGCA AGTTGCACCG GCTGGCCACT TTGTATTTCT
AAAACCACGC GAAGTTCAAC CTGTTACCAA TTTACAAATT
GTTACAAGCC GCCAAGACGG CACAAAACGC TCTTATCAAT
TTGAACTACA AGTGCGTGAA GGGGATGTTT CAGCGGGCAA
TGATACATAT TTTCTGGTAA AGTTTCGTTA TCCAGAAGAT
GAAGCCTTGC GTAAAAAATT AGCCGAAGCA GCGAAAGCGG
CACAACGTGA AGAAAATCCA AAGCAGCAGA AGCTGCACAG
CGTGAAGAAA ATTTTGTCAA TGATGTTTTT AACATCCATG
AAAATTTTGG ACCACGCAAT TGGGCTTATG AAGCGCAAGG
TTCATCCCTC ATTGAACCTG CTTCTGTCTA TGACAACGGT
AAAACAACAA CCCTTTACAT TTTTGGGGCA ATACCGAAAT
CCCTGCCATT TATTCTGGTA TCGCTTGATG GGCAAGATTC
TCTCGTTCCA AAATCAATTA AAGGAACCAG GTTATTGTTC
ATGCCATAGC TGCGCAATTT ACTTTGCGCC GCGGGAATGA
CGTGCTGTGC ATCTTTAATA AAAGATTTGT ACCTGAAGGG
ATTAACCCTG AGACCGGTAC GACATCACCA TCTGTACAAC
GTAGAGTGAA CATAGGAAAT GGTCATGAAG GATGAAATAG
ATGAAAACAA CATAAATGAT CGCAGTACAA TAAAAGACGG
TCAAGGAAAA AAACTGCATT CCAATACAAG TAAAGCAGTT
GCTCTTCTCG TTCTTTTGGG TGTTTGTGGT TATTTAGCGT
ATTCAACGCT TATCACAAAC AAAAAACAGC CGGTTGAACT
TCCAAAAGAG GCGATTATTA AGCAAACAGA GCGTTTCCGC
CCTGCACAGC CCAAGCCTGT ACTCCTCGAG CCAACTGAAA
AAAATAACCT CCTGTTGCCC AAGGTTGAAT TGCCAACGCC
CAAAAGAAAC CAAACAAATG CTGATGATTC ACTCTTAGAA
GCAGCACAAC GTGCTCCTGT CTTAGCCTAT GCCAGCCCAC
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6761
6801
6841
6881
6921
6961
7001
7041
7081
7121
7161
7201
7241
7281
7321
7361
7401
7441
7481
7521
7561
7601
7641
7681
7721
7761
7801
7841
7881
7921
7961

AAAAAAGCCA AGCAAATGCA GAAAAAAATA ACGACACTTC
ACCGAACCAA CTCGAAAGAA AACCTGATGA AACAGCACAA
CGCTTTAATC ATCTTCTCAA ACCGACAAAC CTTGAAGGTA
TTCATGCTTC AACACTTACT AATCGAAACT ACATCATCGC
AATGGGTGCT TCCATTCCAT GTATTTTAGA AACGGCAATC
AGCAGTGACC AACAGGGATT TACCAGTTGT ATCGTTTCTA
GAGATACCAG CCCGGGCCGT CGACCACGCG TATGAACCAA
AACCTGCATA AATTGAGCAA TGAAACTGTC GCGATTGTTT
TAACAAAACT TGAACCTATC AGTACCTTTC TGAAAGATGA
GAGTCTTTTT GAAATTGTCA TCAATCGTCC CTATCAAGTG
ATGACAGAAG GAATTGAGGG ATGGAAAACA ATAGAAGCAC
CAGCTCTCTC ATTTAATGAG CTTATGGGAA TTGCTAAAGT
TGTCGCGTCC TATTCTAAGC AAAATATATC AGAAAAAAAT
CCAATATTAT CAGCCACCCT ACCAGGCAAT GAGCGTATTC
AAATTGTCAT TCCACCTGCA GTAGAAAAAG ACACAATCAG
TATGACAATT CGCAAACCAT CATCGCGGAG TTTTTCACTC
GAAGAGCTGG CAAATAAAGG TCTCTTTTCA GTGTGTGAAC
AAGTCTCATT CACGCCATTG AATGATTATC AATCGCGTTT
TAGTGAACTC AAACACATTG AGCATAACTT AGCCAATGCT
TATTCAAATA AGGATTTTGT CTCCTTTTTA AATCAGGCTG
TAAAATGCCA AAAAAATATT TTGATTGCAG GAAAAACCGG
TTCGGGTAAA ACAACGCTAT CAAAGGCATT AATCGCAAAA
ATTCCCGATG ATGAGCGTAT TATCACCATT GAAGATACAC
CAGAATTGGT CGTACCACAG CCTAATTATG TCTCTATGAT
CTATTCAAAA GATGGTCAAG GCTTAGCCTC TGTTGGTCCA
AAAGAATTGC TTGAATCTGC TTTACGCATG CGTCCTGATC
GCATTCTTTT ACAAGAGCTT CGAGATGGTA CAGCCTTTTA
TTATATCCGC AATGTCAATT CAGGACATCC AGGTTCAATT
ACCACGGTTC ATGCATCAAC AGCACTTGCT GCCTTTGAGC
AAATGACCCT TTTGGTCAAA GAAAGTGAAG GAGGAGGAGA
TTTAGAGCGT GATATTCGAG GGCTGTTGAT TT
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AP.3 – Alignment of various Bartonella GroEL Proteins.
The program AlignX (Invitrogen) was used to prepare a protein sequence alignment for B.
henselae (BH), B. quintana str. Tolouse (BQT) and B. bacilliformis (BB). The predicted B.
bacilliformis Staphylocoagulase binding-motif has been underlined and the amino acids
which differ between B. bacilliformis, B. henselae and B. quintana are red.
BH_GroEL
BQT_GroEL
BB_GroEL

1
50
MAAKEVKFGR EARERLLRGV DILANAVKVT LGPKGRNVVI DKSFGAPRIT
MAAKEVKFGR EARERLLRGV DILANAVKVT LGPKGRNVVI DKSFGAPRIT
MAAKEVKFGR DARERLLRGV DILADAVKVT LGPKGRNVVI DKSFGAPRIT

BH_GroEL
BQT_GroEL
BB_GroEL

51
100
KDGVSVAKEI ELEDKFENMG AQMLREVASK TNDIAGDGTT TATVLGQAIV
KDGVSVAKEI ELEDKFENMG AQMLREVASK TNDIAGDGTT TATVLGQAIV
KDGVSVAKEI ELENKFENMG AQMLREVASK TNDIAGDGTT TATVLGQAIV

BH_GroEL
BQT_GroEL
BB_GroEL

101
150
QEGVKAVAAG MNPMDLKRGI DAAVDEVVAN LFKKAKKIQT SAEIAQVGTI
QEGVKAVAAG MNPMDLKRGI DAAVEEVVGN LFKKAKKIQT SAEIAQVGTI
QEGVKAVAAS MNPMDLKRGI DAAVEAVVAD LFKKAKKIQT SEEIAQVATI

BH_GroEL
BQT_GroEL
BB_GroEL

151
200
SANGAAEIGK MIADAMEKVG NEGVITVEEA KTAETELEVV EGMQFDRGYL
SANGAAEIGK MIADAMEKVG NEGVITVEEA KTAETELEVV EGMQFDRGYL
SANGAEDIGK MIADAMEKVG NEGVITVEEA KTAETELEVV EGMQFDRGYL

BH_GroEL
BQT_GroEL
BB_GroEL

201
250
SPYFVTNAEK MVADLDDPYI LIHEKKLSNL QSLLPVLEAV VQSGKPLLII
SPYFVTNADK MVADLDDPYI LIHEKKLSNL QSLLPVLEAV VQSGKPLLII
SPYFVTNSEK MMVDLDDPYI LIHEKKLSNL QSLLPVLEAV VQSGKPLLII

BH_GroEL
BQT_GroEL
BB_GroEL

251
300
AEDVEGEALA TLVVNKLRGG LKIAAVKAPG FGDRRKAMLE DIAILTSGQV
AEDVEGEALA TLVVNKLRGG LKIAAVKAPG FGDRRKAMLE DIAILTSGQV
AEDVEGEALA TLVVNKLRGG LKIAAVKAPG FGDRRKAMLE DIAVLTSGQV

BH_GroEL
BQT_GroEL
BB_GroEL

301
350
ISEDVGIKLE NVTLDMLGRA KKVNISKENT TIIDGAGQKS EINARVNQIK
ISEDVGIKLE NVTLDMLGRA KKVNISKENT TIIDGAGKKA EINARVNQIK
ISEDVGIKLE NVTLEMLGRA KKVHVSKETT TIVDGAGQKS EINARVSQIK

BH_GroEL
BQT_GroEL
BB_GroEL

351
400
VQIEETTSDY DREKLQERLA KLAGGVAVIR VGGATEVEVK EKKDRVDDAL
VQIEETTSDY DREKLQERLA KLAGGVAVIR VGGATEVEVK EKKDRVDDAL
AQIEETTSDY DREKLQERLA KLAGGVAVIR VGGSTEVEVK EKKDRVDDAL

BH_GroEL
BQT_GroEL
BB_GroEL

401
450
NATRAAVEEG IVAGGGTALL RAANALTVKG SNPDQEAGIN IVRRALQAPA
NATRAAVEEG IVAGGGTALL RAANALAIKG SNPDQEAGIN IVRRALQAPA
NATRAAVEEG IVPGGGTALL RAAKALSIKG KNPDQEAGIG IIRRALQAPA
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BH_GroEL
BQT_GroEL
BB_GroEL

451
500
RQIATNAGEE AAIIVGKVLE NNADTFGYNT ATGEFGDLIA LGIVDPVKVV
RQIATNAGEE AAIIVGKVLE NNADTFGYNT ATGQFGDLIA LGIVDPVKVV
RQIAHNAGEE AAVIVGKVLE NCSDTFGYNT ATAQFGDLIS FGIVDPVKVV

BH_GroEL
BQT_GroEL

501
547
RSALQNAASI ASLLITTEAM VAEVPKKDTP VPPMPGGGMG GMGGMDF
RSALQNAASI ASLLITTEAM VAEVPKKDTP MPPMPGGGMG GMGGMDF

